Design and characterisation of orally dissolving films as a potential new dosage form for paediatrics by Pham, Thu
  
Some pages of this thesis may have been removed for copyright restrictions. 
If you have discovered material in Aston Research Explorer which is unlawful e.g. breaches 
copyright, (either yours or that of a third party) or any other law, including but not limited to 
those relating to patent, trademark, confidentiality, data protection, obscenity, defamation, 
libel, then please read our Takedown policy and contact the service immediately 
(openaccess@aston.ac.uk) 
  
 
1 
 
 
 
DESIGN AND CHARACTERISATION OF ORALLY DISSOLVING FILMS 
AS A POTENTIAL NEW DOSAGE FORM FOR PAEDIATRICS 
 
 
 
    THU PHAM 
Doctor of Philosophy 
 
    Aston University 
     December 2016 
 
 
 
   ©Thu Pham, 2016 
[Thu Pham] asserts [her] moral right to be identified as the author of this thesis. 
 
 
 
 
This copy of the thesis has been supplied on condition that anyone who consults it 
is understood to recognise that its copyright rests with its author and that no 
quotation from the thesis and no information derived from it may be published 
without appropriate permission or acknowledgement. 
 
Aston University 
 
 
 
 
  
 
2 
 
 
Design and Characterisation of Orally Dissolving Films as a potential 
new dosage form for paediatrics 
 
 
THU THI ANH PHAM 
Doctor of Philosophy 
 
Thesis summary 
 
Orally dissolving films (ODFs) have received much attention as potential delivery 
systems for oral administration of drugs to paediatric patients. With their unique 
properties and advantages, the technology offers improved patient compliance and wider 
acceptability, eliminated fear of choking, ease of administration and dosing convenience, 
without the requirement of water. This research focused on the formulation of ODFs with 
suitable physico-chemical and clinical properties as a potential dosage form for paediatric 
use. 
Initial studies focused on screening different film-forming materials used for the 
preparation of orally dissolving films in order to optimise and propose suitable polymers 
and plasticisers with a suitable manufacturing technique. Kollicoat Protect was a selected 
candidate for further studies, due to its excellent film forming capacity with rapid 
disintegration.  
The work also sought to improve the loading capacity, taste masking and drug content 
uniformity of both hydrophilic (dexchlorpheniramine malate) and hydrophobic 
(glipizide) drugs into ODFs, especially for poorly water soluble drugs, through 
complexation with cyclodextrins (CDs) and incorporation with nanoparticles. Results 
demonstrated that CD complexation showed improvement in the solubility profile of 
glipizide, whilst drug loading efficiency and drug content uniformity only improved at 
low doses, based on the limited cavity sizes. Nonetheless, the application of nanoparticles 
achieved good drug loading efficiency for glipizide at higher doses. In contrast, the 
loading capacity and other physico-chemical properties of dexchlorpheniramine maleate 
loaded films remain flexible.     
Further, method development to optimise the determination of disintegration time of 
ODFs proved that the media and media volume has no effect on disintegration time using 
either beaker or the texture analyser method, but the analyser method demonstrated to be 
more suitable for quality control setting of ODFs. Of the stability performance of ODFs, 
films packed with the prototype packaging remained stable over the period of time studied 
at both long term and accelerated conditions, which indicated their robust and clinical use 
through the product developmental stages.  
Keywords: Orally dissolving films, paediatric, Kollicoat protect, mechanical property, 
drug content uniformity, drug loading, poorly soluble drugs, cyclodextrins and 
nanoparticles. 
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1. Introduction 
1.1  Drug delivery to the oral cavity 
It is no surprise that the oral route is one of the most widely accepted ways of 
administering drugs to the body, due to ease of ingestion, convenience, pain avoidance 
and high level of patient compliance (Desu et al., 2013). In addition. the oral cavity 
(mouth) offers an accessible gateway for the delivery of an active pharmaceutical 
ingredient (API), either via the saliva or absorbing via the oral muscosa to achieve local 
or systemic administration (Rathbone et al., 1994). The cavity provides a large surface 
area (100- 200 cm2), with an extent of smooth muscle, a relatively immobile mucosa and 
low enzymatic activity compared to the gastro- intestinal tract (Khafagy et al., 2007).  
 
1.1.1 Anatomical structure of oral cavity 
The oral cavity is structured by the cheek, the hard and soft palate and the tongue (Fig. 
1.1). The total surface area of the human oral cavity is approximately 200 cm2, which 
comprises of 20% surface area of teeth and the remainder attributed to the oral mucosa 
(Wilson, 2005),which are classified into three sections in the oral cavity, depending on 
the deviation of thickness and nature of the mucosa lining. The surface of the oral mucosa 
is composed of stratified squamous epithelium, which is separated by a further, 
underlying basement layer, called the lamina propria and submucosa; these layers contain 
blood vessels, sensory receptors and nerves. The lining mucosa, which is non-keratinised, 
covers the soft palate and other buccal regions, whereas the masticatory mucosa, which 
are composed of keratinised cells, encompasses the hard palate and gingival. The 
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keratinised mucosa contains ceramides and acylceramides, which are believed to relate 
to the barrier function, while only a small amount of ceramides are present in the lining 
mucosa (Shojaei, 1998). The saliva is secreted by three major salivary glands – the 
parotid, submandibular and sublingual glands from the oral cavity– and is influenced 
either directly or indirectly by sympathetic and parasympathetic nerves (Smart, 2005). 
The pairs of parotid and submandibular glands produce mainly serous fluid, whereas the 
sublingual glands generate only mucus containing saliva. Saliva maintains the health of 
oral tissues, as well as functioning as a lubricant for swallowing and a buffering agent, in 
addition to being responsible for the clearance of many drugs; antibacterial activity, taste 
and digestion (Humphrey and Williamson, 2001, de Almeida et al., 2008).  
 
 
     
   
Figure 1.1- Anatomy of the oral cavity. Adapted from (Robinson and Mickelson, 2006) 
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1.1.2 Saliva composition, flow and functions 
Since the oral cavity is the main site for drug delivery for oral dosage forms, the saliva 
composition contributes to the rate of diffusion of drug molecules. Saliva plays an 
important role in drug absorption, by rapidly providing the aqueous environment to 
facilitate drug action. Saliva fluid is a mixture made of a large extent of water 
(approximately 99 %) containing a variety of electrolytes, such as sodium, potassium, 
chloride and bicarbonate, as well as other digestive enzymes, proteins and antimicrobial 
constituents (Kaufman and Lamster, 2002, de Almeida et al., 2008). Different types of 
enzymes, such as lipase, α-amylase and lysozyme help to stimulate digestion in the human 
oral cavity (Wilson, 2005, Walsh and Mills, 2013). 
 
However, the salivary flow rate and its composition changes throughout the lifespan of a 
human; the flow rate of saliva increases in children up to 6 years of age, but the mean 
electrolyte content increases with a decline in saliva flow after that stage. A range of 
unstimulated saliva flow rates in children is generally from 0.22- 0.82 mL/min and 0.33-
1.42 mL/min in adults (Rotteveel et al., 2004, Lam et al., 2014). On the other hand, pH 
is also important factor to drug absorption; the pH of the oral cavity in healthy children 
is 6.6, which is slightly lower than that of adults. In addition, diet and saliva flow rate can 
also have an impact on pH level and, hence, the absorption of drugs (Aps and Martens, 
2005). 
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1.1.3 Routes of drug transport  
Drugs penetrate across cells from saliva by passive diffusion or by an active transport 
mechanism (Kaufman and Lamster, 2002, Bosch, 2014). Passive diffusion is the major 
mechanism by which drug molecules transport via two main pathways: the transcellular 
(crossing thorough the cell membrane) and paracellular (passing spaces between cells) 
routes (Figure 1.2) (Rossi et al., 2005, Sudhakar et al., 2006). Lipophilic molecules are 
subject to transport via the transcellular pathway, as they can easily permeate the 
lipophilic cell membranes, whereas hydrophilic and small molecules pass the lipid layers 
of membranes by being transported paracellularly. However, drug transport mechanisms 
can dominate simultaneously by the two pathways, with one route performing 
predominant permeation (Rossi et al., 2005). 
 
Yet, the route and the rate of drug absorption via permeable membranes may be 
influenced by other physio-chemical factors, including the drug concentration on the 
surface of mucosa, the molecular weight of molecules, the delivery vehicle, the pH of 
saliva and the saliva flow (Reddy et al., 2011, Hooda et al., 2012). For example, the 
absorption of hydrophilic molecules are highly dependent on molecular size (smaller 
molecules diffuse more readily) and low acid dissociation constant (pKa) of drug, where 
the pH value of saliva is prone to alter the drug ionisation (ionised molecules are polar) 
and, hence, facilitating the diffusion.  
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 Figure 1.2- Schematic representation of paracellular and transcellular transport. Adapted from (Andrade 
et al., 2011). 
 
 
1.2  Paediatric dosage forms  
1.2.1 Medicines for paediatric use 
The improvement of medicines for paediatric use can be a challenging task, due to poor 
availability in the drug development process and the lack of understanding of appropriate 
dosage forms. Besides that, numbers of unlicensed and off- label medicines used for 
paediatrics are often given by healthcare professionals, which arise with risk due to lack 
of information, as a consequence of a relatively small market share, leading to a lack of 
financial incentives, as well as challenging clinical trial methodology and recruitment, for 
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what is a heterogeneous patient population (Ivanovska et al., 2014). Indeed, the incidence 
of use of off-label (prescribed outside the terms of the product license) or unlicensed 
(where no license exists) medicine is estimated to range from around 11 % in general 
practice (McIntyre et al., 2000), increasing up to 36% in general paediatric hospital 
admission (Turner et al., 1998) and as much as 90% in neonatal intensive care units 
(Conroy et al., 1999). Besides that, the use of unlicensed and off-label medicines has the 
potential to produce adverse drug reaction in babies and children, with severe effects 
including hypotension, difficulty in breathing, or prolonged sedation (Nunn, 2003, 
Choonara, 2004). 
 
Recently, the Committee for Medicinal Products for Human Use released the reflection 
paper “Formulation of choice for the paediatric population” (EMA, 2006), which 
classifies the paediatric population into six developmental stages: preterm newborn 
infants, term newborn infants (from 0 to 27 days), infants / toddler (from 1 month to 23 
months), children (from 2 to 11 years old) and adolescents (from 12 to 18 years old) 
(Figure 1.3). According to this report, the EMA (European Medicine Agency) have 
proposed a new safety and acceptability guideline for formulation suitability for each age 
group, including the indication and route of administration (Drakulich, 2009). Since 
children grow up through different stages of growth and development, not only dosage 
form, but also the dose regimen, acceptability and palatability must be considered. 
Moreover, the EMA recently published a guideline on pharmaceutical development of 
medicines for paediatric uses in 2013, which further enhances the balance between 
clinical prediction and regulatory assessments of paediatric medicines, in terms of  
facilitating the development and accessibility of medicinal products in the numerous of 
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paediatric population with target age group as proposed in marketing- authorisation 
application (EMA, 2013). Importantly, the regulation of medicinal products should be 
aims for safety and efficacy, which is a critical factor to protect the wellbeing of the 
children (Salunke et al., 2012). In an attempt to rectify this worrying situation, The Best 
Pharmaceuticals for Children Act (BPCA) (2002) took the lead to encourage the 
pharmaceutical industry to perform paediatric studies to improve labelling for patented 
drug products used in children (Christensen, 2012). The European Paediatric Regulation 
(2006), which came into force in 2007, went one step further and has changed the 
landscape of accessibility of medicine products via research and development to enhance 
the safety and quality of medicine for children as it is very important for paediatric 
development. These regulatory approaches to improve paediatric medicines sparked a 
range of research initiatives, such as the European Paediatric Formulation Initiative 
(EUPFi), which has developed an online Safety and Toxicity Excipients for Paediatrics 
(STEP) database to capture the specific need for potential users from the input of industry 
and researchers (Drakulich, 2009, Salunke et al., 2012). 
 
   
 
Figure 1.3- Illustration of different developmental stages in paediatric groups. Adapted from 
(Children, 2013). 
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Nevertheless, age-adapted drug formulations represent a particular challenge in drug 
development for paediatrics; the paediatric formulations are required to deliver variable 
doses of APIs to children with different ages and body weight (Nunn and Williams, 2005), 
whilst children in different parts of the world have different requirements for medicines. 
For examples, young children from poor countries suffering from the malnutrition are 
associated with paracetamol hepatotoxicity, therefore it is necessary to deliver the suitable 
medicine products for children (Vitols, 2003). 
 
Administration of the APIs via the oral route is the most popular choice because of their 
extensive advantages, including low manufacturing cost, ease of administration and pain 
free (Batchelor and Marriott, 2015). Oral dosage forms are generally available in solid 
(e.g. tablets, capsules) or liquid (e.g solutions, suspensions and emulsions); however, 
there are obstacles for young patients to accept the oral medicines as results of swallowing 
difficulty or chewing problems in patients. It estimated that 50% of the specific target 
groups, particularly young children, the elderly and patients suffering from a variety of 
disorder such as stroke or neurological problems, experience difficult in swallowing, 
which leads to  a high incidence of non-compliance and delivery of non-effective therapy 
(Schiele et al., 2012). 
 
In addition, due to the difficulty in swallowing solid dosage forms, particularly for the 
younger age groups, currently most oral paediatric medicines are liquid dosage forms. 
However, liquid formulations generally require more excipients than solid dosage forms 
due to their poor stability. Volume is an important factor for the liquid formulation; the 
dose volume of liquid formulations should ideally be prescribed at less than 5 mL for 
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children under 5 years of age and no more than 10 mL for children from 5 years and older 
(Batchelor and Marriott, 2015). Moreover, the volume is not only important for the 
palatability of the formulation, but also for the accurate measurement of the appropriate 
dose to children. There are also limitations on choice and concentration of excipients for 
paediatric patients; for example, alcohol is not suitable in paediatric formulation because 
of its toxicity to young children (Walsh, 2012). On the other hand, the taste masking 
techniques in drug dosage forms (e.g. sweeteners and flavours) is very important for good 
patient compliance, although the selection of flavouring agents in the formulations 
depends on the physiochemical properties of drugs. Moreover, disease types and regional 
preferences should also be taken into account for treatment weight (Nunn and Williams, 
2005). Furthermore, packaging of paediatric products is also important for their chemical 
and physical stability. They need to be free from any source of contamination with child- 
protection packaging (Maldonado and Schaufelberger, 2011). 
 
1.2.2 Challenges and considerations for paediatric formulations 
First of all, the doses of drugs for children in different age populations is variable; children 
are not small adults and they go through different stages of growth and development. 
Thus, they differ from adults in many aspects, such as body development, drug disposition 
and metabolism and taste preferences (McNally and M.Railkar, 2009). For example, 
infants have slower gastrointestinal movement, less protein binding and slower drug 
metabolism than adults. In addition, the total body water between children and adults is 
also different; neonates have 80% body water, whereas this is just 50-60% in adults. 
Moreover, different paediatric subpopulations have different pharmacokinetic and 
Chapter 1  General Introduction 
 
 
32 
 
 
pharmacodynamics profiles, as they vary with the broad ranges of age and body size/ 
weight of the paediatric population. Therefore, it is a significant challenge for formulation 
scientists to develop an effective medicine suitable for all paediatric subpopulations 
(Stephenson, 2005). 
 
What’s more, the excipient selection in paediatric formulation is different from 
formulations developed for adults. It depends on the functionality and safety profile 
across different populations, illness conditions and treatment duration (Walsh, 2012). It 
is well known that the dosage forms will noticeably impact on the choice of excipients. 
Accordingly of the age differences, the excipients are generally associated with potential 
toxicological risk in different age populations; for instance, ethanol and propylene glycol 
are widely-used excipients in adult formulations, yet they are restricted for use in 
newborns and infants (Zuccotti and Fabiano, 2011). As previously mentioned, the liquid 
formulations are the most preferred dosage form for babies and children under aged of 
six, yet stability becomes another challenge for liquid formulations. Furthermore, to 
improve the shelf life of liquid dosage forms, there are additional concerns associated 
with large amount of excipients in the paediatric formulations (Jenny Walsh, 2012); larger 
amounts of excipients may cause young children to be exposed to potential toxicities. As 
mentioned before, excipients such as propylene glycol and benzyl alcohol –  an excipient 
that can potentially be fatal for neonates – remain the excipients of choice for liquid 
formulation (Allegaert, 2013).  
  
Furthermore, taste masking of paediatric medicines can also be challenging, especially 
for high solubility drugs, which may dissolve rapidly in the mouth (Cram et al., 2009). 
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Paediatric palatability of oral medications is also a significant challenge in the early stage 
of formulation development; the use of sweeteners and flavouring agents are 
commonplace and crucial in paediatric formulations, in order to improve drug palatability 
and children compliance. However, these excipients have been shown to cause adverse 
effects (e.g. dental caries and laxative effect), whilst also potentially causing some 
allergic reactions with unknown reasons (Fabiano et al., 2011). 
 
1.2.3 Alternative paediatric dosage forms 
There exists some comprehensive guidance focusing on formulation preferences within 
the paediatric population, stating that the ideal specification of the formulation should: (i) 
reduce dose frequency; (ii) minimise the size of dosage forms; (iii) ensure convenience 
and ease of administration; (iv) display good taste and (v) contain safe excipients 
(Batchelor and Marriott, 2015, Preis, 2015). The use of “disperse systems” has been 
established as the strategical reconstitution of solid oral dosage forms for paediatric 
formulation. Multi- particulate systems, such as granules and pellets, are useful for 
paediatrics, which can be administrated directly into the mouth or even mixed with food, 
therefore providing ease of swallowing and dose flexibility. Nevertheless, there is an issue 
of incomplete ingestion and, therefore, reduced dose, whilst stability matters also need to 
be reconsidered (Nunn and Williams, 2005). 
 
Mini tablets are also an innovative formulation development, with their tablet diameter 
of less than 3 mm, which have demonstrated fair acceptability from young children 
(Thomson et al., 2009). Other studies found that the young children prefer to accept mini 
tablets (2 mm in diameter) to the syrup formulation (Klingmann et al., 2013). 
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Chewable tablets are another dosage form that are formulated to be mechanically 
processed in the mouth to enhance the disintegration/ or dissolution of the API. Literature 
reports suggested that chewing patterns and efficiency are recorded in children from the 
age three and over (Liu et al., 2014). 
 
Oral disintegrating tablets, are also promising approach for paediatrics that are designed 
to disintegrate quickly within the oral cavity without the need of water (Slavkova and 
Breitkreutz, 2015). However, the tablet formulation is dependent on the properties of 
APIs and taste masking of bitter drugs is necessary with the careful choice of excipients. 
Yet, they are still limited by the dose rigidity, integrity during transportation or handling, 
and, although a low risk of choking and aspiration (particle inhalation), the administration 
of ODTs might be obtrusive for young children (Lam et al., 2014, Batchelor and Marriott, 
2015). 
 
1.3 Orally dissolving films- A novel potential approach 
As a consequence of the issues stated above, particularly with regards to the inability of 
children to swallow traditional oral solid dosage forms, in order to aid patient compliance 
and convenience, the expansion of orodispersible products has emerged, with dosage 
forms of different types, such as oral disintegrating tablets and oral lyophilisates. First 
developed in the late 1970s, the fast-dissolving drug delivery system is a pioneering 
technology, providing an alternative oral dosage form for paediatric, geriatric and non-
compliant patients with difficulties in swallowing or fear of choking (Bala et al., 2013). 
The incorporation of various water soluble drugs into oral disintegrating films (ODFs) 
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has been reported (Nishimura et al., 2009, Shimoda et al., 2009). This new drug delivery 
system gained advantageous potential in the oral route of administration, as they provide 
patients the medicine without the need of swallowing, provide rapid dissolution in a small 
amount of saliva without the consumption of water. 
 
 
1.3.1 Types of Oral Films 
Depending on the design of formulation, the application areas and disintegration time, 
different types of oral films are applicable. Mucoadhesive films and oral patches were 
introduced in the market as buccal sustained drug delivery systems, specifically designed 
for the buccal or sublingual region, whereas the fast dissolving film is placed on the 
tongue. The characteristics of these films are summarised in Table 1.1 (Nagaraju et al., 
2013).  
 
 
 
 
 
 
 
 
Chapter 1  General Introduction 
 
 
36 
 
 
Table 1.1- Properties of different types of ODFs. Adapted from (Bala et al., 2013, Nagaraju et al., 2013). 
 
Properties 
 
Fast release films Mucoadhesive 
films 
Mucoadhesive 
sustained wafers 
 
Area (cm2) 
 
2-8 
 
2-7 
 
2-4 
Thickness 
(µm) 
20-70 50-500 50-250 
Structure Single layer Single or multiple Multiple layer 
Components Soluble polymers Soluble polymers Insoluble polymers 
Drug phase Solid solution Solid or suspension  Solid and/ or suspension  
Delivery 
region 
Tongue Gingival or buccal 
region 
Oral cavity region 
Dissolution 
time 
30s Few minutes  8-10h 
Location of 
action 
Systemic or local Systemic or local Systemic or local 
 
 
1.3.2 Why oral films? Special features 
ODFs have acquired great importance in the pharmaceutical industry, due to their unique 
properties and advantages. They undergo rapid disintegration in the presence of salivary 
fluids of the oral cavity within a few seconds, without the requirement of water. Their 
characteristics offer tremendous advantages in terms of improved patient compliance, 
rapid onset of action, no risk of choking, increased bioavailability and ease of 
administration and portability (Dixit and Puthli, 2009, Irfan et al., 2015). Regarding 
paediatric formulations, oral film delivery system can be beneficial for the small size of 
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dosage form and for those who require accurate doses for monitoring in disease states 
suitable for children at all ages. Furthermore, ODFs offer advantages over other dosage 
forms, where they are more stable and resistant compared to ODTs, which are fragile and 
brittle. In addition, other advantages over ODTs is providing a larger surface area for 
faster disintegration in the oral cavity with great flexibility and eliminated fear of 
swallowing tablets (Hirani et al., 2009). In contrast, although liquid dosage forms are 
flexible and provide ease of administration, accurate measuring is often problematic, 
especially without a dedicated measuring device, whilst poor stability of the liquid 
formulation is the major limiting factor (Borges et al., 2015).  
 
1.3.3 Marketed oral dissolving films and future potentials 
Thin-film strip technology exploits a range of water soluble polymers to incorporate 
various APIs, making the medicines more flexible, robust and stable. The first ODFs were 
commercialised in the market as breath fresheners and healthcare products (Listerine 
Cool Mint Pocket Packs by Pfizer). Following the success of Listerine pocket packs, they 
introduced the Triaminic and Theraflu brands in strip forms for cold suppression. Prestige 
pharmaceutical company launched the first therapeutic oral thin film, Chloraseptic® relief 
strips, with benzocaine in 2003, which was used for the treatment of sore throat. In recent 
times, ondansetron containing oral fast dissolving films, Zuplenz®, was approved by FDA 
for vomiting prevention of cancerous patients before chemotherapy, with each film 
containing either 4 mg or 8 mg API, which dissolves within 20 seconds, thereby allowing 
ondansetron to be easily taken by dysphagia patients (FDA). It was prescribed as 8 mg 
films twice daily for paediatric patients aged 12 or older, whilst paediatric patients less 
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than 12 years old can take 4 mg oral films 3 times a day. Currently, there are a wide range 
of commercial oral fast dissolving films available in the global market, as summarised in 
Table 1.2.  
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Table 1.2- Lists of marketed ODFs.  
Products Ingredients Mode of action Company 
 
Listerine Cool Mint Pocket 
Packs 
 
Cool mint 
 
Mouth fresheners 
 
Pfizer 
Minerals and nutraceutical 
films 
B6, B12, vitamin C Vitamin supplements Paladin Labs (Bioenvelop) 
Energy booster Caffeine, green tea extract Boost energy levels Biofilm 
Donepezil Rapidfilm ® Donepezil Hydrochloride (5 mg and 10 mg). Management of 
Alzheimer’s type. 
Labtec GmbH 
Ondansetron Rapidfilm ® Ondansetron 4mg & 8mg Prevention of nausea and 
vomiting after post 
chemotherapy 
Strativa Pharmaceuticals 
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Onsolis ( fentanyl buccal 
soluble film) 
Fentanyl citrate 200 mcg, 400 mcg, 600 
mcg, 800 mcg, 1200 mcg 
Pain relief for cancer 
patients 
Biodelivery Sciences 
 
Triaminic Thin Strips 
Cough & Runny Nose 
Diphenhydramine (12.5mg) 
 
Anti- allergic Novartis Consumer Health 
Day Time Triaminic Thin 
Strips® Cold & Cough 
Dextromethorphan 3.67 mg (equivalent to 5 
mg Dextromethorphan HBr), Phenylephrine 
HCl 2.5 mg, 
Nasal decongestant Novartis Consumer Health 
 
Theraflu Thin Strips Long 
Acting Cough 
 
Dextromethorphan HBr (15 mg) 
 
Cough suppressant 
 
Novartis Consumer Health 
Suppress Herbal Cough 
Relief Strips 
Menthol (2.5 mg) Cough suppressant Innozen Inc 
Chloraseptic relief strips Benzocaine/menthol (3mg/3mg) Sore throat Prestige Brands 
Snoreeze® strips Peppermint oil Reduce snoring Passion for Life Healthcare 
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1.3.4 Patented technologies 
The development in the field of fast dissolving products, especially for ODFs, has been 
gaining attention and is well accepted by consumers. Some of the patent technological 
platforms of the orally dissolving films are summarised in Table 1.3 (Siddiqui et al., 2011, 
Nagaraju et al., 2013, Borges et al., 2015). 
Table 1.3- ODF patented technologies platform. 
Patented technology Technological platform 
 
SoluleavesTM 
A wide range of flavours, vitamin and APIs incorporated 
into edible thin films for slow release once adhere on the 
oral mucosa.  
 
WaterTabTM 
A designed technology for precise dose of API loaded into 
pre-manufactured body of indigestive strips to prevent heat 
and moisture exposure, thus enhancing product stability. It 
can be used in oral or topical administration. 
 
FoamburstTM 
A special patent derived from Soluleaves technology for 
capsule made from foam film, where a honeycombed 
structure is formed, which deliver flavours for quick 
dissolution with a good mouth sensation. 
 
RapidFilm® 
A patent developed by Labtec GmBH that use non- 
adhesive, water- soluble polymers to incorporate drug 
(maximum 30 mg) for quick release in the mouth. 
 
Bio-erodible muco-adhesive 
(BEMA®) 
The technology is designed for multilayer bioerodible 
films that adhere to the oral mucosa with the unidirectional 
deliver of APIs from the backing layer for quick onset of 
action.  
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1.3.5 Limitations for ODFs 
One of the issues with the ODFs manufacture is their low dose capacity (less than 40 mg 
API),  since the small, thin size is the limiting factor, therefore restricting their use to 
potent drugs that are clinically efficacious at lower doses (Dixit and Puthli, 2009). 
Combinations of more than one drug, especially for poorly water soluble compounds, is 
also a challenging task that could have an impact on the disintegration time and 
dissolution profile of ODFs (Jadhav et al., 2013). Taste masking of bitter drugs is also a 
prerequisite step for ODFs, as films remain in contact with oral mucosa by the hydrolysis 
of saliva. In addition, incorporation of taste masking agents may affect the physical 
properties of ODFs. Another critical issue is to obtain a uniform dose for the individual 
unit of films where they are cut into desired sizes and shapes, which is essential as it is 
important to provide stable levels of drug within the patient, thereby providing a more 
consistent therapeutic effect. Furthermore, most of the polymers used for ODF 
formulation are hydrophilic in nature and sensitive to moisture; thus, an appropriate 
packaging is needed for moisture protection for a long term preservation.   
 
1.4 Strategies to enhance the loading capacity of ODFs 
1.4.1 Solubilisation of poorly water soluble drug 
Most of the drugs being developed in the pipeline today are poorly water soluble (Kakran 
et al., 2012), which remains a challenging task for the design of oral dosage forms. 
Furthermore, poor solubility might also influence the drug distribution within the dosage 
from. To overcome the challenges, various solubilisation techniques have been proposed 
to enhance the solubility profile of the drug substances. 
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Solid dispersion is a main explored technology, which incorporates the poorly soluble 
drug into an inert polymeric carrier. Blending drug particles within the polymer matrix 
prevents the aggregation and, thus, the dissolution of the drug is improved by increasing 
the available surface for wettability or enhancing the amorphicity (Kakran et al., 2012). 
Solid dispersions have been widely employed to enhance the solubility properties of 
different types of drugs, such as paracetamol, nifedipine and ritonavir (Akiladevi et al., 
2011, Lalitha and Lakshmi, 2011, Huang and Dai, 2014). In addition, the formulation of 
the poorly soluble drug, glipizide, as a solid dispersion using hydrophilic carriers such as 
polyethylene glycol and poloxamer, has been extensively reported in the literature 
(Choudhary et al., 2009, Verma et al., 2011, C Patel et al., 2012).  
 
Particle size reduction is another similar approach to enhance the dissolution rate, where 
the improvement of dissolution profile of the drug is achieved through increased surface 
area. Micronisation is, for example, a conventional common method, which has been 
successfully applied to enhance the bioavailability and clinical efficacy of fenofibrate or 
griseofulvin (Vogt et al., 2008, Kawabata et al., 2011). Also, the use of nanoparticles by 
dispersing preformed polymers to produce the colloidal particles in the range of 10-1000 
nm, promotes the dissolution rate of poorly soluble drugs, enhances the drug loading 
capacity and reduces the toxicity level of the excipients (Rabinow, 2004). The 
incorporation of BCS class II drug nanoparticles, e.g naproxen, fenofibrate and 
griseofulvin, into the edible strips using hydroxypropyl methyl cellulose as a film former 
exhibited the enhancement of dissolution performance and bioavailability of those studied 
drugs (Sievens-Figueroa et al., 2012).  
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Cyclodextrins (CDs) have been extensively used in drug development for improving the 
aqueous solubility and bioavailability of those problematic drugs via the formation of 
inclusion complexation. CDs and their derivatives were used primarily for their 
solubilising effect, whilst also serving as drug carriers (Szejtli, 1998). Numerous studies 
have demonstrated the enhancing property in the literature. Hydroxypropyl β-
cyclodextrin (HPCD) was used to develop complexation with prednisolone by solvent 
method in order to improve the dissolution profile, which was subsequently loaded into 
ODFs (Patel and Patel, 2014). The hydrophobic drug etoricoxib incorporated with beta 
cyclodextrin also showed enhancement in the aqueous solubility of the drug, as well as 
achieving good uniform distribution of drug once they are loaded into films 
(Senthilkumar and Vijaya, 2015).   
 
Surfactants are also alternative options for aiding drug dispersion of poorly soluble drug, 
since they can act as dispersing and solubilising agents by reducing the surface tension, 
and potentially may be used for enhancing the dose uniformity of these class II drugs, as 
well as maintaining formulation flexibility with improved stability (Billany, 2002, Mishra 
et al., 2009). Tweens, a non-ionic solubilising agent, are the most commonly used 
surfactants for development of ODFs (Siddiqui et al., 2011, Irfan et al., 2015), whereas 
Span, a non-ionic surfactant belonging to the sorbitan esters group, has a safe history of 
use in food and pharmaceutical formulation (Croda, 2010). 
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1.4.2 Taste masking approaches 
Most drugs have a bitter taste, making taste masking a crucial parameter in the 
development of ODFs, as well as other dosage forms. In particular, palatability of ODFs 
is vital, since the films remain in contact with the oral mucosa by the hydrolysis with 
saliva. As such, several approaches of taste masking are available for enhanced 
performance and acceptability. One of the simplest techniques used in taste masking is 
the addition of taste modifiers, such as sweeteners and flavouring agents for bitter APIs. 
However, the choice of taste modified agent must be compatible with other excipients, 
stability and tolerance for optimal use (Walsh et al., 2014).  
 
Furthermore, coating with polymer is also a suitable approach for improved palatability. 
This method is achieved by introducing a physical barrier on the API itself, or the dosage 
form, from the taste buds of the tongue. As a result, the coating material inhibits the 
release of APIs in the oral cavity and, therefore, only dissolve to release at the enteric pH 
(pH < 5). The advantage of using this technique, especially for ODF formulation, is to 
prevent the contact of drug particles merging on the oral mucosa and, hence, ensuring 
taste masking (Xu et al., 2008).   
 
Cyclodextrin complexation has also been widely used for taste masking of bitter drugs. 
The process is carried out by the formation of inclusion of guest molecules into the CD 
cavity; the bioavailability, solubility and stability of these entrapped drugs is enhanced 
by the complexation. Most of all, they are capable of decreasing the taste perception of 
the drug. However, the extent of taste masking depends upon the size of cavity and the 
size of molecules (Davis and Brewster, 2004). For example, beta CDs are the most widely 
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used and are suitable for encapsulation of a wide range of drugs, especially for cyclic 
molecules. Alpha CDs tend to prove insufficient in drug inclusion, due to having the 
smallest cavity size, while gamma CDs are the largest but display a weaker complex 
ability than the other two CDs (Challa et al., 2005). This method has been reported to be 
more suitable for taste masking for low dose drugs (Sohi et al., 2004). In addition, CD 
complexation has improved taste masking of many unpleasant tasting drugs, but also 
achieved good uniform distribution of drug when incorporated into films (Mahesh et al., 
2010, Poluri et al., 2013, Senthilkumar and Vijaya, 2015). 
 
Although there are a selection of taste masking technologies available to assist the current 
issues of taste masking, a deep consideration of appropriate technique for the palatability 
of paediatric medicinal products is required.   
 
1.5 Film preparation- new challenges and opportunities  
Several manufacturing methods are employed for ODFs, including solvent casting, hot 
melt extrusion, solid dispersion, and rolling. They can be used as one process or 
combination techniques (Figure 1.4). 
 
  
 
 
 
 
Methods of ODF preparations 
Casting Extrusion Rolling 
Solvent 
Casting 
Hot melt 
extrusion 
Solid 
dispersion 
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A)          
  
 
 
B)   
 
 
Figure 1.4- Schematic representation of ODF manufacturing as a commercial systems. Adapted 
from (Science, 2010). 
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1.5.1 Film manufacturing techniques  
Two methods predominate for film preparation: solvent casting method and hot melt 
extrusion (Figure 1.4). The casting process can be defined as the simplest, oldest 
procedure in film manufacturing, which was first introduced at the end of the 19th century, 
driven by the needs of the photographic film industry (Collins, 1990). Lately, this 
technology is becoming a versatile tool for thin film production with high quality control. 
Solvent casting method involves the process where water–soluble polymers are firstly 
dissolved in water to form uniform clear viscous solutions, followed by addition of drug 
and other excipients, to form a homogenous solution. The solvent is subsequently cast on 
the substrate and evaporated during the drying period, resulting in a thin film that can be 
processed into desired properties (Siemann, 2005). Hence, solvent casting is widely 
considered as the method of choice, due to feasibility and low cost of manufacturing (Irfan 
et al., 2015). In hot melt extrusion, the API and other excipients are mixed in a dry state, 
and undergo a heating process without the use of solvents. However, this method has not 
been a selected choice of film manufacturing as the higher temperature could be the cause 
of thermal degradation of film materials, and there are limited suitable film forming 
agents for heating (Crowley et al., 2007, Dixit and Puthli, 2009, Mishra and Amin, 2011). 
Nevertheless, hot melt extrusion has been extensively used for sustained drug release for 
transdermal and transmucosal delivery systems (Repka and McGinity, 2000, Prodduturi 
et al., 2005), tablet and granule manufacturing (Crowley et al., 2007), and ODF 
formulation by exploring a multiple combination of polymers (Crowley et al., 2004, 
Repka et al., 2005).  
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Moreover, novel methods such as inkjet printing and three dimensional (3D) printing  
have become an interesting approach for manufacturing of ODFs, where the dosage 
solution is either sprayed accurately onto the film surface (Scoutaris et al., 2011, Genina 
et al., 2013, Janßen et al., 2013), or the design configuration is created in 3D by deposition 
of thin layers of dosage form (Goyanes et al., 2015). These promising technologies allow 
wide ranges of desired materials in good quantities (Birtchnell and Urry, 2013) and could 
be the platform for producing accurate dosage forms tailored to patients’ needs (Goyanes 
et al., 2015, Karki et al., 2016). Recently, inkjet printing was used for preparation of 
personal dose oral films containing salbutamol sulphate made of potato starch for 
paediatric patients (Buanz et al., 2011). With the advantages of printing technologies in 
terms of flexible dosing, the potential in drug dosing tailoring of ODF could bring benefits 
for patients, regardless of the age. 
 
1.5.2 Factors affecting film manufacturing process 
The physicochemical properties of APIs are the criteria factors that should be primarily 
considered. Drugs should be compatible with a suitable solvent and other film forming 
agents (Mishra and Amin, 2011). Another parameter is the moisture present in the 
solution; the moisture is observed to modify the mechanical properties of film, therefore 
a suitable humidity environment is a subject to be controlled during manufacturing (Rathi 
et al., 2011). 
 
Chapter 1  General Introduction 
 
 
50 
 
 
1.5.3 Principal advantages of solvent casting methods 
Solvent casting technology offers a unique drying process on the surface without the 
application of mechanical or thermal stress (Siemann, 2005). Additionally, both 
conventional and modern casting techniques deliver uniform thickness distribution, high 
optical purity and feasible processing of heat sensitive excipients (Siddiqui et al., 2011). 
However, major drawbacks of conventional tools involve slow production speed and 
require further facilities for handling solvents (Siemann, 2005). Nowadays, the 
technology of solvent casting film promotes the production of wafer and tension-free film 
down to 5 µm in thickness. The use of polymers with high molecular weight can also be 
used for film development (Scheuermann, 2013). 
 
1.6 Mechanism of Film Formulation 
In order to understand the mechanical behaviour of polymers, numerous structural 
characteristics including chemical composition other physical factors should be reflected. 
Classifications of polymers are highly dependent on the types of polymerisation process 
as well as other schematically structures and properties (e.g thermos plastics, rubbers or 
thermosets). 
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1.6.1 Polymer classification 
Polymers are defined as large molecular chains composed of a repetition of small 
molecules (monomers) (ASM International, 2003). They have unique chemical and 
physical properties and are categorised by their structure and properties. They may be 
either linear or branched molecules, whilst the chemical nature of the monomer and the 
flexibility of the polymer chain propose a significant impact on its mechanical 
performance. 
 
ODFs are composed of one or more water soluble polymers (e.g. natural or synthetic), in 
order to dissolve quickly in the mouth. The selection of polymer is the key factor that 
contributes to successful film formulation; depending on the desired formulation design, 
the appropriate selection of type and concentration of polymer is a critical parameter for 
the ensuing mechanical properties, disintegration time, as well as the drug loading of the 
ODFs (Borges et al., 2015). Given that ODFs target fast release and rapid onset of action, 
polymers therefore should be harmless and flexible, exhibit good wetting and spread 
ability, whilst also displaying adequate stability, sufficient peel, shear and tensile 
strengths (Leuner and Dressman, 2000, Dixit and Puthli, 2009). Hence, a variety of 
polymers have been extensively studied to modulate properties of films. Cellulose 
derivatives, especially hydroxypropyl methyl cellulose (HPMC) and hydroxylpropyl 
cellulose (HPC), available at different grades and the substitution groups, are widely used 
as film coating agents, as well as lubricants (Lopes et al., 2006). For example, HPMC 
classified grades K and E are extensively used for film formulation; the use of type K is 
used as a delayed agent for sustained release formulations, whereas type E is more popular 
for being a film former (Karki et al., 2016). Different grades of HPMC have also been 
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studied for the development of fast dissolving films of triclosan, indicating they were 
good film forming materials (Dinge and Nagarsenker, 2008). Similarly, certain drugs, 
such as famotidine or granisetron HCl, loaded into oral film using HPMC exhibited 
satisfactory mechanical properties (Sonawane et al., 2012, Chaudhary et al., 2013). 
Besides that, HPC used as a film former demonstrated good mechanical properties and 
carrying capacity of non-steroidal anti-inflammatory drug, ketorolac tromethamine, for 
buccal delivery (Alanazi et al., 2007). Furthermore, other natural polymers, such as 
starch, sodium alginate as well as pectin are considerable choices for film development. 
Due to wide availability and low cost, starch is considered as the potential polymer for 
the film applications; nevertheless, film forming from starch was found to have a 
limitation of mechanical strength, brittle and crystal formation on films (Nagar et al., 
2011). Modified starch has been developed to improve the product performance and is 
available as maltodextrin or hydroxypropyl starch. Development of films with the 
modified starch, maltodextrin, showed a good quality with fast disintegration time 
(Shamekh et al., 2002, Cilurzo et al., 2010). Sodium alginate is another natural polymer 
that is widely used as a thickening, stabilising and emulsifier agent (Dixit and Puthli, 
2009), but it has also been used to improve drug loading capacity of mucosal films using 
paracetamol and amoxicillin as model drugs (Boateng et al., 2013). Pectin is the popular 
agent for sustained release of drug, therefore is not considered as a potential polymer 
candidate for orally dissolving films with the aims for fast release (Borges et al., 2015, 
Karki et al., 2016).   
 
Synthetic polymers have also been used as polymer matrices for other drug delivery 
systems. Gelatin is well-known as the coating layer for the preparation of hard and soft 
capsules, but has also been utilised in implantable delivery systems, especially as sterile 
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film or ophthalmic film (Nagar et al., 2011). Polyvinyl alcohol (PVA) has also been 
extensively employed as a film former (Nagaraju et al., 2013). Kollicoat® IR and 
Kollicoat® protect (KP) are both new generation pharmaceutical excipients composed of 
polyvinyl alcohol – polyethylene glycol graft copolymer that are freely soluble in water. 
Films developed with these new excipients generate flexible films with great stability 
against moisture and fast disintegration profile (BASF, 2007). 
 
Although the available choices of polymer for use in delivery systems is vast, a careful 
choice of polymer is necessary for producing good quality orally dissolving films with 
desired therapeutic dose for paediatric use.  
 
1.6.2 Molecular mass and distribution 
The distribution of chain length within polymers depends strongly on the intermolecular 
forces between neighbouring molecules, the molecular weight and chain figurations 
(Ward and Sweeney, 2004). Each polymer varies with the chain length and molecular 
weight. The correlation between mechanical behaviour and molecular weight distribution 
of polymer showed that molecular weight distribution of polymer might influence 
indirectly its mechanical behaviour, but directly alter its viscoelastic behaviour and brittle 
strength (Ward and Sweeney, 2004).  Besides that, regarding to chain length of the 
polymer, longer polymer chains lead to reduction of the chain mobility and segmental 
motion of the molecules for supported film; whereas short chains have more free volume 
and less surface density, and hence lowering the glass transition temperature. 
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1.6.3 Interaction forces 
The most recognised attractive forces between polymer chains include electrostatic 
interaction, hydrogen bonding and Van der Waals forces. The electrostatic interaction 
involves the interaction of charged groups, hydrogen bonding is considered as a strong 
physical interaction in self-assembly, whilst Van der Waals force is defined as the 
attraction of intermolecular forces between molecules.  Polymers with strong polar groups 
and numerous hydrogen bonds (e.g. polyvinyl alcohol, polyacrylic acid) exhibit strong 
intermolecular forces, while other non-polar polymers held by weak Van der Waals 
interactions (Cao et al., 2009). Therefore, a wide range of numerous factors should be 
investigated to achieve a better mechanical behaviour of polymers. 
 
1.6.4 Stages of film formation 
The processes of film formation are divided into two categories: dry and wet process 
(Guilbert et al., 1997). There is no water and other solvents needed for the dry process of 
films.  In this process, only heat is applied for drying the film forming materials. For the 
wet process, solvents are added to dissolve the polymers, subsequently drying to remove 
them and form a film product. Therefore, the selection of solvent is important.  
 
The mechanism of film formation is highly dependent on whether the polymer is in a 
dissolved or dispersed state. Film formation from aqueous based polymeric solution is a 
process that spreads onto the surface of substrate, since the polymer is in the dissolved 
state. The stages of film formation undergo three mechanisms, which involve water 
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evaporation, particle packing (nucleation), particle deformation and particle coalescence 
(Fig. 1.5) (Felton, 2013). 
 
Initially, the process starts with wetting and spreading polymeric solution onto the flat 
surface of the substrate. In this stage, the rate of solvent evaporation is the criteria 
parameter for film development. It has been proved that the solution is dried at a constant 
rate (Steward et al., 2000). During drying, the polymer sphere starts packing tightly after 
application due to water evaporation. Subsequently, the polymer spheres deform into 
space filling, which happens at the same temperature for dry particles as well as particles 
casted in the wet film. With continuing drying film, the polymer particles anneal by 
migration of polymer chains to form the film (Figure 1.5). 
 
 
Figure 1.5- Schematic diagram of polymeric film formation.  
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1.6.5 Driving forces of film formation 
Three existing theories have been discussed in literature reviews regarding the driving 
forces of film formation in dispersed state: polymer/ air surface tension (Dillon et al., 
1951), capillarity force or air/ water interfacial tension (Brown, 1956) and osmotic 
pressure (Sheetz, 1956). However, depending on the material’s properties, polymer 
coalescence and film formation occurs as a consequence of any of those above mentioned 
driving forces. 
 
The rate of drying has a strong impact on the film formation and is dependent on the 
relative humidity of the environment. Faster coalescence and increased polymer chain 
interdiffusion has been evidenced of  high humidity conditions (Carlin et al., 2008, Haley 
et al., 2008). 
 
1.7 Quality Control of Orally Dissolving Films and Their 
Challenges 
Several challenges can be encountered when the formulation manufacture is transferred 
from laboratory scale to production scale. The final products should have adequate 
flexibility and good physico-chemical stability. Quality control of films is a pre- requisite 
to ensure the performance of films. 
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1.7.1 Thickness 
Film thickness is directly proportional to the amount of loaded drug. The thickness of the 
ODF can be determined at different locations by digital micrometer gauge to ascertain 
uniformity in thickness. Films should have an ideal thickness of 50 to 1000 µm (Nair et 
al., 2013).  
 
1.7.2 Mechanical properties 
Mechanical properties of ODFs play an important role for physical integrity for ODF 
production, but also for handling matters. Several encountered factors, such as types of 
film forming agents, quantity of plasticiser, film thickness, manufacturing process, 
storage conditions, as well as the use of APIs impact on the mechanical properties of films 
(Preis et al., 2014). Literature revealed different methods to determine the mechanical 
strength, however there are no specifications available for ODF in terms of tensile 
strength and practical applicability (Morales and McConville, 2011). For instance, the 
Texture Analyser is the most common choice for determination of tensile property of 
ODTs, but films need to be cut into the standard template, which is difficult when taking 
into account comparisons due to a variety in sizes and shapes (Boateng et al., 2009). 
Radebaugh et al (1988) designed the promising puncture testing system for polymeric 
films using different polymers. The use of texture analyser (TA.TX2® model, Stable 
Micro Systems) was firstly reported to analyse the mucoadhesion strength of controlled 
release Eudragit buccal films (Wong et al., 1999). Hence, several modifications have been 
developed for adaptable evaluation of this parameter for ODFs (Eouani et al., 2001, 
Prodduturi et al., 2005, Perumal et al., 2008, Garsuch and Breitkreutz, 2009, Preis et al., 
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2014). The most relevant studies can be defined in terms of tensile strength, percentage 
elongation and Young’s modulus, as follows (Dixit and Puthli, 2009, Preis et al., 2014): 
a) Tensile strength 
Tensile strength is the maximum force applied to the film until the film specimen breaks. 
It is calculated by the applied forces of break divided by the cross- sectional area of the 
film. It can be computed with the Eq. (1) 
 
Tensile strength =  
Maximum force was applied
Cross sectional area of film
    (1) 
 
 
 
b) Percentage Elongation 
Elongation is defined as the deformation of film divided by the original length of the 
specimen and is calculated by the Eq. (2). The more plasticiser is added, the stronger the 
elongation of film is. 
% Elongation =  
Length after force was applied
Original length
 x 100    (2) 
 
c) Young’s Modulus 
Young’s modulus or elastic modulus is the measurement for the stiffness of film in the 
elastic region. It is obtained from the ratio of stress over strain using Eq. (3) as follow: 
 
Young′s modulus =  
slope of stress−strain 
cross sectional area x corresponding strain
  (3) 
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Depending on the designed formulations and chosen manufacturing methods, different 
behaviours of mechanical properties obtained from stress –strain curves are illustrated in 
Figure 1.6.  
 
 
Figure 1.6- Behaviours of ODFs with varying mechanical properties, obtained from stress-strain 
curves. Apdated from Felton (Felton et al., 2008). 
 
 
Previous reports described that soft and weak polymers have low tensile strength, low 
percentage elongation and Young’s modulus, whilst soft and hard polymers exhibit hard 
and stronger in the mentioned properties (Heng et al., 2003, Morales and McConville, 
2011). In fact, a wide variation of types of polymers and the choice of manufacturing 
creates the difficulty in establishing the values for these parameters. Hence, there are no 
standardised descriptions for appropriate values for mechanical strength and other studied 
ranges (Preis et al., 2014, Borges et al., 2015). Therefore, dependent on the formulation 
choice and delivery purposes, these crucial features are taken into account for controlling 
the physical strength of ODFs. 
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1.7.3 Disintegration time 
As this is a new innovative technology, a set of associated limitations and challenges arise 
in the quality control of ODF formulations. ODFs are designed for quick release purposes 
when applied onto the tongue. Following the European Pharmacopeia, orodispersible 
tablets (ODTs) should disintegrate in less than 180 seconds (European Pharmacopoeia 
Commision, 2013) and less than 30 seconds by FDA guidance (FDA, 2008); whereas 
ODFs, recently subordinates to the “oromucosal preparations” monographs, only stated 
as “dissolve rapidly” without a defined time limit (European Pharmacopoeia Commision, 
2013), although the disintegration time limit of 30 seconds or less is a recommended value 
for ODFs (Barnhart et al., 2008). However, no standard pharmacopoeia disintegration 
test method for ODFs exists. Literature described that several disintegration test methods 
have been developing to verify the suitable system for disintegration time of ODFs (Table 
1.4) (Hoffmann et al., 2011). Reports showed that the standard pharmacopoeia 
disintegration system, without modifications, for tablets and capsules was applied to 
ODFs (Shimoda et al., 2009, Cilurzo et al., 2011, Liew et al., 2014). The above method 
faces challenges with the end point determination due to film floating in a large volume 
of media (Low et al., 2015). Alternatively, two simple methods for determining the time 
using a small volume of media, such as Petri dish and slide frame, has been studied in 
previous reports (Garsuch and Breitkreutz, 2010, Londhe and Umalkar, 2012, Preis et al., 
2012, Poluri et al., 2013). However, these methods could not provide mechanical 
agitation of water droplets to create a hole or having enough water droplet to cover the 
surface of ODFs (Low et al., 2015). Disintegration time can also be recorded by dipping 
films in a beaker containing 25 mL volume of media with a gentle stirring (Arya et al., 
2010, Tomar et al., 2012, Bala et al., 2013). Other literature reveals the exposition of 
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ODF on a stainless steel wire mesh, where the media is added to the surface until the films 
breaks, which is noted as disintegration time (Mishra and Amin, 2009, Joshi et al., 2012, 
Bala et al., 2014). In some cases, the measurement of swelling behaviour of films was 
applied to predict the disintegration time (Peh and Wong, 1999, Hoffmann et al., 2011). 
On the other hand, those previous methods lack a defined and clear end point for 
disintegration. A novel disintegration test system was designed, with electronic end- point 
detection (Preis et al., 2014). Films were clamped vertically into two clips equipped with 
a brass plate acting as a weight. When the film starts to disintegrate, it causes the dropping 
down of the clip weights, with the end point recorded visually by weight drop with time 
display. Low et al. (2015) set up a modified disintegration test system for ODFs, which 
attached six holder units where films were held in a horizontal position for test, by 
emerging them up and down at the modified speed and stroke. The breaking of ODF from 
the holder is defined as the end point disintegration (Low et al., 2015). Dave et al. (2014) 
introduced the texture analyser as a disintegration testing system; the films are placed on 
the platform where the attached probe, mimicking the oral cavity pressure, moves with 
the trigger force until it touches the film. A small amount of media is applied and time 
for complete disintegration is recorded. The method developed using TA-CT3 texture 
analyser with probe provides clear end-point determination, whilst using small media 
volume aims to be biorelevant to the oral cavity volume (Dave et al., 2014). Hence, an 
appropriate set up disintegration test system that is biorelevant to physiological conditions 
of the oral cavity with the consistency of measured disintegration time is needed for 
quality control settings.
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Table 1.4- A review summary of disintegration test methods.                          
Media volume Test system Description of method 
 
 
 
Small volume 
Petri dish method ODF is emerged into 2 mL of distilled water over the Petri dish until 
film is completely dissolved as noted as disintegration time. 
Slide frame method Films are clamped into slide frame. A drop of water is added to the 
ODF. Time taken by the films to create a hole is recorded.  
Wire mesh method ODF is placed on a stainless steel wire mess where 10 mL of media 
is added to the surface until the films break  
Beaker method ODF is dipped into a beaker containing 25 mL water with a gently 
shaking until disintegration is observed. 
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Swelling studies 
 
Contact angle measurement 
 
Modified disintegration 
apparatus 
The angle determination is carried out by a digital camera between 
a droplet of water and a planner surface of ODF. 
The degree of swelling is measured by the weight change of ODF 
before and after immersion into solution. 
 
Large volume USP disintegration system 
 
Modified disintegration 
apparatus 
ODFs are submerged into disintegration apparatus with certain 
speed until they are completely dissolved. 
ODFs are submerged into disintegration apparatus with certain 
speed until they are completely dissolved. 
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1.7.4 Stability studies 
It is important to carry out stability studies for the prepared formulation to gain the 
information on how a new product is influenced by various exposed environmental 
factors, including temperature, humidity and light, and to identify any degradation in the 
formulation. Recommended storage conditions should be followed by according to 
International Conference on Harmonisation (ICH) guidelines (Q1A (R2)) for use termed: 
long term, intermediate and accelerated (Table 1.5). 
 
Table 1.5- Recommended storage conditions for stability study detailed by the ICH guidelines. 
Study Environmental condition Time period 
Long term 25°C ± 2°C/60% RH ± 5% RH 
or 
30°C ± 2°C/65% RH ± 5% RH 
 
12 months 
Intermediate 30°C ± 2°C/65% RH ± 5% RH 6 months 
Accelerated 40°C ± 2°C/75% RH ± 5% RH 6 months 
 
A new product, such as oral dissolving films, should be stored under controlled 
environment by ICH guidelines at the regular time point to establish the full stability 
profile of the ODF. The chemical instability of the polymer matrix may occur or the 
change of active ingredient may interfere with the matrix (Nagaraju et al., 2013). 
Different parameters of films, such as physical appearance of the film, mechanical 
properties, and drug content, are required to be evaluated during its development. 
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Literature study showed that films were kept in aluminium foil under recommended 
conditions (eg. Long term and accelerated) for three months period (Bala et al., 2013). 
 
1.8 Thesis Aims and Objectives  
The development of dosage formulations for paediatrics is still a big challenge, due to 
lack of mainstream research and development. However, orally dissolving films, a new 
drug delivery system for the oral route, serves as an alternative oral solid dosage form for 
paediatrics. This new system provides patients the medicine without the need of 
swallowing and offers rapid dissolution in a small amount of saliva without the 
consumption of water. Therefore, the overall aim of this project is to develop the ODF 
formulation with suitable physico-chemical and clinical properties as a new potential 
dosage form for paediatric use. 
Therefore, the objectives of the research areas were focused as following: 
 Screening of polymer materials and manufacturing optimisation for formulations 
of ODFs.  
 
 Explore the strategic approaches for taste masking of bitter drugs and drug loading 
improvement, particularly of poorly soluble drugs. 
 
 
 Optimisation of a suitable disintegration testing system and some prototype 
packaging development.
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2.1 Materials 
Pectin from apple, Sodium alginate, Hyproxylmethylcellulose (10,000), Kollicoat 
Protect, Kollicoat Immediate release (IR), Maltodextrin, Starch, Gelatin, Sodium carboxy 
methylcellulose (90,000), Polyvinyl pyrrolidone (K15, K30), Polyvinyl alcohol (31,000- 
50,000), Polyvinyl alcohol (13,000- 23,000), pullulan were purchased from Sigma- 
Aldrich, UK. Glycerol (≥ 99.5 %), polyethylene glycol (PEG) 400 and Tween 80 used as 
plasticiser were obtained from Sigma- Aldrich, UK. Different types of cyclodextrins such 
as alpha, beta, gamma, 2-hydroxypropyl- β- cyclodextrin were purchased from Discovery 
Fine Chemical Ltd (Dorset, UK). Polycaprolactone (average Mw ~14,000), pluronic® F- 
127, phosphate buffer saline were also obtained from Sigma Aldrich (UK). 
 
Dexchlorpheniramine maleate was acquired from Sigma- Aldrich, UK. Metformin 
hydrochloride and glipizide was obtained from Discovery Fine Chemicals Ltd. All other 
materials were of analytical grade. 
 
2.2 Methods 
 
2.2.1 Screening of film former for ODFs pre-formulations 
Different types of water soluble polymers, such as pectin from apple, sodium alginate, 
hydroxypropylmethylcellulose (HPMC) (10,000), kollicoat protect (KP), kollicoat IR, 
maltodextrin, starch, gelatin, sodium carboxy methylcellulose (90,000), polyvinyl 
pyrrolidone (K15, K30), methylcellulose, polyvinyl alcohol (31,000- 50,000), polyvinyl 
alcohol (13,000- 23,000) and pullulan were selected in order to choose the suitable 
polymer for the formulation development of ODFs. Each polymer (10 % w/v) was 
Chapter 2  Materials and Methods 
 
 
68 
 
 
accurately weighed and prepared by dissolving in 10 mL distilled water to form uniform 
clear viscous solution. The solutions were then mixed and stirred to form a homogenous 
viscous solution, which was subsequently degassed under vacuum to remove the air 
bubbles. The solution is finally cast onto a baking tray and dried in the oven at 60 ºC for 
at least 2 hours to form a thin film. The films were carefully removed from the mould and 
cut into desired size and shape (3x2 cm2 per strip) (Alam et al., 2015, Senthilkumar and 
Vijaya, 2015). Casting films were examined for their physical and mechanical properties. 
 
 
Figure 2.1- Images of ODFs developed by the baking tray method. 
Chapter 2  Materials and Methods 
 
 
69 
 
 
2.2.2 Screening of plasticiser and plasticiser concentration 
The selected polymers from the initial screening were studied with plasticiser for their 
compatibility. Glycerol, polyethylene glycol (PEG) 400 and Tween 80 were added in 
varying amounts (5, 10 or 20 µL of plasticiser), to a clear polymer solution (10 mL). Both 
the solutions are then mixed and stirred to form a homogenous viscous solution, which 
was subsequently degassed under vacuum to remove the air bubbles and allowed to dry 
in the oven at 60 ºC for at least 2 hours to form films. Plasticiser that is compatible with 
film forming polymer was further selected for characterisation, including its effect on 
tensile properties and disintegration time as well as the capability of drug loading. 
 
2.3 Preparation of drug loaded ODFs 
 
2.3.1 Metformin HCl 
Polymer solution prepared as described above was used for the loading capacity of drug 
into ODFs. A quantity amount of Metformin HCl at a dose loading of 10 mg, 20 mg and 
30 mg per 3x2 cm2 of ODF was added to the polymer solution. The entire solution was 
sonicated to remove entrapped air and to enhance the drug dispersion. The above method 
was replicated for producing drug loaded films (see 2.2.1). The prepared films were stored 
and studied for physicochemical stability (see chapter 3).  
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2.3.2 Preparation of glipizide- cyclodextrin complexation 
Glipizide and different types of CDs (alpha, beta, gamma, and HPCD) were accurately 
weighed in the molar ratio of 1:1 (drug: carrier). Glipizide-CD complexes were produced 
by the kneading method (Aly et al., 2003, Choudhary et al., 2009), where F1= αCD/ 
glipizide complex, F2= βCD/ glipizide complex, F3= γCD/ glipizide complex, F4= 
HPCD/ glipizide complex. Glipizide was firstly solubilised in 2 mL of ethanol and then 
added to slurry of CD in ethanol to produce a paste. The paste was then kneaded by mortar 
and pestle for one hour to produce a homogenous mixture, followed by drying at 40 0C 
for 24 hours to remove all solvents. 
 
2.3.3 Preparation of glipizide-CD complex loaded films 
Films containing glipizide-CD complexes were prepared using Kollicoat Protect (KP) by 
the solvent casting method. The water soluble polymer (KP) was first dissolved in 10 mL 
distilled water to form a uniform clear solution. Glycerol as plasticiser (1 % w/v) was 
added to all formulations. After the polymer was completely dissolved, each type of 
glipizide-CD complex was added and stirred further in order to form a homogenous 
viscous solution. This solid dispersion was subsequently degassed under vacuum to 
remove the air bubbles. After degassing, the solution was finally casted on the aluminium 
flat surface of Elcometer 4340 Automatic film applicator (Elcometer Ltd., Manchester, 
UK) and dried at 50 ºC for 45 minutes. The films were carefully removed from the surface 
and cut into the desired size and shape (3 x 2 cm2 per strip). The films were stored in a 
desiccator for further analysis (see chapter 4). 
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Figure 2.2- Films developed by Elcometer 4340 Film Applicator. 
 
2.3.4 Preparation of ODF containing anti-histaminic drug  
Films containing Dexchlorpheniramine maleate (DCM) at a dose of 1 mg and 2 mg were 
prepared using Kollicoat protect as a film former by solvent casting method using 
Elcometer 4330 film applicator (see 2.3.3) . DCM and glycerol was added to all 
formulations and stirred further to uniformly incorporate into the solution. The similar 
method was replicated for producing these formulations (see section 2.3.3). Dried films 
were carefully removed and stored in the desiccator till further use. 
 
2.3.5 Preparation of drug loaded nanoparticles 
Glipizide was chosen as a model BCS class II drug, due to its poor solubility and its 
clinical efficacy at low dose. The preparation of glipizide loaded nanoparticles was 
prepared by the solvent displacement method; briefly, an accurate amount of poly-ε- 
caprolactone (0.2- 0.5 % w/v) was dissolved in 10 mL of acetone, under continuous 
stirring with gentle heating for 30 minutes. Glipizide (10 mg drug) was added into the 
dissolved polymeric solution and mixed thoroughly to obtain a homogenous solution. The 
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organic solution was then added dropwise to 10 mL phosphate buffer saline solution 
containing Pluronic F- 127 (0.25 % w/v) and stirred well using a magnetic stirrer for 10 
minutes at room temperature. The resultant nanospheres were formed by rapid solvent 
diffusion, whilst the residual solvent from the nanosphere suspension was removed under 
pressure by a rotary evaporator. The non-entrapped drug particles from the nanospheres 
were further separated by centrifuging them for 30 minutes at speed of 3200 revolutions 
per minutes using centrifugation Universal 32 (Hettich Zentrifugen, Germany). The 
retained supernatant containing nanoparticles was collected and redispersed in the same 
volume of water as before centrifugation. 
 
 
 
  
 
 
 
Figure 2.3- Schematic representation of producing nanoparticles by nanoprecipitation method. 
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2.3.6 Preparation of ODFs loaded with drug containing nanoparticles 
Films containing glipizide nanoparticles were prepared using Kollicoat Protect (KP) as a 
film former by the solvent casting method. The water soluble polymer (10 % w/v) was 
first dissolved in 10 mL distilled water to form a uniform clear solution. Glycerol as 
plasticiser (1 % w/v) was added to the polymeric solution. Once the polymer was 
completely dissolved, the drug-loaded nanosphere suspension was further added to the 
polymer solution and stirred well to ensure the nanoparticles uniformly distributed. This 
solution was finally casted on the aluminium flat surface of Elcometer 4340 Automatic 
film applicator (Elcometer Ltd., Manchester, UK) and dried at 50ºC for 45 minutes. The 
films were carefully removed from the surface and cut into the desired size and shape (3 
x 2 cm2 per strip). The films were stored in a desiccator for further analysis. 
 
Figure 2.4- Process schematic for the casting film containing nanoparticles. 
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2.4 Characterisation of glipizide complexation 
 
2.4.1 Phase solubility studies of glipizide 
Phase solubility studies are carried out to study the affinity binding between CDs and 
glipizide. The technique was assessed by Higuchi and Connors methods (Higuchi and 
Connors, 1965). An excess amount of glipizide and different types of CD complexes were 
added to 10 mL of 70:30 methanol: water containing various concentrations of CDs (0- 
0.025 M). The mixture was shaken for 24 hours on the rotary flask shaker until 
equilibrium was reached. The solution was withdrawn and filtered through filter paper 
(Whatman, Grade 1), followed by drug assay by UV spectrophotometry at 276 nm. The 
experiments were conducted in triplicate. The binding constant (Kc) can be calculated 
using the equation below: 
          K 1:1= slope/ S0 (1-slope) 
Where S0 is the intrinsic solubility of glipizide, and slope is obtained from the calibration 
curve of glipizide concentration against CDs. 
 
2.4.2 Solubility studies of glipizide 
Solubility studies of glipizide were determined using glipizide and complex equivalent to 
10 mg of drug in distilled water and phosphate buffer pH 7.4 stirring for 24 hours, which 
was then assayed by UV spectrophotometry at 276 nm. The solubility studies were 
assessed in triplicate and data were the average values. 
 
Chapter 2  Materials and Methods 
 
 
75 
 
 
2.5 Characterisation of nanoparticles distribution 
2.5.1 Particle sizes, polydispersity index determination 
The average particle size and polydispersity index (PDI) of blank nanoparticles and drug 
loaded nanoparticles was determined by dynamic light scattering particle size analyser 
using NanoBrook 90Plus Zeta (Brookhaven, New York, USA). A cuvette containing 100 
µL of the nanosuspension was diluted with the hydration phase up to 1 mL and all the 
measurement were carried out in triplicate at 25 0C at a 90 0 angle.  
 
2.5.2 Measurement of zeta potential 
The zeta potential of these nanoparticles was measured using an Electrophoretic Light 
Scattering technique with NanoBrook 90Plus Zeta (Brookhaven, New York, USA) at 25 
0C in distilled water. 100 µL of the sample was diluted in 1 mL distilled water. Three 
measurement of samples were carried out for the determination. 
 
2.5.3 Scanning Electron Microscope (SEM)  
To obtain the morphology of nanoparticles located inside ODFs, scanning electron 
microscopy technique was performed. The film sample was cut into small piece and 
placed on the double adhesive carbon tape over an aluminium tub. Samples were further 
coated with gold layer in an Emscope SC500 sputter coater at 20 mA for 1 minute 
(Quorum Technologies, Lewes, UK) before scanning of the samples. The images were 
captured by a field scanning electron microscope (Phillips XL 30, Eindhoven, 
Netherlands). 
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2.6 Preparation of simulated saliva solution 
The simulated saliva solution in this study was prepared according to Koland et al (2011), 
with the formula given in table 2.1. First, 2.382 g of disodium hydrogen phosphate was 
dissolved in 1 litre of distilled water and the solution was stirred until completely 
dissolved. Potassium dihydrogen phosphate and sodium chloride were then added to form 
a homogenous saliva solution. The pH of saliva fluid was adjusted to 6.75 with 
phosphoric acid and it was used as test medium for the disintegration study. 
 
Table 2.1- Composition of simulated saliva solution. The preparation of saliva fluid was adapted from 
(Koland et al., 2011). 
 
Component Quantity 
Disodium hydrogen phosphate 2.382 g 
Potassium dihydrogen phosphate 0.19 g 
Sodium chloride 8.0 g 
Distilled water Up to 1 litre 
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2.7  Evaluations of ODFs 
 
2.7.1 Visual inspection of films 
Developed films were evaluated by visual inspection for their transparency and the 
capability to form a thin film, which should be removed easily from the casting surface. 
They are classified ranging from good to poor (Kulkarni et al., 2010). 
 
2.7.2 Thickness 
The thickness of films was determined by a micrometer dial thickness gauge (Coventry, 
UK). The film was hung on the anvil and the reading on the dial was recorded. Every film 
was measured five times to calculate the average value.  
 
2.7.3 Uniformity in weight 
The uniformity of film weight was carried out by using 10 preparation units (BP, 2013). 
Each film (3 x 2 cm2) was taken randomly and was weighed collectively. The values are 
the mean of 10 samples (n= 10) and the values are expressed as mean ± SD. 
 
2.7.4 Mechanical properties of films 
The mechanical properties of films containing water soluble drug (DCM) and poorly 
water soluble drug (glipizide)  were evaluated using Hounsfield Tensometer, S Series 
testing machine (Tinius Olsen Ltd, Surrey, UK), with load cell 50N. Films with the size 
3x2 cm2 were attached on two clamps at the distance at 30 mm. These films were pulled 
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by two clamps at rate of 50 mm/min. The parameters of mechanical properties including 
tensile strength, elastic modulus and elongation were assessed. Three replicates were 
done by the following equations.  
 
a) Tensile strength 
Tensile strength (N/mm2) =  
Maximum force was applied
Cross sectional area of film
   
   
 
b) Percentage Elongation 
 
% Elongation =  
Length after force was applied
Original length
 x 100     
 
 
c) Young’s Modulus 
Young′s modulus (N/mm2) =  
slope of stress−strain 
cross sectional area x corresponding strain
   
 
 
2.7.5 Determination of moisture uptake 
Films were cut at the size of 3x2 cm2 for evaluation. The moisture uptake was carried out 
by exposing them to an environment at 75 % relative humidity at room temperature (25 
± 2 0C) and in a desiccator for 1 week (Dinge and Nagarsenker, 2008). Each film from 
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different formulations was measured in triplicate and calculated as percent increase in 
weight. 
 
2.7.6 FTIR studies 
To investigate the interaction between drug and excipients in the films, the FTIR spectra 
of each compound were tested in the regional wavelengths of 400 – 4000 cm-1 by Thermo 
Scientific Nicolet IS5 FTIR Spectrometer (Massachusetts, USA) implemented with an 
iD5 reflectance diamonds. A small sample of film and other powders (10 mg) was placed 
securely on the surface of diamond eyes followed by 16 scans to produce the resulting 
spectra.  
 
2.7.7 DSC studies 
Thermal properties of film formulations and other excipients were carried out by DSC 
Q200 V24.4 build 116, TA instrument (Delaware, USA). An empty pan was crimped and 
used as reference. The film sample (3 mg) was cut and then placed in aluminium T zero 
pans. Both the sample and reference pan were heated at the temperature ramp speed of 
10 0C / min in the presence of nitrogen gas as effluent gas. The heat flow was set in a 
range of 20 0C to 250 0C. This was then followed by the graphs expressing the melting 
onset peaks and enthalpy fusion by the TA instrument universal analysis software. 
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2.7.8 HPLC method for glipizide 
The reverse phase HPLC analytical method for glipizide was obtained from an Agilent 
1200 Series (Waldbronn, Germany) with a multiple UV/ Vis detector and a C18 
Phenomenex Luna column (150 x 4.6 mm, 5 µm). The mobile phase was prepared, 
consisting of acetonitrile: phosphate buffer solution (65: 35 % v/v). The mobile phase 
was filtered and sonicated before use. The elution was carried out at the constant flow 
rate of 1 mL/ min and the injection volume of 20 µL under the UV detection at 233 nm. 
The calibration curve was obtained using a range of concentrations from 0.1 to 0.5 mg/ 
mL of standard solution.  
 
2.7.9 Drug loading 
 
A) Glipizide 
The drug loading of glipizide, glipizide film and glipizide complex film was determined. 
Three films (3 x 2 cm2) from the same batch were dissolved in 10 mL of 70: 30 ethanol: 
water (see Appendix 1). The solutions were then filtered and diluted, which were then 
analysed at 276 nm by UV.  The results were expressed as mean of three determinations. 
 
B) DCM 
Each film (3 x 2 cm2) from the same batch containing 1 mg and 2 mg DCM were selected 
randomly. Films were completely dissolved in 100 mL of distilled water. After the 
dilution, the samples were analysed at 254 nm by UV.  The results were expressed as 
mean of three determinations. 
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2.7.10 Drug content uniformity 
The content uniformity of glipizide loaded films was determined by were dissolved in 10 
mL of 70: 30 ethanol: water (see Appendix 1). The solutions were then filtered and 
diluted, which were then analysed at 276 nm by UV. The results were expressed as mean 
of three determinations. Each film’s drug content was compared with the mean measured 
of drug content in the sample. Individual value of film sample should fall within 85- 115 
% specification range of the drug monograph. 
 
2.7.11 Drug entrapment efficiency 
The drug entrapment efficiency of nanoparticles was analysed after the centrifugation of 
nanosuspension by measuring the concentration of non- entrapped drug. The supernatant 
was filtered through a 0.45 µm filter and then analysed by UV spectroscopy at 276 nm.  
The drug entrapment efficiency of nanoparticles was calculated using this following 
formula: 
 
 
 
Drug entrapment effeciency (%) =  
Total amount of added drug − amount of free drug    
Total amount
   x 100 
 
 
 
 
 
2.7.12 Drug release studies 
 
A) Glipizide loaded nanoparticles 
Drug release studies of glipizide loaded nanoparticles were carried out in 50 mL glass 
beaker containing 25 mL simulated saliva fluid (pH 6.8) and phosphate buffer solution 
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(pH 6.8) using the centrifugation. The temperature was set at 37 ± 0.5 0C and was stirred 
at 100 rpm. Aliquot of 5 mL was withdrawn from the dissolution medium at 1, 5, 10, 15, 
20, 30, 45 and 60 minutes and same amount was replaced with the fresh media. The 
amount of drug released was analysed by UV spectrophotometer at the wavelength of 233 
nm. 
 
B) DCM 
For drug release studies, ODFs loaded with DCM were performed in a 50 mL glass beaker 
containing 25 mL simulated saliva fluid (pH 6.8) and phosphate buffer solution (pH 6.8). 
The temperature was set at 37 ± 0.5 0C and each film was stirred at 50 rpm. During the 
experiment, the dissolution medium (3 mL) was withdrawn at 1, 2, 3, 4, 5, 6, 7, 8, 9 and 
10 minutes and was replaced with the equal amount of fresh solution. The amount of drug 
released was analysed by UV spectrophotometer at the wavelength of 254 nm. Each 
sample was done in triplicate. 
 
2.7.13 Stability studies 
The stability studies followed the guidance of ICH for the ODFs as new pharmaceutical 
formulations. These studies were carried out by storing films at long term (25 ± 2 0C and 
60 ± 5 % RH) and accelerated stability condition (40 ± 2 0C and 75 ± 5 % RH). All film 
samples were monitored at the initial day, 1 month and 3 months and evaluated for visual 
inspection for any change in appearance, mechanical properties, moisture content, 
disintegration time and drug content uniformity (see chapter 5).   
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2.8 Statistical Analysis 
Statistical analyses were performed using GraphPad software version 6.0 (California, 
USA). Data analyses were compared using one way analysis of variance (ANOVA) and 
pair – wise multiple comparison by Tukey’s test, with differences between means with p 
< 0.05 being considered significant for all the experiments. Each study represented the 
mean of triplicate results (n=3) ± standard deviation of this set of records, unless 
otherwise stated. Standard deviation was used as errors in the figures. 
Chapter 3                                                                           Preliminary studies of film formulation 
 
 
84 
 
 
 
 
 
 
 
 
 
 
Chapter 3 
Preliminary studies of film formulation  
  
Chapter 3                                                                           Preliminary studies of film formulation 
 
 
85 
 
 
3.1 Introduction 
Polymers, which may include both natural and synthetic materials, are widely used in 
pharmaceutical formulation, since they are generally well tolerated in the body and have 
a high capacity of drug loading. Thus, polymers have attracted interest for their 
application in dissolvable film formulations for fast and convenient drug delivery. 
 
When used as the basis for oral dissolving films with rapid disintegration in the mouth 
cavity, the film-forming polymers should be harmless and flexible, exhibit good wetting 
and spread ability, whilst also displaying adequate stability, sufficient peel, shear and 
tensile strengths (Leuner and Dressman, 2000, Dixit and Puthli, 2009). 
 
According to the classification of a polymer’s mechanical properties, an ideal oral 
dissolving film (ODF) should have moderate tensile strength, high percentage elongation 
and low Young’s modulus (Nalluri et al., 2013). Indeed, a successful ODF formulation is 
dependent on the selection of polymer and polymer concentration, as they not only impact 
on the mechanical properties, but also influence the release of the active ingredient into 
the oral cavity through disintegration. Yet, there are no specific requirements or 
limitations that are defined to ensure the appropriate mechanical properties of films (Preis 
et al., 2014). 
 
Many different polymers for use in oral films are proposed in the patent literature, and 
various research groups have introduced different materials. As polymers govern the 
release profile of the drug, their choice is the main criterion for the selection of the 
intended release profile and site of action (i.e. local or systemic effect). Pullulan is the 
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first natural polymer, obtained from starch by the fungus Aureobasidium pullulans, 
employed for edible films (Leathers, 2003). The transparency, flexibility and low oxygen 
permeability profile of pullulan make it of great use in food associated applications; edible 
films made of pullulan have shown great potential in food coating materials, as they 
protect fats and vitamins in food from oxidation, therefore helping retain the flavours and 
quality (Cheng et al., 2011). Alternatively, pullulan can be used as a food additive. With 
regards pharmaceutical applications, the strong adhesive and anti- static property of 
pullulan can be exploited for use as a tablet binder as well as a coating agent for hard 
capsules (Prajapati et al., 2013). The most common cellulose derived film forming 
polymers, such as hydroxypropyl methyl cellulose (HPMC) and hydroxylpropyl cellulose 
(HPC), are extensively used as film coating agents, as well as lubricants, because of their 
low cost and biodegradable properties. The cellulose based polymers are available in 
different grades depending on the degree of substitution and viscosity; the higher grade 
of polymers function as delayed agents for sustained release formulations (Lopes et al., 
2006), whereas the lower grade polymers are used for immediate release formulations 
(Kou et al., 2011). For instance, HPMC has been shown to act as a protective coating 
agent for diclofenac sodium tablets at 25 mg, delivering a faster rate of drug release in 
the GIT environment (Roy et al., 2009). Different grades of HPMC have also been studied 
for the development of fast dissolving films of triclosan, indicating they were good film 
forming materials (Dinge and Nagarsenker, 2008). Sodium alginate is a natural, water- 
soluble polysaccharide derived from brown seaweeds, which is widely used in the 
pharmaceutical industry because of its safety and availability. Due to its colloidal 
properties, sodium alginates have been used as thickening, stabilising and emulsifier 
agents, but also utilised for film formation (Nagar et al., 2011). Films prepared from 
sodium alginate showed great potential for controlled drug release systems (Juliano et al., 
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2008). Besides that, sodium alginate has been used to improve drug loading capacity of 
mucosal films using paracetamol and amoxicillin as model drugs (Boateng et al., 2013). 
Pectin is also a natural polymer extracted from fruits and apples. It has a good capacity 
of loading drug, even at low pH function, and pectin is widely used for sustained release 
of drugs (Dixit and Puthli, 2009, Borges et al., 2015). Kollicoat® IR and Kollicoat® protect 
(KP) are both new generation pharmaceutical excipients composed of polyvinyl alcohol 
– polyethylene glycol graft copolymer that are freely soluble in water. They have been 
successfully used as a film former for tablet coating for instant release formulations 
(Nagar et al., 2011). Kollicoat® IR also works as a wetting binder and pore former in 
sustained released coatings (BASF, 2007), whilst films formed of Kollicoat protect 
showed both great protection against moisture vapour with taste masking effect with the 
addition of polyvinyl alcohol compared to Kollicoat® IR (Yadav, 2013). With special 
advantages including instant release profile, great flexibility, good film forming agent 
with taste masking and moisture barrier properties, this novel polymer, KP, has a sound 
rationale for its use as an alternative potential candidate to currently used polymers for 
ODFs.  
 
Plasticisers have been considered as one of the significant factors in the formulation of 
ODFs, since it strongly affects the mechanical properties of films, such as the flexibility 
and tensile strength, by reducing the glass transition temperature (Tg) of the polymers 
(Rahman and Brazel, 2004, Roth and Dutcher, 2005, Cao et al., 2009). The selection of 
plasticiser and its concentration depends on the polymers and solvents in the formulation, 
whilst it should also be compatible with the drug and the other components (Cao et al., 
2009, Vieira et al., 2011).  
 
Chapter 3                                                                           Preliminary studies of film formulation 
 
 
88 
 
 
3.1.1 Glycerol 
Glycerol is a colourless, viscous compound that has versatile uses and applications in the 
food and pharmaceutical industry. It has three hydrophilic hydroxyl groups that result in 
high miscibility in water and a hygroscopic nature (Fundo et al., 2011). Glycerol plays a 
major role in increasing the hydrophilic character of films and acts in a plasticising 
manner on the mechanical properties; several studies have reported the effect of glycerol 
on tensile strength, water permeability and thermal properties of films made from sodium 
alginate, starch and gelatine (Vanin et al., 2005, Lukasik and Ludescher, 2006). 
 
3.1.2 Polyethylene glycol  
Polyethylene glycol (PEG) is one of the most popular excipients used in pharmaceutical 
formulations. It has been utilised as an ointment, tablet lubricant and plasticiser due to 
low toxicity (Topchiyeva, 1990). Depending on the molecular weight of PEGs, they are 
graded in different forms; the higher, solid grade PEGs (PEG > 900 Daltons) are usually 
used as lubricant for tablets, but they also improve the aqueous solubility and dissolution 
of poorly water soluble drugs (Joshi et al., 2004, Paus et al., 2015). The solid grade can 
be used either alone or in combination for tablet-coating polymers. The low liquid grade 
PEGs (200-600 Daltons) are used to enhance the water permeability and dissolution for 
formulations coating. PEGs have been widely employed as a plasticiser for prevention of 
film rupture and to improve the flexibility; e.g. PEG 400 was used as a plasticiser for 
diclofenac sodium tablet coatings (Roy et al., 2009). 
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3.1.3 Tween 80 
Tween 80 is one of the hydrophilic surfactants most commonly used as a non- ionic 
solubilising agent for poorly soluble drugs, as an emulsifier in foods and cosmetics, and 
as a wetting agent for oral suspension (Leuner and Dressman, 2000, van Zuylen et al., 
2001, Savjani et al., 2012). It has been shown to reduce the surface tension of two phases 
and it can also perform as a plasticiser, whilst reports have also shown that Tween 80 is 
capable of improving the drug permeability for P-glycoprotein substrates (Zhang et al., 
2003). Furthermore, Tweens are the most commonly used surfactants for development of 
ODFs, since they may accommodate film dissolution, in addition to enhancing the 
immediate release of incorporated API (Kalyan and Bansal, 2012, Irfan et al., 2015). 
 
The aim of this investigation was to screen different film- forming materials used for the 
preparation of oral dissolving films, with assessment of mechanical properties and 
disintegration behaviour in order to optimise and propose suitable polymers and 
plasticisers for film formulations. 
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3.2 Results & Discussion 
3.2.1 Visual inspection of blank films 
The successful development of film formation is highly dependent on the properties of 
polymers; the film forming capacity of the polymer is defined as the ability to form a film 
that can be easily removed from the casting surface without damage or rupture, with 
classifications ranging from good to poor (Kulkarni et al., 2010). Hydrophilic polymers 
are widely used in film formulation, since the hydrolysis of the polymer when in contact 
of saliva aids the rapid dissolution of APIs (Dixit and Puthli, 2009, Irfan et al., 2015). 
 
Initial studies were carried out to determine which type of polymers would be most 
suitable for film formulation; different hydrophilic polymers were chosen to develop 
preliminary studies of visual inspection, mechanical properties and other 
physicochemical characterisations. The homogenous polymer solution was casted to a 
non- stick metal mould. Based on the previously stated definition of film former capacity, 
polymers such as kollicoat IR, maltodextrin, starch, gelatin, sodium carboxy 
methylcellulose (90,000), polyvinyl pyrrolidone (K15, K30), methylcellulose, polyvinyl 
alcohol (31,000 - 50,000), polyvinyl alcohol (13,000 - 23,000) and pullulan showed that 
the blank films were sticky, which were difficult to peel, or resulted in no film forming 
(Figure 3.1 A C, D). Film forming from starch was found to have a limitation of 
mechanical strength and also crystal formation on the film (Nagar et al., 2011) (Figure 
3.1 B); starch is composed of two main natural constituents, amylose and amylosepectin, 
which are responsible for the ageing of starch films by the loss of water by evaporation 
and physical ageing during heating, which leads to re-crystallisation (Dureja et al., 2011). 
Chapter 3                                                                           Preliminary studies of film formulation 
 
 
91 
 
 
Indeed, films made from starch are heat-sensitive during the casting process due to poor 
water permeability (Van Soest and Knooren, 1997), whilst it has been reported that 
unplasticised starch films contained high levels of amylose, which causes a decrease in 
water vapour permeability and an increase in tensile strength  (Nagar et al., 2011, Pathare 
et al., 2013). Polyvinyl pyrrolidone films are generally tacky in nature due to its 
hygroscopic property (Ali and Quadir, 2007). Films made of pullulan and Kollicoat® IR 
were difficult to peel due to their strong adhesive properties.  
 
Four polymers –  sodium alginate, pectin from apples, HPMC (average Mwt 10,000) and 
KP – showed a smooth, transparent appearance with good film forming capacity ( Figure 
3.1E, F, G and H). Therefore, these four hydrophillic polymers were selected for further 
studies, because they exhibited the capacity of being film formers, as well as being 
transparent and non- sticky (Figure 3.1E, F, G, and H). They are also low heat - sensitive 
polymers which are the suitable choice for fast release systems. 
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Figure 3.1-Visual image of polymer blank film A) PVP K 30 B) starch C) Kollicoat IR D) pullulan- too 
difficult to peel or no film formation whereas E) sodium alginate F) Pectin from apple G) Kollicoat protect 
H) HPMC (Mwt= 10,000)- achieved smooth texture with good film capacity after casting on the non- stick 
metal mould. 
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3.2.2 Mechanical properties of blank films  
Following initial screening, four selected polymers were used to prepare films and further 
evaluate the resulting mechanical properties (Table 3.1). Mechanical properties of film 
formers are important with regards to film casting, handling and drug release. Results 
showed that unplasticised films exhibited adequate mechanical properties by exhibiting a 
low tensile strength but high percentage elongation, therefore producing soft and tough 
films. In addition, the strength of each film strip was directly dependent on the polymer 
type and concentration. 
 
Table 3.1- Mechanical properties of blank films made from HPMC (10,000), SA, pectin and KP by initial 
screening. Films were cut at the size at 3x2 cm2 (mean ± SD, n=3). Statistically significant differences are 
noted as follow: ns (p >0.05) in tensile strength; **** (p <0.0001) in % elongation and Young’s modulus 
between polymer types, followed by two way ANOVA. 
 
Polymer 
types 
Film 
forming 
capacity 
Thickness 
(mm) 
Mechanical properties  
Tensile 
strength 
(N/mm2) 
Elongation  
(%) 
Young’s 
modulus 
(N/mm2) 
 
HPMC 
(10,000) 
 
Good 
 
0.14 ± 0.01 
 
6.64 ± 0.36 
 
25.34 ± 1.82 
 
23.08 ± 2.60 
SA Good 0.18 ± 0.01 3.82 ± 0.49 37.78 ± 1.27 11.09 ± 0.83 
Pectin Good 0.21 ± 0.01 4.76 ± 0.21 25.54 ± 0.40 17.10 ± 2.33 
KP Good 0.09 ± 0.01 4.72 ± 0.53 51.08 ± 2.93 10.01 ± 0.30 
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In this case, the thickness of blank films relates to the extent of barrier properties towards 
water vapour; films made of pectin have a higher thickness than the KP films, as pure 
pectin has a low ability to absorb water vapour and a high level of structural 
discontinuities caused by the drying conditions at high content of pectin in the films, 
which generates thicker films, in agreement with previous studies (Galus et al., 2012, 
Meneguin et al., 2014). SA and KP have a lower Young’s modulus than the other 
polymers, which indicates films were flexible and softer to stretch due to their natural 
properties. Although starch and pullulan are both natural products, mechanical properties 
of films made from them are highly dependent on different chemical structure and 
functional attributes. Films made from starch exhibit poor mechanical properties due to 
its poor water permeability and the brittle nature of starch, thus affecting film forming 
ability (Krogars et al., 2003). In contrast, pullulan possesses superior adhesive which 
makes it difficult to peel (Chaen, 2011).  
 
3.2.3 Selection of plasticiser 
Glycerol, Tween 80 and PEG 400 (1% v/v) were studied to optimise the formulation, 
since each may influence the physical properties of films. Films prepared using Tween 
80 (Figure 3.2) and PEG 400 (Figure 3.3) as the plasticiser did not possess good 
appearance and also caused films to become harder and more brittle, which affects its 
appearance and handling. Therefore, Tween 80 and PEG 400 were considered to be 
incompatible with KP, SA, HPMC and pectin films, which is in agreement with reports 
elsewhere (Galgatte et al., 2013). As they are polysaccharide - based films, these 
polysaccharides are generally resistant to fats and oil, which results in the formation of 
an oily layer on the surface of the film with the addition of Tween 80 and PEG 400,  hence 
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affecting the film appearance and handling (Vieira et al., 2011). On the other hand, it can 
be seen that films prepared using glycerol resulted in better appearance with good film 
forming compared to those prepared by other plasticisers at the same polymer 
concentration (Figure 3.4). As a result, glycerol was chosen as a suitable plasticiser in 
these formulations, as it has shown excellent plasticising ability due to stability and 
compatibility with the polymers used here, with previous results also confirming that 
glycerol has been an appropriate plasticiser for sodium alginate and CMC (Chillo et al., 
2008, Boateng et al., 2009, Boateng et al., 2013).  
 
 
         
      
 
Figure 3.2- Visual image of polymeric film A) Pectin made from apple, B) Kollicoat protect, C) sodium 
alginate and D) HPMC (Mwt = 10,000)  using Tween 80 as plasticiser- Films turned yellowish or cloudy 
and were too brittle after casting on the non- stick metal mould.  
 
A B 
C D 
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Figure 3.3- Images of the plasticised films made from A) Pectin, B) SA C) HPMC (10,000), D) Kollicoat 
protect using PEG 400 as plasticiser. Films did not exhibit good appearance or they were too brittle to form 
films. 
 
                    
                  
Figure 3.4- Images of the plasticised films made from A) Pectin, B) KP, C) SA D) HPMC (10,000) using 
glycerol as plasticiser. Films exhibited good appearance and smooth texture with good film capacity.  
A B 
C 
A B 
C D 
D 
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3.2.4 Effect of plasticiser concentration 
Varying amounts of plasticiser was added to investigate the impact of plasticiser (in this 
case, glycerol) on the physicochemical properties of films (elastic behaviour, 
disintegration properties). As expected, the higher portions of plasticiser have a 
statistically significant impact on the mechanical properties of films (p < 0.05, ANOVA 
followed by Tukey’s test) (Table 3.2). Tensile strength and Young’s modulus properties 
of KP, SA and Pectin reduced significantly at the highest concentrations of plasticiser (20 
µl), which indicated that KP and pectin films became even softer when the amount of 
plasticiser was increased, having a strong effect on the Young’s modulus. Whilst for 
HPMC films, there was no significant difference in tensile strength and % elongation (p 
> 0.05, ANOVA followed by Tukey’s test), but a significant difference in Young’s 
modulus (p < 0.05, ANOVA followed by Tukey’s test). This could be the antiplasticising 
effect of plasticiser within the polymer systems. The migration of glycerol from the film 
matrix enables the HPMC molecules to strongly interact with plasticiser when the 
plasticiser concentration is above its compatibility limits, hindering polymer mobility. 
Hence, no change in mechanical properties of HPMC was observed (Sanyang et al., 
2015). 
 
It was observed that the thickness of each film formulation was increased with an increase 
in glycerol content; the films were produced with a high content of glycerol molecules in 
the film forming solution, leading to more glycerol molecules occupying the void of the 
polymer matrix and interacting with the polymer chains, thus creating an increased 
distance between the polymers within the matrix, which thereby lead to them being 
thicker (Fundo et al., 2014). Similar results have also highlighted the effect of plasticiser 
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concentration on film thickness (Imran et al., 2010, Jouki et al., 2013, Razavi et al., 2015, 
Sanyang et al., 2016).  
Table 3.2- Mechanical properties of HPMC, SA, pectin and KP films at different glycerol concentration 
added at 5 µl , 10 µl and 20 µl .Film size taken at 3x 2 cm2 (mean ± SD, n=3). Elongation and elastic 
modulus are also important parameters for films, since they provide an indication of the deforming 
properties and flexibility of films; the more brittle the film, the lower the elongation value. Statistically 
significant differences are noted as follow: ns (p> 0.05) in tensile strength; **** (p <0.0001) in % 
elongation and Young’s modulus between polymer types at different plasticiser concentrations, followed 
by two way ANOVA. 
 
Polymer Amount of 
plasticiser  
Film 
forming 
capacity 
Thickness 
(mm) 
Mechanical properties  
Tensile 
strength 
(N/mm2) 
Elongation 
(%) 
Young’s 
modulus 
(N/mm2) 
 
HPMC 
(10,000) 
5 µl  Good 0.10 ± 0.01 8.93 ± 0.55 34.37± 3.18 25.54 ± 0.80 
10 µl  Good 0.17 ± 0.01 10.33± 1.47 30.84 ± 0.49 33.51 ± 4.75 
20 µl  Good 0.34 ± 0.01 5.55 ± 0.20 31.24 ± 3.39 17.94 ± 2.34 
 
Pectin 
5 µl  Good 0.07 ± 0.01 9.74 ± 0.59 35.60 ± 3.24 27.40 ± 0.84 
10 µl  Good 0.16 ± 0.01 4.19 ± 0.63 29.39 ± 2.92 14.21 ± 0.83 
20 µl  Good 0.34 ± 0.01 0.69 ± 0.10 55.77 ± 4.29 1.24 ± 0.10 
 
Sodium 
alginate 
5 µl  Good 0.12 ± 0.01 3.73 ± 0.19 31.90  ± 1.31 11.71 ± 0.95 
10 µl  Good 0.22 ± 0.01 3.38 ± 0.69 48.93 ± 2.10 6.89 ± 1.13 
20 µl  Good 0.30 ± 0.01 0.40 ± 0.08 68.37 ± 8.70 0.58 ± 0.60 
 
Kollicoat 
Protect 
5 µl  Good 0.09 ± 0.01 5.26 ± 0.66 44.78 ± 1.68 11.77 ± 1.05 
10 µl Good 0.16 ± 0.01 2.48 ± 0.20 58.53 ± 2.66 4.23 ± 0.21 
20 µl  Good 0.36 ± 0.01 0.36 ± 0.03 23.30 ± 0.89 1.54 ± 0.15 
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Higher concentrations of plasticiser in all formulations studied produced softer, more 
flexible films by reducing the tensile strength and elastic modulus, whereas the % 
elongation was increased. For example, the tensile strength of HPMC decreased from 
10.33 to 5.55 N/m2 and that of pectin reduced from 9.74 to 0.59 N/mm2. This is because 
the more plasticiser added to the homogenous polymer solution, the greater number of 
plasticiser molecules interact with the polymer chains, which thereby weaken the 
intermolecular forces within the polymer molecules and possibly integrating H-bonding 
of glycerol to polymers. Thus, the films become more flexible and soft. Similar results 
have been reported for the effect of glycerol on films (Cheng et al., 2006, Fundo et al., 
2011, Fundo et al., 2014).  
  
3.3 Disintegration time 
Disintegration time is defined as the time needed for a substance to disintegrate 
completely in a given volume of solution (USP37, 2008).  
 
The European Pharmacopeia only states that ODFs “dissolve rapidly” without a defined 
time limit (European Pharmacopoeia Commision, 2013), although the limit of 
disintegration time of 30 seconds or less is a recommended value for ODFs (Barnhart et 
al., 2008), whilst FDA guidance for a related dosage form, orally disintegrating tablets 
(ODTs), suggests a disintegration time of less than 30 seconds but European 
Pharmacopeia state less than 180 seconds (European Pharmacopoeia Commision, 2013). 
The disintegrating time of films was within the range of 6 to 30 seconds (table 3.3). 
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Results showed that the effect of plasticiser on disintegration time was different for 
various polymers (p> 0.05, ANOVA).  
 
Table 3.3- The disintegration time of HPMC, SA, pectin and KP films with glycerol amount added at 5 µl, 
10 µl and 20 µl. Film at 3x2 cm2 were dissolved in 25 mL distilled water at 37 0C (mean ± SD, n=3). No 
statistical difference in disintegration time of different films by amount of plasticiser was observed using 
one way ANOVA, ns (p>0.05).  
 
Polymer Amount of plasticiser Disintegration time 
(s) 
 
HPMC (10,000) 
5 µl glycerol 26 ± 1.15 s 
10 µl glycerol 23 ± 0.58 s 
20 µl glycerol 22 ± 0.58 s 
 
Pectin 
5 µl glycerol 23 ± 1.15 s 
10 µl glycerol 17 ± 0.58 s 
20 µl glycerol 30 ± 0.58 s 
 
Sodium alginate 
5 µl glycerol 11± 0.58 s 
10 µl glycerol 11 ± 0.58 s 
20 µl glycerol 14 ± 0.58 s 
 
Kollicoat Protect 
5 µl glycerol 11 ± 0.58 s 
10 µl glycerol 7 ± 0.58 s 
20 µl glycerol 10 ± 0.58 s 
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Films with weaker tensile strength (section 3.2.4), due to ease in polymeric chain 
movements by the plasticising effect, show an increase in the film water affinity through 
the hydrophilic property of the plasticiser, since the three hydroxyl groups present in the 
glycerol molecules are available for water adsorption (Cheng et al., 2006, Chillo et al., 
2008); all of which leads to the ODF requiring less swelling time, thereby producing fast 
disintegration. In contrast, KP is a synthetic copolymer composed of polyvinyl alcohol – 
polyethylene glycol, which allows itself to act as an internal plasticiser, thus, it dissolves 
faster than other film formulations (Nagar et al., 2011). Given the results from this and 
the previous section, it was observed that 10 µl glycerol in the film formulation was the 
optimum amount to yield the desired mechanical properties and disintegration time in 
accordance with relevant guidance. 
 
3.4 Effect of drug loading 
3.4.1 Mechanical properties of drug loaded films 
The formulations showing the ideal characteristics from the results above were further 
selected for drug loading. Metformin hydrochloride, an oral anti-diabetic drug, was 
chosen as a water soluble drug model for this study. HPMC was not selected further for 
drug loading due to being sticky or difficult to peel off from the non- stick mould and 
turning cloudy upon drug loading. HPMC films become cloudy due to the poor loading 
capacity of the produced ODF, and it has been reported that HPMC type E, as HPMC 
Mwt 10,000, is associated with films being brittle and non-peelable at low concentrations 
(Mahesh et al., 2010).  
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Table 3.4- Film thickness of Metformin HCl- loaded SA, KP and Pectin polymeric films at dose loading 
at 10 mg, 20 mg and 30 mg. The thickness of films made from SA, KP and Pectin increases with a higher 
drug loading (mean ± SD, n=3).  No statistical difference in thickness of different films by amount of dose 
was observed using one way ANOVA, ns (p>0.05).  
 
 
 
Dose 
 
Film thickness (mm) 
SA KP Pectin 
 
10 mg 
 
0.13 ± 0.005 
 
0.12 ± 0.005 
 
0.18 ± 0.006 
20 mg 0.15 ± 0.005 0.14 ± 0.006 0.20 ± 0.005 
30 mg 0.16 ± 0.005 0.14 ± 0.006 0.21 ± 0.005 
 
The average thickness of drug loaded films for SA, KP and pectin varied from 0.13 to 
0.20 mm with an increase of drug loading from 10 mg to 30 mg (Table 3.4). It was 
observed that the presence of drug significantly influenced the mechanical properties (e.g. 
tensile strength, % elongation and Young’s modulus) of the polymeric films in 
comparison to drug free film formulation (p < 0.05, ANOVA followed by Tukey’s test), 
with similar observations recorded for all three types of polymers, as expected (Figure  
3.5 A, B and C). As more hydrophilic drug molecules occupy the polymer matrix, greater 
interactions occur with the polymer chains, which thereby weaken the intermolecular 
forces, thus reducing the mechanical properties of all films (Mali et al., 2008). 
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Figure 3.5-  The influence of drug loading on mechanical properties of drug- loaded films - A) sodium 
alginate B) Kollicoat protect C) Pectin from apple at different dose strength: 10 mg, 20 mg and 30 mg 
compared to blank films ( mean ± SD, n= 3). Statistically significant differences are noted as follow: ns (p> 
0.05) in tensile strength; **** (p <0.0001) in %  elongation and Young’s modulus of SA, KP and Pectin 
films at different amount of drug loading, followed by two way ANOVA. 
 
An increase in drug loading also had an effect on all formulations, although this was 
dependent on polymer type (Figure 3.5 A, B and C). For KP films, increasing the drug 
loading from 10 mg to 30 mg showed no significant difference in tensile strength (p > 
0.05, ANOVA followed by Tukey’s test), yet significant differences were seen in % 
elongation and Young’s modulus (p < 0.05, ANOVA followed by Tukey’s test). Whilst 
for pectin films, there was no significant difference in tensile strength and % elongation 
(p > 0.05, ANOVA followed by Tukey’s test), but a significant difference in Young’s 
modulus (p < 0.05, ANOVA followed by Tukey’s test), which indicated that KP and 
pectin films became even softer when the amount of drug was increased, having a strong 
effect on the Young’s modulus. This indicates that the presence of water- soluble drug in 
a higher concentration promotes softening of the polymer, suggesting that the drug could 
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have an additional plasticising effect on the films produced. Moreover, it is seen that drug 
loading affects the mechanical properties of the polymeric film, due to the differences in 
chemical structure of the polymer. KP film is a highly flexible polymer due to the 
presence of polyvinyl alcohol that acts as an internal plasticiser (BASF, 2007). Pectin 
generated thicker films with an increase in drug loading, whilst extra force was required 
for breaking the films, which indicates a higher tensile property of pectin compared to the 
other two polymers. The higher Young’s modulus value of pectin corresponds to the 
stiffness of films due to its colloidal thickening properties (Galus and Lenart, 2013). SA 
films have the lowest mechanical properties compared to KP and Pectin, showing that 
films become ductile and more flexible as more drug molecules are incorporated into the 
material, promoting a higher mobility between polymer chains. Also, Metformin HCl is 
a hygroscopic drug, and therefore responsible for moisture uptake during handling (Barot 
et al., 2010). 
Results illustrated that drug loading has a significant effect on the mechanical properties 
within the boundaries investigated.  
 
3.4.2 Disintegration time of drug loaded films 
The disintegration time of drug loaded films is generally faster than that of blank films. 
All drug loaded films were completely dissolved in less than 40 seconds, fulfilling the 
criteria of fast dissolving films (Table 3.5). KP films showed the shortest disintegration 
time – within 5 seconds for all levels of drug loading – due to the hydrophilic nature of 
the polymer and the plasticising effect of the drug, which is readily soluble in water, 
whereas pectin based films required more than 20 seconds to fully dissolve, but still less 
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than one minute; due to its highly colloidal properties, pectin tends to dissolve slowly as 
it is a high molecular weight compound composed of a complex of heteropolysaccharides, 
whose carboxylic acid groups are present in ester form, which are responsible for the 
extent of solubility of pectin (Nagar et al., 2011, Galus et al., 2012). SA is a hydrophilic 
colloidal polymer, which consists of the sodium salt of alginic acid, that makes films 
dissolve quickly in water (within 10 seconds). 
  
Table 3.5- Disintegration time of drug-loaded films made from sodium alginate, Kollicoat protect and 
pectin. Film at 3x2 cm2 were dissolved in 25 mL distilled water at 37 0C (mean ± SD, n=3). No statistical 
difference in disintegration time between SA and KP films, but recorded significantly difference in Pectin 
films by amount of dose was observed. 
 
Film forming 
polymer 
Amount of 
drug loading 
Disintegration time of films (s)  
 
Sodium alginate  
No drug 
10 mg  
12  ± 1.15 s 
8 ± 0.58 s  
20 mg 9 ± 0.58 s 
30 mg 10 ± 1.53 s 
 
Kollicoat Protect 
No drug 
10 mg  
7  ± 0.15 s 
5 ± 0.58 s 
20 mg 5 ± 0.58 s 
30 mg 4 ± 0.58 s 
 
Pectin 
No drug 
10 mg 
45 ± 1.58 s 
42 ± 2.65 s 
20 mg 40 ± 2.08 s 
30 mg 25 ± 2.08 s 
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 Incorporating higher quantities of API can be seen to influence the disintegration profile 
of films; films with weaker tensile properties and high flexibility (section 3.4.5) require 
less time for rupture of the films, which is evident with faster disintegration times for all 
formulations upon high levels of drug loading (Sungthongjeen et al., 2004). Pectin films 
disintegrated faster as the facilitate action of hydrophilic drug, especially at higher doses. 
 
3.4.3 FTIR studies 
To investigate the interaction between metformin HCl and polymers in the films, the 
FTIR spectrum of the polymer, drug, physical mixture and drug-loaded films were tested 
between wavelengths 4000 – 500 cm-1 by Thermo Scientific Nicolet IS5 Spectrometer. 
KP demonstrates  a broad absorption band at 3302 cm-1, corresponding to the hydroxyl 
group, sharp bands at 1727 to 1709 cm-1 and 1041 cm-1 of the stretching vibration of (-
C=O) group, with the C-H stretch vibration occurring in the region of 2361 to 2155 cm-1 
(Figure 3.6). Sodium alginate displays a broad absorption band at 3274 cm-1 of the 
hydroxyl group, sharp bands recorded at 1593 and 1081 cm-1 of the asymmetric stretching 
vibration of carboxyl (-COO) group and  characteristic bands at 2361 to 2155 cm-1 
assigned to C-H stretch vibration (Figure 3.7) (Daemi and Barikani, 2012). Pectin 
exhibited a broad absorption band at 3375 cm-1 of O-H stretch, sharp band at 1733 cm-1 
of the stretching vibration of (-C=O) group and strong bands at 1014cm-1 of C-O 
stretching band (Figure 3.8) (Seslija et al., 2016) 
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Figure 3.6- FTIR of Metformin HCl, KP, physical mixture and drug loaded KP films 
 
The incorporation of drug at 10 mg dose into the film caused a significant reduction in 
the intensity and band shift from 1727 to 1715 cm-1 for the -CO group observed in all 
spectra. A new band formation at 1087 cm-1 in the drug-loaded film (10 mg) indicated the 
possible strong arrangement of C-O group due to hydrogen bonding (Figure 3.6, 3.7 and 
3.8). However, the intensive absorption bands of drug were observed in the films with 20 
mg drug loading. The N-H stretching of C=N-H group has strong absorption peak at the 
range of 3387 - 3156 cm-1. A weak intensity band at 1035 cm-1 corresponded to C-N 
stretching was observed and this could overlap with the C-O band from the polymer. The 
drug interaction with polymer at higher doses can explain further the influence of amount 
of drug loading on the mechanical properties of these film formulations by showing a 
strong peak intensity of drug in the spectrum of all film loaded drugs (20 mg). The 
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apparent differences between the drug loaded films and the physical mixtures might be 
masked by the film peaks, particularly as they were used in less quantity than the polymer.  
     
Figure 3.7- FTIR of Metformin HCl, SA, physical mixture and drug loaded SA films. 
 
    
Figure 3.8- FTIR of Metformin HCl, pectin, physical mixture and drug loaded Pectin films. 
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3.4.4 Disintegration time of commercial products 
Several commercialised ODFs, such as Listerine and Nicotine strips, were studied for the 
disintegration times for comparison to the developed ODF formulations. The reported 
data showed that Listerine displayed a rapid disintegration (7 seconds) (Dave et al., 2014), 
whereas the disintegration time of NiQuitin strip containing 2.5 mg API was 120 seconds. 
In contrast, Gas- X® thin strips, containing 62.5 mg API, disintegrates within 60 seconds 
(Table 3.6). The disintegration time reflects on the amount of drug loading and the type 
of polymer used based on the release target. Listerine Oral Care strips, using pullulan as 
a film former with loading of inactive ingredients, showed fast release as pullulan is a 
hydrophilic polymer (Nagar et al., 2011). Nicotine strip was formulated using Eudragit 
L100 polymer, which is a combination of methacrylic acid and ethylacrylate, for 
controlled time release of active ingredient via pH- dependent swelling (Sonje and 
Chandra, 2013). Modified starch was chosen for developing Gas- X® thin strips as it is 
widely used for coating of immediate release dosage forms with a low production cost 
(Dixit and Puthli, 2009, Nagar et al., 2011). Due to its high solubility profile, film 
formulations made of KP polymer displayed the shortest disintegration time, comparable 
to commercial ODF products. Results confirmed that the optimised film formulations 
have satisfactory physicochemical properties compared to market products based on the 
type of polymer chosen for fast delivery system. 
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Table 3.6- Comparison of disintegration time of drug- loaded film formulation and commercial products. 
 
Formulation Drug loaded film formulation Commercial products 
SA Pectin KP Listerine 
® 
Gas- X thin 
strips 
Niquitin 
strips 
Dose 10 mg 10 mg 10 mg N/A 62.5 mg 2.5 mg 
Time (s) 8 ± 0.58 42 ± 2.65 5 ± 0.58 7 ± 1.1 58 ± 2.7 120 ±0.58 
 
 
3.5 Uniformity of dosage form 
It is important for new dosage forms to achieve the consistency of dosage units. Each 
batch unit should comply within the acceptable limit of the label claim, 85- 115 %, 
according to British Pharmacopeia (BP, 2013). The quality control is carried out by two 
methods: weight variation or uniformity of content. Both SA and KP film formulations 
were assessed according to the standard of British Pharmacopeia, followed by the relevant 
testing for solid dosage forms (BP, 2013). Pectin was not selected further for this test due 
to films being so brittle with high amount of drug loaded when peeling off. 
 
3.5.1 Uniformity of weight  
The deviation of individual weight from the drug-loaded SA films at 10 mg and 20 mg 
dose loading was 2.54 ± 0.22 mg (% RSD of 8.55) and 2.92 ± 0.28 mg (% RSD of 
9.56)), respectively. The weight uniformity of drug- loaded KP films at 10 mg and 20 
mg dose loading was 2.88 ± 0.33 mg (% RSD of 9.97) and 2.94 ± 0.25 mg (% RSD of 
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8.44), respectively. Each batch of formulation showed RSD of less than 10%. Thus, 
the preparation met the criteria of BP (2013) weight uniformity (Table 3.7).  
 
Table 3.7- Summary of weight uniformity of SA and KP film formulation at 10 mg and 20 mg drug dose 
(mean ± SD, n= 20). 
 
Formulation  Weight uniformity 
(mean ± SD), n= 20 
% RSD 
SA film-10mg Met HCl 2.54 ± 0.22 8.55 
SA film-20mg Met HCl 2.92 ± 0.28 9.56 
KP film- 10mg Met HCl 2.88 ± 0.33 9.97 
KP film- 20mg Met HCl 2.94 ± 0.25 8.44 
   
3.5.2 Uniformity of content 
Although the general acceptable limit of the label claim of each unit should be 85- 115 
%, depending on the dosage form, drug type and doses, the criteria are stated differently 
in the monograph. The criteria of BP content uniformity for Metformin HCl should be 
within the range of 98.5-101 % (BP, 2015). However, the content percentage of 
metformin HCl in the films was found to be 114.44 ± 4.67 % and 113.42 ± 6.59 % for SA 
and KP films, respectively (Table 3.7). Thus, these preparations failed to meet the criteria 
of content uniformity, which indicated that metformin HCl distributed unevenly in the 
films. Since the portion of film used for analysis was taken from the centre of the dried 
films, drugs were accumulated in the middle of the baking mould after drying, which may 
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explain the reason of higher percentage content uniformity. Therefore, using a baking 
mould for solvent casting may not be the most appropriate method for film preparation. 
 
3.6 Method Development of Film Manufacturing 
As mentioned in section 3.5.2, the previous method is not the appropriate method for film 
development due to the failure to achieve the required content uniformity. Hence, an 
alternative system, employing the Elcometer 4340 film applicator, was investigated to 
accomplish the criteria and produce reproducible uniform films under mini industrial 
scale. 
 
3.6.1 Elcometer 430 Film Applicator 
 The Elcometer Film Applicator is a robust, reliable, easy handling equipment for 
applying uniform and reproducible film products, based on the principal application of 
solvent casting technology. Solvent casting method involves the process which water - 
soluble polymers are firstly dissolved in water to form uniform clear viscous solutions 
with the following addition of drug and other excipients, to form a homogenous solution, 
subsequently cast on the substrate and evaporated during the drying period (Siemann, 
2005). The applicator is operated by numerous controls mounted on the front panel of the 
instrument (Figure 3.9).  
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Figure 3 9- Schematic parts of Elcometer 4340 Motorised Film Applicator 
A-Table, B- Substrate, C- Carriage, D- Carriage speed, E- Carriage return, F- Carriage start, G- Control 
system, H- Temperature control/ display. 
 
3.6.2 Uniformity of Content  
Following on from the optimisation process above for the content uniformity of films, 
metformin HCl loaded KP and SA films were carried out for further investigation using 
the Elcometer. Results showed that all films achieved the desired content uniformity 
when uniformity in thickness is maintained, as expected (see table 3.8), compared to the 
baking tray method. This indicates that metformin HCl distributed evenly in the films 
and, hence, the Elcometer Film Applicator was ideally chosen for further study of film 
formulation and development. 
 
B 
A 
F 
C 
D 
G
G 
E 
H 
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Table 3.8- Comparison of content uniformity of Metformin HCl loaded films using baking tray and 
Elcometer method. 
Parameters 
 
Baking Tray  Elcometer method 
SA film KP film SA films KP films 
Thickness (mm) 0.13 ± 0.005 0.12 ± 0.005 0.14 ± 0.01 0.14 ± 0.01 
Content 
uniformity  
114.44 ± 4.67 % 113.42 ± 6.59 % 99.15 ± 4.45 % 101.35 ± 4.25 % 
 
 
3.7 Conclusion 
In order to optimise the formulation of ODFs, it is first critical to screen the components 
used in the formulation, as they can greatly influence the physicochemical and 
mechanical properties of the films produced. The choice of polymers to be used as film 
formers are important, as they are the major component in the formulation and can 
influence not only the tensile properties of the films, but also impact on drug release. 
After initial screening of a range of polymers, SA, pectin, and KP were selected as film 
forming polymers, as they exhibited good texture with excellent film forming capacity; 
other polymers were excluded from further studies, as they were difficult to peel or no 
film developed. These selected polymers were studied with plasticisers (glycerol, PEG 
400 and Tween 80), with only glycerol proving to be suitable, as films obtained adequate 
mechanical properties to handle, possibly due to glycerol being a molecule with smaller 
molecular weight and size, thus possibly achieving greater interaction by H- bonding with 
the film forming polymers. Different amounts of plasticiser used also significantly 
influences the mechanical properties as well as the disintegration time of films. The 
tensile properties of all film formulations were decreased with an increase in the 
plasticiser amount (5 µl, 10 µl and 20 µl per 3 x 2 cm2 strip), indicating that the 
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plasticising effect has taken place. Amount of plasticiser (10 µl glycerol) achieved the 
optimum mechanical properties in the film formulation. Results indicated that the film 
forming was governed by the amount of plasticiser and the amount of polymer could 
influence on the structural rearrangement of films. The reason is that glycerol on the 
polymer chains reduce the spaces of polymer molecules, which are available for the 
hydroxyl groups for water adsorption (Cheng et al., 2006). 
 
Drug loading of the selected film formulations resulted in further reductions in tensile 
properties (e.g. tensile strength and elastic modulus of films were reduced, but the 
percentage elongation was increased) at different dose strengths. The results showed that 
the loading of drug into films produced more flexible films, as further plasticising effects 
have occurred, due to the hydrophilic nature of the drug investigated. The disintegration 
time of drug-loaded films was faster than that of blank films, which was expected, since 
films with weaker tensile strength require less swelling, thereby producing fast 
disintegration. The study of drug- polymer interaction using FTIR suggested the 
interaction of polymer and drug via the formation of hydrogen bonding. All films showed 
good uniformity in weight. However, the content uniformity of films failed to meet the 
pharmacopeia criteria due to uneven distribution of drugs in the films. These results 
showed that the solvent casting method by baking mould was not suitable for oral 
dissolving film preparation. A new alternative method has been approached for further 
ideal film development in order to achieve content uniformity.  
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Overall, the optimisation of formulations for oral dissolving films was achieved through 
the selection of parameters such as preparation method of casting films, polymer selection 
and properties of drug that produced films with desired properties. 
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Chapter 4 
Investigation into the effect of cyclodextrin 
complexation on drug loading, content 
uniformity and solubility of poorly water soluble 
drug loaded ODFs 
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4.1 Introduction 
The rate and extent of drug absorption is governed by two key factors; the solubility and 
permeability of a drug (Miller et al., 2012). According to the Biopharmaceutical 
Classification System (BCS), drug candidates are divided into four classes based on their 
permeability and solubility profile (Amdion et al., 1995, Yu et al., 2002) (Table 4.1). A 
highly soluble drug is a substance that, at the highest dose strength, is soluble in 250 mL 
or less of aqueous media over the pH of 1- 7.5 at 37 0C, while a highly permeable drug 
achieves the extent of absorption of greater than 90 % of the total administrated dose 
(FDA, 2015). Class I drugs dissolve rapidly across the gastrointestinal membrane when 
administrated, with the rate limiting step of this class  of drug being the gastric emptying 
rate when the dissolution is fast. In contrast, class II comprises relatively poorly water- 
soluble drugs, with aqueous solubility of < 0.1 mg/ mL, yet with a high absorption profile; 
thus, in-vivo dissolution becomes the rate limiting step in this case. Class III drugs 
encompasses water soluble substances that have permeability as the rate of limiting step 
for absorption; hence, it is vital to design this drug class to be released rapidly for 
maximising its residence time in the gastrointestinal tract in order to improve 
permeability. Conversely, class IV drugs are mainly water insoluble drugs, which also 
suffer from poor permeability and, as a result, exhibit poor oral bioavailability. Currently, 
it its estimated that a large number of new chemical entities (up to 70 %) undergoing 
development are generally high molecular weight, poorly soluble and lipophilic 
compounds, which affects the rate and extent of oral drug absorption across the 
gastrointestinal mucosa (Kakran et al., 2012, Ku and Dulin, 2012, Kurkov and Loftsson, 
2013). Despite their high permeability, the associated low aqueous solubility and slow 
release of drugs in the gastrointestinal tract results in low oral bioavailability, leading to 
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consequences such as ineffective treatment, frequent dose escalations to achieve 
therapeutic effects, and increased levels of toxicity (Kawabata et al., 2011).  
 
Solubility is a fundamental parameter that plays an important role for oral dosage forms 
to reach desired therapeutic drug concentrations following absorption via oral 
administration (Savjani et al., 2012). Most of active pharmaceutical ingredients (APIs) 
used during the formulation design and development stages are poorly-water soluble. 
They are eliminated from the gastro-intestinal tract (GIT) before getting absorbed in the 
systemic circulation, which causes limited bioavailability. Whereas, the permeability is 
the diffusion of drug across the GIT membrane (Martinez and Amidon, 2002), which is 
also a crucial step in the determination of bioavailability, is determined by the 
physicochemical factors of drug, including molecular size, polar-/non-polar surface area, 
lipophilic or hydrophilic property, as well as other physiological properties of GIT (e.g. 
GIT pH, blood flow, gastric emptying and absorption mechanism) (Martinez and 
Amidon, 2002, Song et al., 2004, Dahan et al., 2009).      
   
Moreover, in addition to the issues pertaining to solubility and permeability, most 
therapeutic drugs have a bitter taste and it becomes a serious problem affecting patient 
compliance and acceptability, particularly to paediatric patients. Hence, several 
techniques of taste masking have been employed to provide a palatable and pleasant taste, 
including using sweetening agents (Sohi et al., 2004), coating with polymers (Douroumis, 
2007), ion- exchange resin (Puttewar et al., 2010) or forming complexation (Arima et al., 
2012).   
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Furthermore, development of new formulations with high drug loading becomes a 
challenge as a result of poor powder flowability and sticky tendency, which affects the 
content uniformity of the final dosage form (Shanmugam, 2015). Regarding to ODF 
formulations, a high amount of drug loading is an even greater problematic issue for film 
development, since the size of dosage form is the limiting factor (Dixit and Puthli, 2009). 
Besides that, a poor solubility profile of a drug, especially those belonging to BCS class 
II, could influence the disintegration/ dissolution of the film in the oral cavity as a 
consequence of the limited amount of saliva solution in the oral cavity (Shanmugam, 
2016), thus negating the intention of fast disintegration without the need of water.   
 
Table 4.1- Biopharmaceutical Classification System of Drug Substances adapted 
from Wu and Benet (Wu and Benet, 2005) . 
 High solubility Low solubility 
High permeability Class I 
Acetaminophen 
Chlorpheniramine 
Midazolam 
Nifedipine 
Class II 
Diclofenac 
Glipizide 
Ibuprofen 
Loratadine 
   Low permeability Class III 
Captopril 
Cetirizine 
Metformin 
Ranitidine 
Class IV 
Amphotericin B 
Ciprofloxacin 
Furosemide 
Neomycin 
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As solubility and permeability are the important factors that determine the bioavailability 
of APIs, solubility can be modified by different strategies to enhance the solubility profile, 
such as salt formation for both acidic and basic drugs (Berge et al., 1977, Elder et al., 
2013), pH adjustment (Vemula et al., 2010), particle size reduction (Rabinow, 2004), 
solid dispersion (Vo et al., 2013) and complexation (Loftsson and Duchene, 2007). 
Particle size reduction can be achieved by milling and creating nanosupensions, which 
produce smaller particle sizes with great surface area. However, milling and other 
techniques can lead to aggregation of particles and, consequently, reduction in flow 
capacity and wetting properties due to restricted surface area; as well as an extreme 
amount of mechanical forces applied to drug substances, which induce drug degradation, 
resulting in insignificant or no dissolution improvement. Alternatively, the complexation 
of poorly soluble drugs with cyclodextrins has been used to improve the aqueous 
solubility, palatability and  stability of drugs due to their unique structures and their ability 
to modify the physicochemical properties of guest molecules (Miranda et al., 2011).  
 
4.1.1 Complexation 
Discovered in 1891 by Villiers (Villiers, 1891), cyclodextrins (CDs) are natural 
molecules comprising a family of cyclic oligosaccharides derived from starch through 
fermentation in a cyclic manner to produce six, seven and eight glucopyranose units 
known as α, β, γ CDs, respectively (Figure 4.1) (Vyas et al., 2008). CDs possess the 
shapes of truncated cone made up from 1,4 glycosidic bonds with a hydrophilic exterior, 
whereas the internal cavity creates the lipophilic character consisting of a specific volume 
(Loftsson and Duchene, 2007).  
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Figure 4.1- General chemical structure of beta cyclodextrin comprising of seven glucopyroranose units, 
where n=1. Correspondence of “n” to 0 or 2 represents the structure of alpha and gamma CD, respectively. 
 
The cavity size is the major parameter to define their binding affinity of each sub- group 
natural CD for complexation (Challa et al., 2005, Concha-Santos et al., 2013). For 
example, beta CDs are the most widely used and are suitable for encapsulation of a wide 
range of drugs, especially for cyclic molecules. Alpha CDs tend to prove insufficient in 
drug inclusion due to having the smallest cavity size, while gamma CDs are the largest 
but display a weaker complex ability than the other two CDs (Challa et al., 2005). 
 
   
Figure 4.2- Schematic diagram of the formation of inclusion complexation of drug and cyclodextrins. 
Adapted from Mura (Mura, 2014). 
Chapter 4  CD complexation loaded ODFs 
 
 
124 
 
 
These molecules were used primarily for their solubilising effect, whilst also serving as 
drug carriers through the formation of inclusion complexes to accommodate many drugs 
(Fig. 4.2), including polar, non-polar, aliphatic and aromatic molecules (Szejtli, 1998). 
Yet, the aqueous solubility of natural CD molecules is still limited due to strong 
intermolecular hydrogen bonding, which affects the complexation. Various CD 
derivatives were synthesised to extend the physicochemical properties and inclusion 
capacity for enhancing the aqueous profile. They exhibit a higher degree of substitution 
of hydrogen bond- forming hydroxyl group, and even by lipophilic methoxy functions, 
results in dramatic improvement in their aqueous solubility compared to the traditional 
CDs (Loftsson and Duchene, 2007). For example, synthetic derivatives of β-CD, such as 
methyl-β-CD and hydroxypropyl β-CD (HPCD), are also accessible for formulation of 
poorly soluble drugs, as they offer better solubility, but their use is limited by the level of 
toxicity and cost (Miranda et al., 2011). Depending on the properties of the different 
types, CDs have found extensive use in pharmaceutical formulation; hydroxypropyl β-
CD and sulfobutyl ether-βCD, serving as the hydrophilic CDs, are widely used for 
improvements in dissolution and absorption of poorly water-soluble drugs (Hirayama and 
Uekama, 1999), whereas the hydrophobic CDs, such as ethylated and acylated CDs,  are 
useful as carriers for sustained release of water-soluble drugs (Loftsson and Brewster, 
1996). Chemical modifications of CDs were investigated for enhancement of  the 
transdermal and rectal absorption of drugs for local and systemic use (Matsuda and 
Arima, 1999), as well as to improve the chemical stability of peptide and protein drugs 
(Bilati et al., 2005, Vyas et al., 2008). The introduction of hydrophilic polymer on drug 
– cyclodextrin complexation have shown an enhancement in the solubilising effect of 
CDs for irbesartan, a poorly water- soluble drug, by studying a range of polymer 
concentrations (Loftsson and Brewster, 1997, Mura et al., 2001, Hirlekar et al., 2009) . 
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Complexation of CD also improves the palatability of many bitter drugs as they inhibit 
the contact of drug particles to taste buds, thereby providing taste masking effect (Sohi et 
al., 2004).   
 
4.1.2 Glipizide, poorly water- soluble model drug  
Glipizide (Figure 4.3) has the molecular formula C21H27N5O4S with the molecular weight 
of 445.535 and a water solubility of 37.2 mg/ L (DrugBank, 2015). 
 
  
 
Figure 4.3- The chemical structure of glipizide 
 
Glipizide is used as an oral and short acting anti- diabetic drug. It belongs to the second 
generation of sulfonylurea, which is more potent in the suppression of the blood glucose 
level in patients with type 2 diabetes. It works as a potassium blocker by binding to the 
potassium channel receptor on the cell surface of the pancreas, resulting in depolarisation 
of the channel. Consequently, this depolarisation triggers the opening of voltage - gated 
calcium channels, which induce the release of insulin. Glipizide was introduced into the 
market under brand names of Glucotrol, Glucotrol XL, GlipiZIDE XL, Minidias, 
Glibetin. They are prescribed in tablet forms available at 2.5 mg, 5 mg and 10 mg.  
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This study aims to formulate ODFs for paediatric patients, incorporating the poorly 
soluble drug, glipizide, an oral anti- diabetic drug for the treatment of type II diabetes. 
The objective was to study the effect different types of CDs on the improvement of 
aqueous solubility of glipizide by forming inclusion complexes and enhancing the 
perception of bitter taste of drug, as well as potentially increasing the drug loading and 
content uniformity within the ODF.  
 
4.2 Results & Discussion 
4.2.1 Phase solubility studies of glipizide 
The phase solubility diagrams of glipizide with different types of CDs within the 
concentration range studied displayed a typical AL type, where the aqueous solubility of 
the drug increases linearly as the function of CD concentration (Figure 4.4), thus proving 
a certain degree of its inclusion complexation in aqueous solution. The linear correction 
with slope less than 1 indicating the formation of a 1:1 complexation is achieved. The 
binding constant showed an increase of 34 M-1, 83 M-1, 200 M-1 and 222 M -1, for α CD, 
γ CD, β CD and HPCD, respectively. The lower stability constant given by the  α -  and  
γ- CD complexes suggests that the weaker interactions are more labile, thus leading to 
the premature release of drug (Szejtli, 1984). On the other hand, the higher stability 
constant of β CD and HPCD could show the better compatibility of the guest molecule 
and the strength of the interaction by partial fit into the CD cavity (Szejtli, 1984, Becket 
G S, 1999). 
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Figure 4.4- Phase solubility diagram of glipizide- alpha CD (), glipizide-beta CD (), glipizide- 
gamma CD (∆) and glipizide- HPCD () systems in water at 25 ± 0.5 0C (mean ± SD, n=3). A 
typical AL type was observed, where the aqueous solubility of the drug increases linearly as the 
function of CD concentration. 
 
 
4.2.2 Solubility studies 
The solubility profiles of glipizide and the CD complexes are shown in table 4.2. The 
solubility of glipizide in water was found to be 0.036 mg/mL, which is in agreement with 
the literature value (Dehghan et al., 2010), whereas the use of CDs significantly enhanced 
the solubility of glipizide in both water and PBS (p < 0.0001, ANOVA followed by 
Tukey’s test). Also, there were significant improvements in solubility of the poorly water 
soluble drug, glipizide, by individual CD complexes in comparison to each other (p < 
0.05, Tukey’s test) at the two media. Although there was an increase in solubility for 
glipizide in water, alpha CD complexation showed less efficiency in increasing the 
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solubility profile in water than the other CDs, as alpha CD itself has a limited aqueous 
solubility due to the strong intermolecular hydrogen bonding, thus restricting some 
hydroxyl groups coming into contact with water (Sapkal, 2013). In contrast, F4 
formulation (HPCD complexation) showed great enhancement in the aqueous profile of 
this drug, as HPCD is a chemical modification of beta CD having a higher solubilising 
effect in water, compared to the pure drug (p < 0.001 Tukey’s test). On the other hand, 
the aqueous profile of the poorly soluble drug, glipizide, gained improvement by using 
the beta or gamma complexation, despite the fact that these natural CDs molecules still 
retained their limited aqueous solubility due to strong intermolecular hydrogen bonding 
(Loftsson and Duchene, 2007). 
 
Table 4.2- Comparison of solubility profile of glipizide from various complexes in distilled water and 
phosphate buffer solution pH 7.4 (n=3, mean ± SD). All the complex formulation showed statistically 
significant difference compared to the pure glipizide either in distilled water or PBS solution with p < 
0.0001, two way ANOVA, Tukey’s test). The aqueous profile of glipizide enhanced by the effect of 
individual CD complex, p < 0.05. 
 
Formulation Solubility in distilled 
water (mg/ml) 
Solubility in phosphate 
buffer pH 7.4 (mg/ml) 
Pure Glipizide 0.036 ± 0.001 0.199 ± 0.003 
Alpha CD/ Gli complex 0.22 ±  0.002 0.33 ± 0.002 
Beta CD/ Gli complex 0.34 ± 0.001 0.57 ± 0.005 
Gamma CD/ Gli complex 0.37 ± 0.002 0.38 ± 0.002 
HPCD/ Gli complex 0.41 ± 0.004 0.46 ± 0.016 
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However, it was observed that the CD complexation enhanced the solubility of glipizide 
more effectively in the phosphate buffer solution. As expected, the solubility of glipizide 
increased in higher pH since glipizide is a weak acidic drug with pKa of 5.9, thus glipizide 
becomes more ionised in solution – the weakly acidic sulfonylurea groups of glipizide 
become protonated at higher pH,  due to the delocalisation of the nitrogen electron pair 
from the sulfonyl group (Jamzad and Fassihi, 2006). Nevertheless, the complexation 
revealed no great effect for F3 and F4 formulation either in water or PBS solution. This 
is possibly as a consequence of the drug and CD complexes forming water-soluble 
aggregation via hydrogen bonding, promoting solubilisation of the drug through non- 
complexation formation (Maragos et al., 2009). 
 
4.2.3 FTIR studies  
FTIR analysis was performed on glipizide, KP, CD and drug- loaded films at 5 mg dose 
(Figure 4.5, 4.6, 4.7 and 4.8). The IR spectrum of pure CD (i.e. alpha, beta, gamma and 
HPCD)  was characterised by a broad peak at 3329 cm-1 due to strong hydrogen bonding, 
and small sharp peaks at 2931 cm-1, 1633 cm-1, 1409 cm-1, 1023 cm-1 and 996 cm-1, 
corresponding to stretching associated with the absorbance of O-H, C-H, C-O functional 
group, respectively (Figure 4.5, 4.6, 4.7 and 4.8) (Gil et al., 2004, Dua et al., 2011). 
Glipizide showed the major double peaks at 3329- 3241 cm-1 due to NH-CO stretch, as 
well as other prominent peaks at 1651 cm-1 (CONH stretching), 1598 cm-1 (C=N stretch), 
1370 cm-1 (SO2NH Stretching), 1142 cm
-1 (cyclohexyl stretching), 1651 cm-1 (C=O, 
Urea) (Behera et al., 2008, Jain and Saraf, 2009). KP demonstrates a broad absorption 
band at 3200 cm-1 of hydroxyl group, sharp bands at 1727- 1709 cm-1 and 1041 cm-1 
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associated with C=O stretching. The position of all absorption bands remained the same 
as in the spectrum of each component in the spectrum of the physical mixture. However, 
no peak of drug and complex was observed in the KP film, which suggests that the NH 
group of Glipizide emerged with the broad band of alpha CD in the same region of 
hydroxyl group. Furthermore, the drug and the complex could potentially form hydrogen 
bonding due to their broad band observed at the hydroxyl regions. Yet, these may well be 
masked by the film peaks, particularly as they were used in less quantity than the KP. 
Hence, other analyses are needed to determine its presence in the film formulation. 
 
      .
 
Figure 4.5- FTIR of glipizide, alpha CD, KP and glipizide - CD complex and drug-loaded KP film. 
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Figure 4.6- FTIR of glipizide, beta CD, KP and glipizide - CD complex and drug-loaded KP film. 
 
     
 
Figure 4.7- FTIR of glipizide, gamma CD, KP and glipizide - CD complex and drug-loaded KP film. 
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Figure 4.8- FTIR of glipizide, 2- HPCD, KP and glipizide - CD complex and drug-loaded KP film. 
 
4.2.4 DSC studies 
The thermogram of alpha CD exhibits three exothermic peaks at 80 0C, 106 0C and 120 
0C, which correlates to previous reports in the literature (Figure 4.9) (J Szejtili, 1988). In 
case of the DSC curve for beta CD, the wide endothermic peak was recorded from 86.22 
0C- 118.66 0C corresponding to the dehydration of water molecules within the CD cavity 
(Figure 4.10) (Dua et al., 2011). Pure gamma CD exhibited the broad endothermic peak 
in a range of temperature of 50 0C – 150 0C, which is corresponding to the evaporation of 
water (Figure 4.11) (Gil et al., 2004). Because of its amorphous form, HPCD showed a 
broad endothermic peak at about 96 0C and this peak is related to dehydration of water 
molecules within the CD cavity (Figure 4.12) (Kohata et al., 1993). Pure powdered 
glipizide displayed a melting endothermic peak at 213.30 0C with the fusion enthalpy of 
302.6 J/g, which suggests that the drug is in the anhydrous crystal form. The thermograms 
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of the glipizide- CD complexes express the presence of each component at a similar 
temperature to those thermograms of the raw materials due to their physical mixing. 
Blank KP films showed mainly the dehydration of water from 52- 91 0C, since KP is a 
polyvinyl alcohol-polyethylene glycol graft copolymer, where the polymer chains are 
composed of large amount of hydroxyl group (-OH group). The change of the drug 
melting peak position from 213.30 0C to 156 0C and intensity in glipizide- CD complex 
loaded film formulations could be attributed to the inclusion of glipizide in the CD cavity, 
which can sterically hinder the melting formation of the drug or a possible reduction in 
crystallinity upon complexation, where the changes were not recorded with the glipizide- 
CD complex scans. The appearance of low peak density of drug corresponds to the low 
amounts compared to the polymer that might masked the CD complex and possibly the 
reason that some of these thermal events cannot be detected well (Figure 4.9, 4.10, 4.11 
and 4.12). Overall, DSC data did not show Tg of KP, and the effect of drug on Tg, 
perhaps, polymer and the complex remain its amorphous form. 
  
Figure 4.9- DSC of glipizide, alpha CD, KP and glipizide - CD complex and drug-loaded KP film.  
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Figure 4.10- DSC of glipizide, beta CD, KP and glipizide - CD complex and drug-loaded KP film. 
 
  
 
Figure 4.11- DSC of glipizide, gamma CD, KP and glipizide - CD complex and drug-loaded KP film. 
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Figure 4.12- DSC of glipizide, HP CD, KP and glipizide - CD complex and drug-loaded KP film. 
 
4.2.5 Moisture content 
According to the moisture content allowance relating to Kollicoat protect (up to 5 %) 
(BASF, 2007), blank KP films remained stable as they achieved the acceptable boundary 
for moisture content (BASF, 2007). This is attributed to the strong barrier properties of 
KP against water vapour (Yadav, 2013). Percentage moisture uptake varied within the 
range of 0.45 ± 0.17 % to 1.02 ± 0.13 % at room temperature and of 0.52 ± 0.28 % to 
1.53 ± 0.21 % in desiccators at room temperature (Figure 4.13). Nevertheless, these two 
storage conditions showed no significantly changes in weight for all films studied 
between day 0 to day 7 (p > 0.05, ANOVA followed by Tukey’s test), further confirming 
the barrier properties of KP against water. It was also seen that beta CD/ glipizide 
complex loaded films have the lowest moisture content in both conditions (p < 0.01, 
ANOVA followed by Tukey’s test), since beta CDs possess a high number of 
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intramolecular hydrogen bonding between the matrix that causes a decrease in the chain 
mobility, thus restricting the permeability of water vapour (Loftsson and Duchene, 2007). 
Conversely, alpha and gamma CD complexes possess weaker interactions within the 
cavity, which are more labile to exposure to water vapour in room temperature. However, 
the moisture content of HPCD complex loaded KP films is higher than that of the other 
natural CDs (p < 0.05, ANOVA followed by Tukey’s test); since HPCD is a chemical 
derivative of natural beta CD, where an increase in substitution level is optimal for 
complexing capacity, this could distort the CD ring structure by weakening the 
intramolecular hydrogen bonding, which possibly allows water molecules to be more 
readily absorbed into the matrix (Miranda et al., 2011). The incorporation of a 
complexation with less hydrophilic character inside the hydrophilic polymer could  
reduce the water absorption of films in comparison with the control blank film, as there 
may be cross- linking between the polymer and the complex, and hence minimising the 
migration of CD molecules and the drug molecules towards the polymer surface, causing 
the reduction of water absorption (López-de-Dicastillo et al., 2011) .  
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Figure 4.13- Moisture studies for blank KP films and films containing glipizide-CD complexes at A) room 
temperature (25 ± 20C) and B) in the desiccator at day 1 and day 7. The percentage moisture uptake is 
measured based on the final weight of the film in comparison to the initial weight of the film when freshly 
prepared at initial day. No significantly difference in the weight of films stored at room temperature and in 
desiccator from the initial day to day 7 (p< 0.05, Tukey’s test). 
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4.2.6 Mechanical properties of films  
 
4.2.6.1 The effect of CD complexation 
 
The mechanical properties of ODFs were evaluated through their strength and elasticity.  
A soft, adequately strong film should retain moderate tensile strength, high % elongation, 
and low elastic modulus (Mashru et al., 2005). All film achieved uniformity in thickness 
(0.14 µm) regardless to different types of complexation. Films loaded with different types 
of glipizide-cyclodextrin complex at 10 mg dose were flexible, transparent and non- 
sticky. Results showed that all films exhibited moderate tensile strength and recorded an 
increase in % elongation for the different CD formulations, which indicates films become 
more flexible in the order F1< F2< F3< F4 (Figure 4.14).  
 
However, mechanical properties of all film formulation were insignificantly reduced by 
the incorporation of inclusion complex by different sub- classes of CDs.  A slight 
reduction was apparent in tensile strength and Young’s modulus of glipizide/ complex 
loaded films, but there was no major changes in these parameters compared to the controls 
(p > 0.05, ANOVA followed by Tukey’s test), possibly as a consequence of the addition 
of CD complexes to the films causing aggregation and break down of the polymer matrix, 
which enhances the molecular mobility and free volume of polymer network (Fundo et 
al., 2014). In contrast, there were no significant changes in mechanical properties of films 
by individual CD complexes in comparison to each other (p > 0.05, ANOVA followed 
by Tukey’s test) (Figure 4.14). Since the drug has been incorporated in the CD cavity, 
there was no interaction with the polymer and the CD cavity, as consequently, no 
significant impact on the tensile properties of films for each example of CD were 
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observed. Based on the results, ODFs containing glipizide-CD complexes are soft and 
tough, exhibiting a low tensile strength but high percentage elongation (Felton et al., 
2008) with or without the addition of complexation. 
 
  
 
Figure 4.14- Mechanical properties of KP film containing glipizide-CD complex at 10mg dose where F1= 
αCD/ glipizide complex, F2= βCD/ glipizide complex, F3= γCD/ glipizide complex, F4= HPCD/ glipizide 
complex (n=3, mean ± SD). No statistical difference was observed using one way ANOVA followed by 
Tukey’s test , between different types of CD complex loaded films and the controls, ns (p >0.05)  
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4.2.7 Drug loading – dose escalation study 
The drug loading capacity of pure drug into the KP films achieved 90.0 ± 0.30 %, 80 ± 
0.35 %, 60 ± 0.24 %, 50.26 ± 0.45 % and 42.83 ± 0.28 % at a dose of 2.5 mg, 5 mg, 10 
mg, 15 mg and 20 mg, respectively (Figure 4.15).The use of CD complexation showed a 
significant enhancement in the drug loading of glipizide into KP films compared to pure 
drug itself (p < 0.01, ANOVA, Dunnett’s test). In the case of films incorporating 
glipizide-CD complexes, the drug loadings were achieved up to 93.0 ± 0.28 %, 94.30 ± 
0.25 %, 96.50 ± 0.44 % and 97.20 ± 0.43 % at 2.5 mg dose for F1 to F4, respectively. 
The high achievement in drug loading is the possible use of a small dose (2.5 mg) and a 
better inclusion of drug inside the CD cavity with an increase in volume size of the 
different sub classes of CD. However, at a dose of 5 mg, the drug loading of F1 and F3 
were 62.5 ± 0.23 % and 88.0 ± 0.20 %, respectively, but were higher for F2 and F4, up to 
91.30 ± 0.24 % and 92 ± 0.12 %, respectively. Indeed, the drug loadings were 
significantly higher with the beta, gamma and HPCD complexes at 5 mg dose compared 
to without the use of CDs (p < 0.001, ANOVA followed by Dunnett’s test), suggesting 
efficient inclusion of the drug within the hydrophobic cavity. However, a considerably  
lower drug loading was evident for the alpha CD complex, compared to the control (p < 
0.001, ANOVA followed by Dunnett’s test), possibly as a consequence of the smaller 
cavity size associated with alpha CDs, which leads to insufficient drug inclusion (Challa 
et al., 2005). In contrast, there was a significant decrease in the percent drug loading 
efficiency with an increase in drug loading in the formulations (p < 0.001, ANOVA 
followed by Dunnett’s test). KP films incorporating glipizide-CD complexes at a dose of 
10 mg reached 43.35 ± 0.36 %, 49.30. ± 0.08 % , 53.65 ± 0.83 %  and  68.8 ± 0.54 % of 
drug loading for alpha CD, gamma CD, beta CD and HPCD, respectively. Again, a 
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significant reduction in loading efficiency was observed for films incorporating glipizide-
CD complexes a dose of 20 mg, to 13.69 ± 0.69 %, 13.83 ± 0.44 %, 17.50 ± 0.53 % and 
35.89 ± 0.92 % for alpha CD, gamma CD, beta CD and HPCD, respectively (p < 0.0001, 
ANOVA followed by Dunnett’s test). This suggests that there may be a lack of space 
available within the ODFs for a specific volume size of CD and/or drug, since a similar 
downward trend was also apparent for drug loading without CDs. In addition, for the 
lower loading associated with alpha CD - drug complex and gamma CD - complexes may 
be due to weaker drug-CD interactions, whereas other complexes show greater drug 
loading, indicating stronger drug-CD interactions, which is supported by the evidence of 
the stability constant values (see part 4.2.1). Amongst the different CDs investigated, 
HPCD complexes achieved the most efficiency in drug loading, as a consequence of the 
broader cavity volume as well having a better compatibility with the guest molecule and 
the strength of the interaction with the CD cavity, as evidenced from previous results (see 
section 4.2.1 and 4.2.2). 
  
Furthermore, results indicate the limitation for drug loaded into film, since the maximum 
amount of drug able to be efficiently loaded into the ODFs, both with and without 
complexation, appeared to be around 12 mg, after which point no further drug could be 
loaded, regardless of initial dose added. Nevertheless, although the complexes provided 
no benefit with regards to drug loading at the higher doses, and in some instances were 
disadvantageous in this regard, there would still be the added benefit of taste-masking 
and enhanced stability compared to drug alone. 
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Figure 4.15- Dose escalation study of glipizide loaded CD complexation- Results showed the reduction in 
drug loading up to 20 mg of glipizide due to the availability of the cavity volume of each CD (mean ± SD, 
n=3). Statistically significant differences are noted as follow: ns (p> 0.05); * (p <0.05); ** (p <0.01); *** 
(p <0.001); **** (p <0.0001), two way ANOVA). 
 
4.2.8 Drug content uniformity determination 
Since glipizide is poorly soluble in water, achievement of drug content uniformity, which 
is vital for patient safety and efficacy since a uniform dose will provide consistent dosing 
and, therefore, more predictable and stable levels of drug within the patient, thereby 
providing a more consistent therapeutic effect, becomes a challenging parameter for 
formulation of dosage forms, especially for ODFs with limitation of drug loading.  
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The drug content of glipizide without the addition of CD complexation is on the limits of 
the acceptable boundaries for drug content uniformity (85 -115 %, BP 2013), suggesting 
poor distribution within films, whereas the content of uniformity of glipizide from ODF 
formulations loaded at 5 mg with the various CD complexes not only showed within the 
criteria standard, but also improved significantly in dose uniformity compared to the 
control (p < 0.0001, ANOVA  followed by Dunnett’s test) (Figure 4.16). Furthermore, 
the complexes improved drug loading at low doses, but it has proved that the content 
uniformity of poorly soluble drug is enhanced by the use of CD complexation. In addition, 
regarding to the clinical aspects, the use CD complexation could provide the additional 
benefit to the taste-masking and enhanced stability of bitter drugs. 
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Figure 4.16- Drug content uniformity of 5 mg glipizide loaded ODF with and without CD. Results reported 
in 3 replications (mean ± SD, n=3). Dash line indicates the criteria for content uniformity of ODFs. 
Statistically significant differences are analysed using one way ANOVA with the variance as followed; 
**** (p <0.0001). 
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4.2.9 Disintegration time 
The disintegration test was carried out in 25 mL distilled water (Fig 4.17). ODFs are 
desired to dissolve quickly for fast release within a minute (Kalyan and Bansal, 2012). 
Disintegration profiles of orally dissolving films of glipizide demonstrated acceptable 
design, with all film formulations dissolving completely within 15 seconds, as expected 
due to the presence of the hydrophilic film former.  
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Figure 4.17- Disintegration time of blank films, KP film loaded glipizide only and KP films containing 
drug -CD complexes in 25 ml distilled water at 37 0C (mean ± SD, n=3). Statistical different was observed 
using one way ANOVA followed by Dunnett’s post- test, between different types of CD complex loaded 
films and the controls, with the variance as follow: ** (p < 0.01); **** (p < 0.0001). 
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However, there is a significant increase in disintegration time when the films were loaded 
with glipizide- CD complexes compared to the blank film (p < 0.0001, ANOVA followed 
by Dunnett’s test) and KP film loaded with glipizide without complexation (p <  0.05, 
ANOVA followed by Dunnett’s test). The time for films to dissolve between control and 
glipizide without complexation was also found to be significantly different (p < 0.01, 
ANOVA followed by Dunnett’s test). The time taken for blank films to disintegrate was 
only 7 seconds, as it is readily soluble in water, whilst it took longer time for CD complex 
loaded KP films to dissolve completely, as more time is required to uptake more water 
molecules for breaking the complexation and polymer matrix. Besides that, low moisture 
content recorded for complex loaded films, respectively (see 4.2.5- moisture studies), 
which probably implement on a longer disintegration time of films based on the strong 
barrier of KP against water, and thereby, it takes more time for water being absorbed into 
the polymer matrix. In contrast, there is no significant difference for each sub-class CD 
complexation in breaking up the films, as they have a similar chemical structure (p> 0.05, 
ANOVA, Dunnett’s test) (Challa et al., 2005).  
 
 
4.3 Conclusion 
Glipizide formed a stable inclusion complex with CDs with a typical AL type. The 
stability constant showed a linear increase of 34 M-1, 83 M-1, 200 M-1 and 222 M -1 for α 
- CD, γ- CD, β - CD and HPCD, respectively, with a range of cavity size available for 
each type of CD. The stability constant of complexation is strongly dependent on the 
strength of the interactions of the guest molecule and the CD cavity. The solubility profile 
of glipizide was enhanced by incorporating within the complexes in both water and PBS 
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solution, which is to be expected, with a higher improvement of solubility of glipizide in 
PBS due to the high degree of ionisation from the weak acidic group. All film 
formulations were flexible, transparent and non- sticky and achieved uniformity in 
thickness (0.14 µm) and drug content (85-115%) at lower drug loadings. Glipizide-CD 
complex loading of the selected film formulations resulted in further reductions in tensile 
properties (e.g. tensile strength and elastic modulus of films were reduced, but the 
percentage elongation was increased) as observed in the order of α-CD β-CD, γ-CD, and 
HPCD complexation. The results showed that not only plasticiser but also complexation 
can potentially act as further plasticising agent, as the complex could aggregate and break 
down the polymer matrix, which enhances the molecular mobility and free volume of 
polymer network. There was no change in moisture content of film formulations in room 
temperature and oppositely reduced in the desiccator (p > 0.05). However, the interaction 
bonding within the cavity is responsible for moisture content determination as the 
evidence of beta CD/ glipizide complex loaded films have the lowest moisture content in 
both conditions, compared to other complexation due to alpha and gamma CD complexes 
possessing the weaker interactions within the cavity, which are more labile to expose to 
water vapour in room temperature. The disintegration time of films and glipizide-CD 
complex-loaded films was less than 20 seconds in 25 mL distilled water, due to the 
presence of hydrophilic film former. FTIR suggested that the NH group of Glipizide 
emerged with the broad band of CD in the same region of hydroxyl group and be masked 
by the film peaks, particularly as they were used in less quantity than the polymer. DSC 
data did not show Tg of KP, and the effect of drug on Tg, perhaps, polymer and the 
complex remain its amorphous form. Drug loading efficiency reduced significantly for 
all film formulation with an increase in amount of doses of pure drug and drug complexes 
into films (up to 20 mg),  due to poor loading capacity of cavity volume of CDs (p <0.05) 
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whilst they could impart taste masking and enhance stability. Overall, CD complexation 
showed the improvement solubility profile of poorly soluble drug- Glipizide. CD 
complexation improved uniformity of drug loading available at low dose based on the 
limited cavity sizes. 
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Chapter 5  
Evaluation and physicochemical characterisation 
of dexchlorpheniramine maleate loaded orally 
dissolving films 
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5.1 Introduction 
Allergy rhinitis is a common, chronic condition that results in inflammation by pollen or 
dust, with classic symptoms of nasal congestion, itching and sneezing, whilst severe 
conditions could lead to the impairment of quality of life and sleep disturbance 
(Rosenwasser, 2002, Kemp, 2009). It is estimated that between 10 to 20 % of the 
population of the population are affected by the disorder, with the prevalence increasing 
to upwards of 40 % within the paediatric community (Small and Kim, 2011). In most 
cases, the frequency of allergy increases with age depending upon on the geography, 
genetic and living environment (Mandhane et al., 2011), with rates of exposure to 
allergens increased in older children aged from 13 to 14 compared to younger age group 
(Skoner, 2001). Besides the avoidance of allergens, several pharmacotherapeutical 
clinical treatments of allergy have been implemented, such as the use of corticosteroids, 
antileukotrienes and antihistamines, with the latter being the most traditional choice. The 
use of first generation H1 antihistamine is widely available and has shown great potential 
as first-line medication for both intermittent (seasonal) and persistent (perennial) allergic 
rhinitis (Simons, 2003). Moreover, antihistamine is a common API for treatment of cough 
and cold, runny nose and sneezing, with many different dosage forms available, such as 
tablets, capsules, oral syrups and spray solutions. Indeed, one of the commercially 
available dosage forms is based on the fast drug delivery systems as orally disintegrating 
tablets (ODTs) containing loratadine at 10 mg dose strength for relieving seasonal 
allergies; however, this is not licensed for children under 6 years old  and, since ODTs 
are still a solid monolithic oral dosage form, there remains concerns over choking. Using 
orally dissolving films, as alternative new system to traditional oral dosages, bring 
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potential benefits for rapid onset of action and ease of administration especially for quick 
relief of allergy.  
 
Dexchlorpheniramine maleate (DCM), an active isomer of chlorpheniramine, is a H1 
antagonist from the first generation of anti-histamines (Fig. 5.1). DCM is a white, 
odourless, crystalline powder that is freely soluble in water and soluble in alcohol. It has 
the empirical formula C16H19ClN2•C4H4O4, with the molecular weight of 396 
(DrugBank).  
 
 
 
 
Figure 5.1- The chemical structure of DCM 
 
DCM belongs to the alkylamine derivatives and its sedative activity is twice as potent as 
chlorpheniramine.  DCM is used for systemic relief of allergic conditions, such as 
urticaria and angioedema or even for the treatment of common coughs and colds.  DCM 
is mainly given orally and sometimes delivered topically.  
 
DCM is available at 2 mg oral dose for every 4 to 6 hours. According to the BNF, DCM 
is available at 500 micrograms for children aged from 2 to 6 years and 1 mg for those 
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aged 6 to 12 years every 4 to 6 hours in the treatment of allergic rhinitis (BNF, 2010).  
DCM is the choice of drug for paediatric patients, due to its high solubility and acceptable 
bioavailability. 
 
 
Aim & objectives 
This chapter aims to investigate the formulation of ODFs containing antihistamine for 
fast onset of action for allergy relief at the suitable clinical doses for children.  
 
The objectives were to investigate:  
 The physico-chemical and mechanical properties of ODFs following 
incorporation of the anti-histamine DCM. 
 
 The development of a more suitable testing system for quantification of 
the disintegration time of ODFs, by studying the impact of test media 
and media volume on the disintegration behaviour; 
 
 The development of prototype packaging and their ability to maintain 
ODF stability at different storage conditions. 
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5.2 Result & Discussion 
5.2.1 Mechanical properties 
The mechanical properties of films containing DCM was assessed based on the setting 
method in chapter 2 (see 2.7.4). The thickness of the films before and after DCM loading 
was uniform (Table 5.1), whilst the texture of films was flexible, transparent and non- 
sticky, regardless of drug loading. Results showed that the mechanical properties of drug 
loaded films reduced slightly compared to control films, possibly due to the plasticising 
effect of the drug (Table 5.1).  
Table 5.1- Mechanical properties of blank film and DCM loaded KP film at dose 1 mg and 2 mg at size 3 
x2 cm2. Drug loading has no effect on the mechanical properties of film due to small amount of drug present 
(p >0.05, one way ANOVA, Dunnett’s test).  
 
Dose Thickness 
(mm)  
(n=5) 
Mechanical properties  
Tensile 
strength 
(N/mm2) 
Elongation  
(%) 
Young’s modulus 
(N/mm2) 
Control 0.14 ± 0.001 4.72 ± 0.53 51.08 ± 2.93 10.01 ± 0.03 
1 mg  0.14 ± 0.001 3.16 ± 0.10 52.58 ± 3.57 6.03 ± 0.58 
2 mg 0.14 ± 0.001 3.02 ± 0.11 49.01 ± 4.52 6.27± 0.80 
 
Even though in a low amount, the hydrophilic drug molecules are able to occupy the 
polymer matrix, thereby interacting with the polymer chains, which possibly leads to a 
reduction in the mechanical properties of films (Repka et al., 1999). However, this 
difference was not deemed to be significant (p > 0.05, one way ANOVA, Dunnett’s test). 
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Indeed, an increase in dose loading seems not to have any effect on mechanical properties 
of films, as a low amount of drug was used (p > 0.05, one way ANOVA, Dunnett’s test) 
(Table 5.1). 
 
5.2.2 FTIR Studies 
DCM showed the major double peaks at 3329- 3241 cm-1 due to N-H stretch vibration. 
Other prominent peaks at 1697 cm-1 (C=O stretching), 1598 cm-1 (C=N stretch), 
carboxylate 1353.31 cm-1 and Maleate 860.78 cm-1. KP demonstrates a broad absorption 
band at 3200 cm-1 of hydroxyl group, sharp bands at 1727- 1709 cm-1 and 1041 cm-1 
associated with C=O stretching (Figure 5.2). Physical mixture demonstrated the 
superposition of pure drug and polymer. Although no major peak of drug was observed 
in the KP film, due to emerging of bonding in the same regions, new bond formation was 
recorded at 1093 and 1038 cm-1, which suggests that the maleate group of DCM interacted 
with the polymer, which may explain the reduction in mechanical properties of films as 
a consequence of the potential plasticising effect of drug. In addition, these may well be 
masked by the film peaks, particularly as they were used in less quantity than the KP. 
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Figure 5.2- FTIR of DCM, KP, physical mixture and drug-loaded KP film. 
 
5.2.3 DSC studies 
The DSC curves obtained for pure drug and optimised formulation are shown in Figure 
5.3. Pure powdered DCM displayed a single sharp endothermic peak at 112.96 0C with 
the fusion enthalpy of 88.31 J/g, which suggests the drug was in the crystalline form 
(Figure 5.3). Blank KP film recorded the distinctive melting peak at 206.33 0C and a 
broad peak at 76 0C responsible for the dehydration of water, since KP is a polyvinyl 
alcohol-polyethylene glycol graft copolymer. The thermal curve of the physical mixture 
showed the corresponded melting to the superposition of polymer and pure drug. A 
change in thermal behaviour of polymer and drug might be an indication of interaction 
between drug and polymer as seen in FTIR (see 5.2.2).In contrast, no peak of drug was 
observed in the DSC for the drug loaded film. However there is drug present, as confirmed 
by other analyses (e.g. drug loading, FTIR), but the nature of incorporation into the film 
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may help to preserve the amorphous nature of the drug, which could possibly the polymer 
inhibits the recrystalline state of the drug (Konno and Taylor, 2008, de Oliveira et al., 
2016).  
   
 
Figure 5.3- DSC thermograms of DCM (---), KP (—  .), physical mixture (— --) and drug-loaded KP 
film (—). 
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5.2.4 Disintegration time 
5.2.4.1 Method suitability and development 
Orally dissolving films are novel potential dosage forms, designed to disintegrate in the 
mouth upon hydrolysis with saliva. Since this is a relatively new pharmaceutical 
formulation, there is no standard pharmacopoeial disintegration test procedure specified 
for ODFs. Furthermore, the current conventional disintegrating tests (for tablets) that are 
described in the pharmacopoeia have been utilised to characterise ODFs (Donauer and 
Löbenberg, 2007). In this case, it is difficult to assess the disintegration profile due to its 
rapid disintegration with media. In addition, the conventional testing system is also 
challenging for visual inspection for end point determination, especially to film- forming 
polymers that swell immediately and float on the surface. Besides that, using 900 mL 
volume of test solution is not applicable to the condition of the buccal cavity in terms of 
media and volume, and, thus, is considered as not suitable for characterisation of ODFs 
(Bi et al., 1996, Harada et al., 2006, Kakutani et al., 2010, Preis et al., 2014). On the other 
hand, various alternative methods have been proposed in the literature to facilitate the 
assessment of the disintegration behaviour of ODFs. The petri dish and slide frame 
methods are considered as the simplest processes, where the film is placed in the 
stationary surface, with water dropping from a syringe until it tears apart, which is taken 
as the disintegration time (Figure 5.4) (Irfan et al., 2015). Although the small volumes of 
droplet solution might be an appropriate saliva volume, these two methods show no 
mechanical agitation, which does not reflect on the human oral cavity (Preis et al., 2013, 
Irfan et al., 2015). The use of wire mesh is also an alternative method for measuring the 
disintegration time of ODFs, but the same problem is taken into account as films are 
immobile during the procedure (Joshi et al., 2012). Each of the previously stated methods 
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suffer from a lack of a clearly defined end point, which may inevitably lead to an 
overestimate for disintegration time, as well as no mechanical force supplied, thereby 
considered insufficient for imitation of physiological conditions. Indeed, the 
disintegration testing system should be presented in a dynamic condition, where the 
movement is the influential factor on the performance of ODFs. An alternative analytical 
approach, that implements the dynamic situation, is one where the films are dipped into 
a glass beaker filled with 25 mL of water with gentle stirring (Arya et al., 2010, Preis et 
al., 2013). Moreover, a method employing an attached cylindrical probe with exerted 
force that mimics as oral cavity pressure, is contemplated as a realistic, dynamic reflection 
of the physiological environment of human mouth (Abdelbary et al., 2005, Szakonyi and 
Zelkó, 2013). As such, the work described in the subsequent sections of this chapter 
describes a developmental approach to a more relevant and suitable testing method for 
the disintegration time of ODFs.  
 
A)                                                                              B)  
                                                                                                        
Figure 5.4- Schematic presentation of the disintegration system A) Petri dish and B) slide frame  
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5.2.4.2 Texture Analyser- A promising approach 
Several studied methods, including the pharmacopoeia test currently used for the 
quantification of the disintegration time of ODFs, might be ineffective when used for 
prediction as a quality control parameter. The texture analyser instrument has previously 
been considered as a practical operating approach to evaluate the disintegration time of 
orally disintegrating tablets, which is proposed by many researchers (Dor and Fix, 2000, 
El-Arini and Clas, 2002, Brniak et al., 2015). In this test system, a moving probe is 
employed, with a constant force applied to an object (e.g. tablet or film). The object of 
interest (e.g. tablet or film) is placed onto the flat surface and then submerged in a defined 
volume of disintegrating medium, with subsequent application of the exerted force, which 
imitates the action of a tongue. The end point of disintegration time is determined once 
the object is completely broken down, as determined by the contact of the probe with the 
underlying flat surface upon which the object is initially placed (Szakonyi and Zelkó, 
2013, Scheuerle et al., 2015). This apparatus system has previously been reported as a 
precise and convenient operating structure that more closely reflects the conditions of the 
human mouth, in addition to providing a clear visual assessment for disintegration 
(Szakonyi and Zelkó, 2013). Furthermore, using the texture analyser approach provides 
a better correlation with the in vivo disintegration time, as it demonstrates a simulation of 
the dynamic condition (Dor and Fix, 2000, Abdelbary et al., 2005, Szakonyi and Zelkó, 
2013). Based on the factors outlined above, the beaker method and texture analyser 
method show a good reflection of the dynamical condition that is applicable to the 
determination of the disintegration profile of ODFs; therefore, they were investigated for 
evaluation of the disintegration activities for films. 
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The disintegration time of the ODFs were determined by two systems for comparison. It 
was carried out by using TA-CT3 texture analyser with probe (Figure 5.5) or using the 
commonly employed method of simply stirring in a beaker. The disintegration test system 
conducted by CT3 texture analyser (TEXTUREPRO CT, Brookfield) requires films to be 
placed on the platform, where it mimics a lower oral cavity. The probe was set at pre - 
speed of 1.0 mm/ second with 5 g trigger load force. The probe, which acts to simulate 
oral cavity pressure, moves until a trigger force is sensed when it touches the film. As 
soon as the probe touches the film, 1 mL of media is added. The other system was using 
the commonly employed method of simply stirring in a beaker. The disintegration time 
was recorded when films completely break down.   
 
 
 
 
 
 
 
 
Figure 5.5- Schematic presentation of the Text analyser TA-CT3 model (TEXTUREPRO CT, Brookfield) 
with probe attached. 
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5.2.5 Media suitability 
In addition to the limitations of current analytical methods to determine the disintegration 
time of ODFs, the media employed in such methods is also questionable. Currently, water 
is the most commonly used media, which lacks many of the components of saliva, 
resulting in a potential impact on disintegration time of ODFs. With this in mind, to obtain 
the effect of media composition on the disintegration profile, the use of distilled water 
and simulated saliva fluid at pH 6.8 were used for investigation at 25 0C and 37 0C. 
 
5.2.5.1 Impact of media volume 
Along with the media itself, media volume is also an important controlling factor that 
could influence the disintegration behaviour of the dosage form, especially to ODFs, as 
they are quickly hydrolysed upon contact with the saliva. As a consequence of the lack 
of pharmacopoeial methodology for the testing of ODFs, the disintegration testing system 
employed for tablets or capsules, using large media volume, is often applied to ODFs 
(Abdelbary et al., 2005, Harada et al., 2006). For instance, using 900 mL as media volume 
to films could provide inconsistent results for determination of the end point for 
disintegration time, as a loss of visual detection can be problematic due to film floating 
or even hydrating immediately upon the contact with the media (Narazaki et al., 2004, 
Mishra and Amin, 2009). Furthermore, this condition does not reflect on the condition of 
the human mouth. Moreover, a method for quantification of disintegration time using a 
small media volume is more suitable and biorelevant to saliva volume, in order to better 
replicate the disintegration process in the oral cavity, which is applicable to this novel 
dosage form, ODFs.  
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As such, the impact of media volume on the disintegration time of ODFs was additionally 
investigated. These films (3 x2 cm2) were tested in a 50 mL beaker containing 1 mL or 
25 mL of either distilled water or simulated saliva solution at 25 0C and 37 0C, with gentle 
stirring. 1 mL of the same two media were also analysed for probe methodology. 
 
5.2.5.2 Disintegration time of ODFs 
All films were dissolved in less than 25 seconds. Results showed that the use of distilled 
water and saliva solution as test medium resulted in almost similar disintegration time of 
the studied films (Figure 5.6.A). There was no significant difference in the disintegration 
time for dissolving films incorporated with 1 mg and 2 mg dose of DCM at 25 0C and 37 
0C (p > 0.05, ANOVA followed by Tukey’s test). The time recorded for ODF 
incorporating 1 mg to completely dissolve were 20 ± 2.65 s, 21 ± 2.00 s and 22 ± 1.15 s 
in 25 mL distilled water, 1 mL distilled water and 1 mL saliva solution at 25 0C, 
respectively. However, films containing higher dose loaded films show a trend for faster 
disintegration time at the same temperature, which indicates the fast, water – solubility 
property of DCM. As evidence, films dissolved 19 ± 1.53 s, 19 ± 2.08 s and 17 ± 0.58 s 
in the test media. In this study, artificial saliva solution was used which clearly indicated 
that the distilled water and saliva solution is similar to each other and, hence, they both 
have no impact on disintegration profile of ODFs, whilst higher loading of drug has direct 
relationship with faster rate of disintegration at the higher temperature ( maximum 15 
seconds). Although, the artificial saliva used here is composed of 99 % water and other 
inorganic components (Humphrey and Williamson, 2001), whereas, in comparison, the 
actual saliva fluid consists electrolytes, enzymes, proteins and other antimicrobial 
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constituents that maintain the health of oral cavity (de Almeida et al., 2008); all of which 
could further impact on disintegration time, so may require further investigation. 
(A) 
 
 
(B) 
  
Figure 5.6- Disintegration time of ODFs loaded with dexchlorpheniramine maleate at 1 mg and 2 mg 
recorded by (A) dissolving in beaker and (B) use of texture analyzer with probe in distilled water and 
simulated saliva solution at 25 0C and 37 0C (mean ± SD, n=3). 
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5.2.6 Impact of test volume 
Media volume is an important controlling factor that could influence the disintegration 
behaviour of the dosage form, especially to ODFs as they are quickly hydrolysed upon 
contact with the saliva. Both systems revealed almost similar results of disintegration 
times of ODFs loaded at two different dosage strengths (Figure 5.6.B). A small beaker 
was used as a test vessel, where films were placed into 1 mL or 25 mL of distilled water 
with gentle stirring. The disintegration time of films was recorded to be approximately 
20 seconds, as a result of film swell rapidly when in contact with the large surface area 
of the beaker. As seen, the test volume did not have a strong impact on the disintegration 
time of ODFs. However, small volume of used media (1 mL) provide an accurate 
stimulation of the saliva production of the human mouth.   
 
5.2.7 Impact of the method 
The probe system generated shorter disintegration times compared to the beaker method. 
The disintegration times recorded for films loaded with 1 mg DCM were 17 ± 1.53 s in 
saliva and 20 ± 2.52 s in distilled water, while ODF loaded at 2 mg dose have 
disintegration times of 18 ± 2.52 s in water and 17 ± 0.58 s in saliva solution at 25 0C, 
suggesting that films were under additional force that mimics oral cavity pressure, where 
it appears to be reflective of the movable platform of the human mouth. Again, even 
shorter times were observed for both drug loaded films at two dose strength at 37 0C, e.g. 
15 ± 1.00 s and 13 ± 1.00 s in distilled water; 12 ± 1.00 s and 11 ± 0.58 s in saliva for 1 
mg and 2 mg, respectively. 
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As mentioned, both solutions were similar, which did not lead not to diverging results in 
those cases. Nevertheless, using small beakers as test vessels can be challenging for visual 
inspection, as it was subject to individual judgement of a defined end- point, which may 
lead to a bias in results. The probe method developed in this study provides clear end-
point determination and is, therefore, more suitable for control performance, where it 
performs as a convenient operating structure that demonstrates a simulation of the 
dynamic conditions of the human mouth and deliver precise results in terms of 
reproducibility. 
 
5.2.8 In - vitro drug release study 
Both DCM as a pure powder form and loaded into ODFs exhibited rapid dissolution. Pure 
DCM released up to 90 % of the total amount of drug within 3 minutes in simulated saliva 
solution (pH 6.8) (Figure 5.7), as the drug itself is very hydrophilic, whilst the drug loaded 
films achieve a similar amount of release (90% of drug) after 4 minutes (Figure 5.7). 
There was no significant difference in release profile of pure drug between 2 and 3 
minutes (p > 0.05, ANOVA followed by Tukey’s test), but it was recorded significantly 
for drug loaded ODF at the same time points (p < 0.05 ANOVA followed by Tukey’s 
test). The slightly delayed release of drug from the film formulation may be attributable 
to the drug molecules requiring some time to diffuse out from the polymeric films. The 
quick release of the drug was observed in PBS solution (Figure 5.7). The fast dissolution 
performance in both media conditions can be attributed to the relatively high solubility 
profile of the API in both conditions in a low amount of drug loading, as well as the 
hydrophilic nature of the film forming polymer or perhaps the components in the saliva. 
Chapter 5  DCM loaded ODFs 
 
 
165 
 
 
D ru g  re le a s e  s tu d ie s
T im e  (s )
%
 c
u
m
u
la
ti
v
e
 d
r
u
g
 r
e
le
a
s
e
0 1 2 3 4 5 7
1
0
0
2 0
4 0
6 0
8 0
1 0 0
P u re  d r u g  in  s a liv a
D C M  lo a d e d  f ilm s  in  s a liv a
P u re  d ru g  in  P B S  (p H  6 .8 )
D C M  lo a d e d  f ilm s  in  P B S  (p H  6 .8 )
 
Figure 5.7- Dissolution profile of DCM and DCM - loaded films in simulated saliva solution (pH 6.8) 
and.in PBS solution (pH 6.8) (mean ±SD, n=3). 
 
5.2.9 Drug content uniformity 
It is essential to have uniformity of API throughout the polymeric films, which is vital for 
patient safety and efficacy, since a uniform dose will provide consistent dosing within the 
patient, thereby providing a more consistent and predictable therapeutic effect. According 
to the BP criteria, content uniformity for dosage units of DCM should be within the range 
of 85 - 115 % (BP, 2016). The drug content uniformity of the DCM loaded ODFs prepared 
here was recorded at 99.40 ± 4.79 % and 99.87 ± 5.15 % (expressed as mean ± RSD) for 
1 mg and 2 mg dose, respectively, which is within the acceptance criteria, suggesting the 
uniform distribution of DCM within films. 
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5.2.10 Stability studies 
Due to the fact that films can be susceptible to breaking/tearing and absorption of 
moisture from the environment, packaging also plays a crucial part in practical film 
performance and stability. According to the WHO guidelines on GMP for pharmaceutical 
preparations, the products must be kept in a well closed package or moisture - proof packs 
and protected from any sensitive environment, such as light, moisture and mechanical 
damage (WHO, 2002). In terms of stability, the packaging materials should have no 
interaction with the pharmaceutical products. Indeed, depending on the use and the route 
of administration of medicine products, different requirement of packaging materials are 
highly considered for maintaining the integrity of products (FDA, 1999). For example, 
the most common forms of packaging for solid dosage forms, such as tablets or capsules, 
are blister package and aluminium foil. Moreover, these materials provide supportive and 
barrier properties, which also have a use for film packaging. However, plastic/ paper 
provides more economical viability and is widely used for primary packaging (e.g 
ointment, tablet boxes), but they also can be used for strip packs (see Figure 5.9 A), 
whereas foil packaging offers a better protection than plastic for films. Nevertheless, the 
design of packaging from pharmaceutical compliance should be administrated in a safe 
manner (e.g delivery accurate dosing and compliance); ease of usage to the patients and 
economical (WHO, 2002). Based on these reflective properties of these packaging 
materials, the prototype packagings were chosen to study for investigation of a suitable 
packaging material for oral dissolving films. 
 
Currently, there are various packaging systems for oral dissolving films, including foil- 
paper or plastic pouches. Peelable pouches are an example of a single pouch packaging 
Chapter 5  DCM loaded ODFs 
 
 
167 
 
 
for oral fast dissolving films (Figure 5.9 A), in order to provide high protection from the 
moisture in the air. Whereas, other different packaging materials employed for ODFs are 
demonstrated as examples in Figure 5.9 B and C. Blister card can also be used for film 
packaging. The blister container composes of two parts: the blister and the lid stock. The 
blister material is generally plastic and the lid stock is sealed with paperboard or 
aluminium (Panda et al., 2012). The blister packs are further divided as heat sealed 
blisters, which are laminated with thermoformed plastic mould, and cold blisters, which 
consist of cold forming of aluminium- based laminate film, where both are sealed with 
aluminium lid material. Besides that, aluminium foil is the most widely preferred choice 
used for packaging format, especially for packaging films, due to its great protection from 
moisture and humidity (Nagaraju et al., 2013).  
 
                                
      
Figure 5.8- Examples of different types packaging for ODFs: A) peel pouch B) plastic blister C) paper                                        
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The results in this chapter, therefore, depict the use of prototype packaging as a potential 
approach for ODF packaging; indeed, a durable, airtight and tamper proof packaging is 
of significant importance for a single dosage form for a special purpose, in line with 
pharmaceutical industrial requirements.  
These studies were carried out by storing drug-loaded films sealed by the prototype 
packaging in climate controlled stability cabinets, set to ICH conditions of either 25 ± 2 
0C and 60 ± 5 % RH or 40 ± 2 0C and 75 ± 5 % RH. Films were wrapped either in 
aluminium foil or sealed in cold blister tablet packaging and stored for 90 days (See 
Figure 5.10). 
 
                              
Figure 5.9– Packaging storage of films in aluminium foils and tablet blister for stability studies at 25 ± 2 
0C and 60 ± 5 % RH and at 40 ± 2 0C and 75 ± 5 % RH. 
 
 
5.2.10.1 Visual inspection  
 All film samples remain unchanged in colour in aluminium foil and blister when stored 
at both long term (25°C / 60 % RH) and accelerated (40°C / 75 % RH) conditions (Figure 
5.11 and 5.12). Films were clear, transparent and non- sticky. Only slight changes in 
appearance could be observed with packaging in blister, since it was necessary to fold the 
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films to ensure that they would fit in the blister packs that were available, which led to 
the shape becoming distorted as a result of storage. Hence, in this instance, aluminium 
foil would appear to be the better choice for packaging of ODFs, which has previously 
been shown as the recommended packaging for oral films for protection of dosage forms 
from moisture (Heer et al., 2013). However, it may be that a more suitable sized blister 
pack, or one that is bespoke for the dimensions of the film, could alleviate the slight 
deformations seen here.  
 
     
            
 
Figure 5.10- Visual appearance of DCM loaded films -1a) in foil & blister at day 1; 1b & 1c) in foil at 30 
days and 90 days; 1d & 1e) in blister at 30 days and 90 days at long term storage humidity condition (25 ± 
2 0C and 60 ± 5 % RH).  
 
 
 
A) C) B) 
D) E) 
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Figure 5.11- Visual appearance of DCM loaded films -1a) in foil & blister at day 1; 1b & 1c) in foil at 30 
days and 90 days; 1d & 1e) in blister at 30 days and 90 days at accelerated storage humidity condition (40 
± 2 0C and 75 ± 5 % RH).  
 
 
 
5.2.10.2 Impact of storage conditions on mechanical properties of ODFs 
Mechanical strength is a vital parameter to evaluate the robustness and flexibility of 
ODFs, as it is essential for handling and storing, allowing consumers to take a safe, 
adequate level of medicine while maintaining the integrity of samples. When analysing 
the effect of types of packaging on the mechanical properties of ODF loaded with DCM 
(Figure 5.13), results showed that there was no significant difference in tensile properties 
of all film formulations at 25 0C, which indicated that films remains strong and flexible 
(p > 0.05, ANOVA followed by Tukey’s test). 
 
B) C) 
D) E) 
A) 
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Figure 5.12- Mechanical properties of ODFs loaded with at 25 0C/ 60% RH and 40 0C/ 75% RH in blister 
and in in foil after 90 days (mean ± SD, n=3). No change in mechanical properties of OFDs at long term 
conditions, but films became weaker in the accelerated conditions after 90 days. 
 
On the other hand, films became weaker after 90 days when stored at accelerated storage 
conditions, which resulted in a significant reduction in tensile strength (p < 0.05 ANOVA 
followed by Tukey’s test) and a slight increase in percentage elongation of films. This 
change varied for blister and foil packaging, with the tensile strength reduced from 3.53 
± 0.50 N/mm2 to 2.70 ± 0.33 N/mm2 for ODFs in blister packaging, and a reduction from 
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3.11 ± 0.53 N/mm2 to 2.45 ± 0.63 N/mm2 for films packed in foil. This is possibly due to 
residual water absorbed on the film samples at the accelerated condition, as expected (see 
5.7.3). As a result, the moisture could weaken the intermolecular forces between the 
polymer chains, whilst enhancing an increase in the water absorption through the 
hydrophilic property of the plasticiser; thus, films became softer (Bhattacharya et al., 
2014). 
 
5.2.10.3 Moisture content  
KP is a polymer with a strong barrier against water vapour (Yadav and Ansari, 2013). 
The percentage of moisture uptake of ODFs varied in both types of packaging, with an 
overall increase in moisture uptake when storing in both conditions up to 3 months. Film 
samples have a low percentage moisture uptake (up to 4 %) recorded at both humidity 
conditions at the initial day. However, the trend of increase in moisture observed varied 
between 6 % to 9 % for foil and blister at 25 0C / 60%  RH and 40 0C / 75% RH, 
respectively, but recorded the highest value (up to 9%) at higher temperature (accelerated 
condition) after 3 months (Figure 5.14) (Singh et al., 2013). It was observed that there 
was no significant difference impact on moisture studies after 90 days, regardless of types 
of packaging, at 25 0C / 60% RH (p > 0.05, ANOVA followed by Tukey’s test). In 
contrast, results obtained were found to be statistically significant on the moisture content 
for ODF packed with blister at 40 0C / 75% RH (p < 0.05, ANOVA followed by Tukey’s 
test). With the addition of plasticiser, plasticiser molecules interact with the polymer 
chains, which thereby weaken the intermolecular forces within the polymer molecules 
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and possibly integrating H-bonding of glycerol to polymers, that induces the higher 
exposure for moisture sorption (Fundo et al., 2014) 
 
Moreover, moisture analysis provides the information on the suitability of the type of 
packaging for particular dosage forms; it can be seen that the measured percentage 
moisture uptake was higher when films were packed in blisters, hence suggesting that 
blisters are not a suitable choice for packaging in this case. Having said that, the quality 
of the packaging studied here are not as the industrial standard quality, nor bespoke to the 
ODFs produced, which might lead to issues of moisture uptake. As a result, the need of 
airtight packaging of ODFs should be considered to prevent any change in 
physicochemical properties of ODFs. 
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Figure 5.13- Moisture studies of DCM loaded ODFs packed in aluminium foil and blister.  Films were 
stored at (A) 25 ± 2 0C and 60 ± 5 % RH and (B) at 40 ± 2 0C and 75 ± 5 % RH (mean ± SD, n=3).No 
significantly difference were observed for films stored at long term condition, but recorded significantly 
change in moisture uptake for films stored at the accelerated condition (p <0.001, Tukey’s test), from day 
1 to day 90. 
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5.2.10.4 Impact of storage conditions on disintegration time 
Despite perceived changes in mechanical properties and moisture uptake on storage, as 
described in the sections above, all films were still able to dissolve within 25 seconds 
either in distilled water or saliva solution after 3 months, regardless of packaging type or 
storage condition. Indeed, the type of packaging has no significant impact on the 
disintegration time of films when stored at 25 0C/ 60 % RH, since all samples barely 
changed on the disintegration behaviour (p > 0.05, ANOVA followed by Tukey’s test) 
(Figure 5.15.A). However, the shift in longer disintegration time was observed in the 
accelerated condition at 40 0C/ 75% RH, which could be due to the hardening of the 
polymer following exposure to high temperature over a period of time, in addition to the 
increased moisture uptake (Figure 5.15.B). The moisture uptake could depolymerise and 
disrupt the chemical cross-links between the polymer chains, especially to those side 
chains group (-OH group) which are susceptible to the chemical degrading reaction, 
causing polymer degradation under the influence of moisture (Vogt et al., 2004).  
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A) 
 
 
B) 
 
 
Figure 5.14- Disintegration time of ODFs loaded DCM at A) 25 0C/ 60% RH and B) 40 0C/ 75% RH 
in blister and in foil after 90 days (mean ± SD, n=3). 
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5.2.10.5 Drug content uniformity 
In addition to ensuring that the drug remains uniformily dispersed in the polymeric films 
upon storage, it is also crucial that the degradation of the drug is minimised and remains 
within an acceptable range of the initial amount (85 -115 %) (BP, 2016). ODFs containing 
DCM showed the drug content was within the permissible criteria for those films placed 
in both blister and aluminium foil packaging films at long term (25 ± 2 0C and 40 ± 5 % 
RH) and accelerated stability condition (40 0C ± 2 0C and 75 ± 5 % RH ). Therefore, the 
drug showed uniform distribution within films and retained its physically stability over 
the time period of stability studies (Figure 5.16). 
 
 
 
 
Figure 5.15- Drug content uniformity of ODF loaded DCM in blister and aluminium foil packaging films 
at long term (25 ± 2 0C and 60 ± 5 % RH) and accelerated stability condition (40 0C ± 2 0C and 75 ± 5 % 
RH). 
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5.3 Conclusion 
 
The ODFs formulated here, loaded with antihistamic drug, dexchlorpheniramine maleate, 
at 1 mg and 2 mg dose, achieved desirable physical and mechanical properties, drug 
content uniformity with a suitable clinical use for quick onset of action, which is 
beneficial in management of allergic rhinitis with an ease of administration. The study 
initially aimed to focus on the development of a suitable disintegration test system to 
quantify the disintegration time for ODFs, since no standard pharmacopoeia 
disintegration test method for ODFs exists. It was seen that the use of distilled water and 
simulated saliva solution has no significant impact on the disintegration time of ODFs 
conducted by either a TA-CT3 texture analyser with probe or simply stirring in a beaker 
(p > 0.05, ANOVA followed by Tukey’s test). In contrast, the amount of test media did 
not lead to crucial differences in disintegration time of ODFs, since they were carried out 
in a dynamic condition. The loading of drug has a direct relationship with lowering 
disintegration time, as does an increase in temperature. The measurement method using a 
small beaker as a test vessel can be challenging for visual inspection, as it was subject to 
individual judgement of a defined end- point, whereas the probe method developed in 
this study using a small media is more biorelevant to the oral cavity volume and provides 
clear end-point determination and it, therefore, is more suitable for quality control setting 
of ODFs. Pure DCM and drug loaded films released up to 90 % of the total amount of 
drug within 3 minutes in simulated saliva solution and PBS solution at pH 6.8. All films 
remained clear, transparent and non- sticky in blister and foil packaging over a period of 
three months. Only slight changes in the shape of films could be observed with packaging 
in blister, as a result of the effect of folding to accommodate the film within the available 
blister packaging. Hence, aluminium foil is the better choice for packaging of ODFs. 
Chapter 5  DCM loaded ODFs 
 
 
179 
 
 
There was no significant difference in mechanical properties of all film formulations at 
both these two humidity conditions, which indicated that films remain strong and flexible. 
An increase in moisture uptake was observed for ODFs packaged in foil and blister at 
both storage conditions, but was higher when films were packed in blisters, hence 
suggesting that blisters are not a suitable choice for moisture protection for ODFs. Despite 
certain changes being perceived in terms of physical characteristics, the disintegration 
time for all ODFs remained less than 25 seconds, and all films achieved good content 
uniformity and remained stable at both storage conditions over a period of time, 
regardless of the type of packaging. Hence, these formulations are more robust and, 
therefore, potentially more viable industrially and clinically through the product 
developmental stages.  
 
Chapter 6  Nanoparticles loaded ODFs 
 
 
180 
 
 
 
 
 
 
 
 
 
 
 
Chapter 6 
Preparation and Characterisation of ODFs 
loaded with nanoparticles encapsulating a poorly 
soluble drug  
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6.1 Introduction 
According to the BCS classification system, class II drugs are known for their poor 
solubility and high permeability, resulting in limited dissolution and poor oral 
bioavailability; hence, such drugs remain challenging for formulation of oral dosage 
forms. A variety of technological approaches have been utilised to enhance the 
dissolution profile of drug substances, such as pH adjustment (Vemula et al., 2010), solid 
dispersion (Kakran et al., 2012, Vo et al., 2013) and cyclodextrin complexation (Loftsson 
and Duchene, 2007). Alternatively, one of the common technologies involves the 
reduction of particle sizes to overcome these issues. The use of nanoparticles, by 
dispersing preformed polymers or by polymerisation to produce the colloidal particles in 
the range of 10- 1000 nm,  promotes the dissolution rate of poorly soluble drugs, enhances 
the drug loading capacity and reduces the toxicity level of the excipients (Rabinow, 2004, 
Vauthier and Bouchemal, 2009). Therefore, the field of polymer nanoparticles has been 
expanded to exploit their use as a particulate carrier system in a range of fields, based on 
their unique properties, ranging from medicine to biotechnology as a drug delivery system 
(Anton et al., 2008, Ahlin Grabnar and Kristl, 2011).   
 
Nanoparticles are defined as solid colloidal particles with a carrier system under sub-
micron units that comprises nanospheres and nanocapsules (Mora-Huertas et al., 2010). 
The nanoparticulated system has a polymeric matrix that encapsulates the API within the 
polymeric layer, which is advantageous for poorly water soluble drugs as this can increase 
the surface area to volume ratio of drug particles, whilst also improving the stability of 
the API and enhancing the uptake by the intracellular cells (Jung et al., 2000, Reis et al., 
2006). For instance, this system has been extensively used in the delivery of both low 
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molecular weight drugs, as well as peptides and proteins (Ahlin Grabnar and Kristl, 
2011). 
Moreover, depending on the physico-chemical properties of the drug, the choice of 
preparation method of nanoparticles is considered by many features, including route of 
delivery, requirement of sizes, or site of target to achieve the efficient encapsulation of 
the API and, hence, improve the therapeutic performance of such problematic drugs. 
 
 
Figure 6.1- Schematic representation of nanosphere structure. Adapted from (Deda and Araki, 2015). 
 
 
6.1.1 Nanoprecipitation method 
Developed by Fessi (Fessi et al., 1989), the nanoprecipitation method, also alternatively 
defined as solvent displacement method, is one of the most commonly reproducible 
techniques to prepare nanoparticles. The production of nanoparticles is based on two 
phases: the organic solvent phase (containing the polymer) and the aqueous phase. The 
organic phase consists of a solvent (e.g. acetone, ethanol, hexane) that is water miscibile 
and easily evaporates during the displacement process in the presence of polymer (either 
Polymeric 
matrix 
Entrapped 
Drug 
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natural, semi- synthetic or synthetic form). On the other hand, the aqueous phase contains 
non-solvent substance with the addition of surfactants. A literature review demonstrated 
the enhancement of both hydrophilic and hydrophobic drugs into nanoparticles using the 
nanoprecipitation method (Barichello et al., 1999). For example, Cucurbitacin, a 
hydrophobic molecule that is being entrapped into poly (D,L-lactic-co-glycolic acid) using 
nanoprecipitation method, showed a great extent of drug loading of this drug (Alshamsan, 
2014). Also, preparation of nanoparticles containing atorvastatin calcium, using 
Polycaprolactone (PCL), revealed high entrapment efficiency and a satisfactory drug 
stability (Ahmed et al., 2014).  
 
Moreover, the field of nanoparticles loaded ODFs remains as a new technology. 
Transformation of nanoparticles into films would overcome the drawback of poor 
dissolution and limited bioavailability, due to the great surface area to volume ratio of the 
drug particles. Previous studies have demonstrated that the incorporation of BCS class II 
drug nanoparticles, e.g naproxen, fenofibrate and griseofulvin, into the edible strips using 
hydroxypropyl methyl cellulose as a film former exhibited the enhancement of 
dissolution performance and bioavailability of those studied drugs (Sievens-Figueroa et 
al., 2012). The loading of lercanidipine nanoparticles into oral films performed good in 
vitro dissolution and ex vivo permeation through buccal mucosa (Chonkar et al., 2016). 
 
6.1.2 Aim and Objectives 
 
This chapter focuses on the incorporation of orally dissolving films with poorly water 
soluble drug loaded nanoparticles for enhancing the bioavailability of glipizide. 
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The objectives were:  
 To investigate the feasibility of nanoparticles developed by nanoprecipitation 
method loaded into ODF formulations. 
 To efficient delivery of hydrophobic drug, glipizide, in order to improve their 
dissolution performance. 
 To investigate the capacity of drug loading using nanoparticles distribute within 
the ODFs. 
 To enhance the perception of bitter taste of drug and uniformity distribution. 
 
6.2 Results and Discussion 
6.2.1 Effect of the amount of polymer used 
Varying concentrations of polymer were used for nanoparticle formulations (PCL) to 
investigate the impact on the distribution of nanoparticles and the behaviour of blank 
nanoparticles by dispersion from the films. It was very clear that the particle size is 
significantly influenced by the amount of PCL used in the preparation of these blank 
nanoparticles; the average particle size was observed to increase with an increase in PCL 
concentration (Figure 6.2) (p < 0.001, ANOVA followed by Tukey’s test). In contrast, 
the changes in the polydispersity index (PDI) of the blank formulation was found 
insignificant (p > 0.05, ANOVA followed by Tukey’s test). The average effective 
diameter of blank nanoparticles before incorporation into the ODF  was measured at 208 
± 4.79 nm, 220 ± 3.53 nm, 225 ± 4.03 nm and 244 ± 5.02 nm and the polydispersity index 
of 0.102 ± 0.007, 0.098 ± 0.012, 0.106 ± 0.014, 0.101 ± 0.015 with an increase of 
concentration from 0.2 % w/v to 0.5 % w/v, respectively (Figure 6.2 A). Low values of 
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PDI indicate a narrow size distribution within the particles, which may be expected, since 
these were blank (i.e. drug-free) formulations (Figure 6.3 A). On the other hand, in case 
of blank nanoparticles dispersed from film, a significant change in diameter of those 
nanoparticles was recorded compared to that of before dispersion at the same polymer 
concentration (p <0.05, ANOVA followed by Tukey’s test), while there was no 
significant impact on the polydispersity index, despite a slight increase in PDI values (p 
> 0.05, ANOVA followed by Tukey’s test). Following the incorporation and subsequent 
dispersion from films, the mean size was collected at 228 ± 3.49 nm, 231 ± 2.35 nm, 260 
± 1.34 nm and 279 ± 2.19 nm (Figure 6.2 A) and the polydispersity index of 0.119 ± 
0.053, 0.102 ± 0.018, 0.111 ± 0.015, 0.109 ± 0.010 (Figure 6.3 A). This could be the 
extent of agglomeration of particles, due to particles getting into close contact with the 
film forming polymer during the drying process, and, consequently, larger particle sizes 
are formed (Susarla et al., 2013). Another possible reason is that an increase in PCL 
concentration in the maintained volume of organic phase (10 mL), could increase the 
viscous forces, resisting the droplet breakdown as the viscosity of the organic phase is 
increased, forming larger size of particles (Steiner et al., 2016). Also, the evaporation 
time is considered as an important parameter of particle sizes, as the process time for 
allowing the nanoparticles formation from emulsion droplet via the diffusion of organic 
solvent. As the evaporation time was carried out in a short period of time, the organic 
solvent did not have enough time to diffuse out of the emulsion droplets before the 
droplets are getting hardened, resulting in the larger particle sizes (Sharma et al., 2016).   
However, a similar observation was seen for the particle sizes and polydispersity index 
of drug loaded nanoparticles before and after dispersion into film solution. There was a 
significant increase in the size for drug-loaded nanoparticles before and after 
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incorporation into the film (p < 0.001, ANOVA followed by Tukey’s test). The particle 
size increase from 184.89 ± 2.36 nm, 214.75 ± 1.43 nm, 232.19 ± 2.58 nm and 284.65 ± 
3.89 nm before dispersion to 257.85 ± 2.31 nm, 276.70 ± 3.26 nm, 284.38 ± 4.61 nm and 
291.45 ± 2.16 after dispersion to film, with the concentration PCL range of 0.2 to 0.5 % 
w/v, respectively (Figure 6.2 B). Increasing the amount of polymer concentration lead to 
an increase in viscosity of the organic phase, which enhances the entrapment of drug, 
resulting in the formation of larger nanoparticles. There was no significant difference 
recorded for polydispersity index of those nanoparticles either before mixing or after 
mixing, although there was an increase in polydispersity index (p > 0.05, ANOVA 
followed by Tukey’s test) (Figure 6.3 B).    
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Figure 6.2- The effect of organic phase on the particle sizes of A) blank nanoparticles and B) glipizide 
loaded nanoparticles before and after dispersion to the film formulation. Error bars represent as standard 
deviation. Results express as mean ± SD, from three replicates. Statistically significant differences are noted 
as (p <0.001) in particles sizes before and after dispersion. 
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Figure 6.3- The effect of organic phase on the polydispersity index of A) blank nanoparticles and B) 
glipizide loaded nanoparticles before and after dispersion to the film formulation. Error bars represent as 
standard deviation. Statistically insignificant differences are noted as (p >0.05) in polydispersity index of 
particles before and after dispersion. Results express as mean ± SD, from three replicates. 
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6.2.2 Zeta potential 
The zeta potential of blank nanoparticles and drug loaded nanoparticles was measured 
before and after incorporation into the film. All the nanoparticles exhibited neutral zeta 
potential. The measurement of zeta potential of blank nanoparticles was varied from -
3.39 ± 0.64 mV to - 7.07 ± 0.35 mV before incorporation in the range of 0.2 – 0.5 % w/v 
PCL. There was a significant increase in zeta potential for blank nanoparticles in the 
presence of 0.4 and 0.5 % w/v PCL before incorporation (Figure 6.4 A). However, after 
dispersion of blank nanoparticles into KP films, it was observed that a significant 
reduction in zeta potential was apparent, in the same order as the film forming polymer 
and the surfactant molecules are located on the surface of the nanoparticles (p < 0.05, 
ANOVA followed by Tukey’s test).  
Moreover, the incorporation of drug also influenced the zeta potential of the 
nanoparticles. Results showed that a similar effect on the zeta potential was observed for 
the nanoparticles containing drug (Figure 6.4 B). It is possible that the presence of 
surfactant reduces the surface tension of the two phases. Since the measurement of zeta 
potential is based on the magnitude of electrostatic repulsion, it was clear that the 
reduction in zeta potential was obtained with the addition of surfactant as well as drug 
particles that might coat on the surface of nanoparticles.  
 
 
Chapter 6  Nanoparticles loaded ODFs 
 
 
190 
 
 
Z e ta  p o te n tia l o f b la n k  n a n o p a rtic le s
Z
e
ta
 P
o
te
n
ti
a
l 
(m
V
)
B
e f
o
re
 in
c o
rp
o
ra
t i
o
n
A
ft
e r
 in
c o
rp
o
ra
t i
o
n
-1 5
-1 0
-5
0
0 .2  %  w /v   P C L
0 .3  % w /v   P C L
0 .4  %  w /v  P C L
0 .5  % w /v  P C L
A )
 
 
 
Z e ta  p o te n tia l o f d ru g  n a n o p a rtic le s
Z
e
ta
 p
o
te
n
ti
a
l 
(m
V
)
B
e f
o r
e  
in
c o
rp
o r
a t
io
n
A
ft
e r
 in
c o
rp
o r
a t
io
n
-1 5
-1 0
-5
0
0 .2  % w /v  P C L
0 .3  % w /v   P C L
0 .4  % w /v  P C L
0 .5  % w /v  P C L
B )
 
 
Figure 6.4- The effect of organic phase on the properties of blank and drug nanoparticles before and after 
dispersion from film formulations on zeta potential of A) blank nanoparticles and B) drug-loaded 
nanoparticles. Statistically significant differences are noted as (p <0.001) in zeta potential before and after 
dispersion. Results are expressed as mean ± SD, from three replicates.  
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6.2.3 Disintegration time 
The disintegration testing is carried out using the probe method (see chapter 5). The time 
taken for ODFs containing either blank nanoparticles or drug loaded nanoparticles to 
dissolve completely was less than 20 seconds, as films were under additional force that 
mimics oral cavity pressure (Figure 6.5). As seen, there was no significant difference in 
the disintegration time of the films containing blank nanoparticles varying at different 
concentration of PCL polymers in saliva solution (p > 0.05, ANOVA followed by 
Tukey’s test). The times recorded for ODFs incorporating blank nanoparticles to 
completely dissolve were 11 ± 2.6 s, 12 ± 1.0 s, 12 ± 1.0, and 12 ± 1.0 s, from 0.2 % w/v 
to 0.5 % w/v PCL, respectively. However, there is a slight increase in disintegration time 
when drug-loaded nanoparticles were incorporated into the films; 11 ± 1.50 s, 12 ± 2.08 
s, 14 ± 0.58 s and 14 ± 0.58 s from 0.2 % w/v to 0.5 % w/v PCL, respectively, but this 
was not deemed significant compared to the blank film (p> 0.05, ANOVA followed by 
Tukey’s test). It is possible that, as more organic particles are embedded in the films with 
an increase in PCL concentration, more time is required to gain the access for water 
molecules for breaking the polymer matrix of the film forming polymer, hence a longer 
disintegration time (Steiner et al., 2016). 
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Figure 6.5- Disintegration time of KP film loaded blank nanoparticles and KP films containing drug –
nanoparticles in 1ml saliva solution at 37 0C (n=3 ± SD). Statistical different was observed using one way 
ANOVA followed by Dunnett’s post- test, between drug nanoparticles loaded films and the controls using 
different concentrations of PCL (p > 0.05) indicated that non significance.  
 
6.2.4 Mechanical properties 
The mechanical properties of films was measured to ensure the integrity and sufficient 
physical properties for handling and storage. The thickness of the films before and after 
nanoparticles loading was uniform (0.14 µm). When analysing the effect of nanoparticles, 
either with or without drug loading, on the mechanical properties of ODF, results revealed 
that the loading of nanoparticles seems not to have any effect on these properties of films 
with an increase in PCL amount (p > 0.05, ANOVA followed by Dunnett’s test) compared 
to the control blank (Table 6.1). This is because, especially with the nanoparticles 
encapsulating with drug, they were further incorporated into ODFs. 
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Table 6.1- Comparison of mechanical properties of blank control film with ODF containing blank 
nanoparticles and drug nanoparticles a variable concentration of PCL (0.2 – 05 w/v) at size 3 x2 cm2. 
Nanoparticles loading has no effect on the mechanical properties of film (p > 0.05, one way ANOVA, 
Dunnett’s test).  
 
Formulation 
Mechanical properties  
Tensile 
strength 
(N/mm2) 
Elongation 
 (%) 
Young’s 
modulus 
(N/mm2) 
 
Control film 
 
4.72 ± 0.53 
 
51.08 ± 2.93 
 
10.01 ± 0.03 
Blank nanoparticles  (0.2 % 
w/v PCL) loaded films  
3.07 ± 0.82 50.44 ± 1.01 7.51 ± 2.05 
Blank nanoparticles  (0.5 % 
w/v PCL) loaded films  
5.07 ± 0.77 61.00 ± 3.84 10.52 ± 1.09 
Drug nanoparticle (0.2 % w/v 
PCL) loaded films 
4.30 ± 0.79 52.68 ± 2.68 6.92 ± 1.01 
Drug nanoparticle (0.5 % w/v 
PCL) loaded films 
5.31 ± 0.107 63.09 ± 4.82 9.18 ± 1.01 
 
Further examining the effect of nanoparticles on the mechanical properties of ODF 
formulation with an increase of PCL concentrations, results showed that there were no 
significant differences in tensile properties of all film formulations containing blank 
nanoparticles with increasing PCL concentrations (Figure 6.6). Despite a minor increase 
in mechanical properties (e.g. tensile strength, % elongation and Young’s modulus), films 
remain strong and flexible (p > 0.05, ANOVA followed by Tukey’s test). Similarly, a 
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small increase in mechanical properties of films observed when glipizide loaded 
nanoparticles were incorporated into films. There was no significant difference observed 
in those parameters with an increase in PCL amount (p > 0.05, ANOVA followed by 
Tukey’s test). However, incorporation of poorly water soluble drug nanoparticles can be 
seen to influence the mechanical profile of those films compared to films with blank 
nanoparticles (Figure 6.7) (p < 0.05, ANOVA followed by Tukey’s test). As evidence, 
the tensile strength of drug loaded nanoparticles increases; for example, it increases from 
3.07 ± 0.82 N/mn2 to 4.30 ± 0.82 N/mn2 using 0.2 % w/v PCL. In addition, a similar effect 
was observed for other film formulations. It is possible that poorly water soluble drug 
nanoparticles, with glipizide as a model drug, could potentially perturb the particles in 
the film forming polymer, which retained less water upon drying due to a decrease in the 
water affinity through the hydrophilic property of the polymer, resulting in an increase in 
mechanical properties (Krull et al., 2015).  
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Figure 6.6- Mechanical properties of blank nanoparticles loaded ODF with a variable concentration of 
PCL (0.2 – 05 w/v). Results are expressed in triplicate, mean ± SD.  
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Figure 6.7- Mechanical properties of glipizide nanoparticles loaded ODF with a variable concentration of 
PCL (0.2 – 05 w/v). Results are expressed in triplicate, mean ± SD.  
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6.2.5 In - vitro drug release 
The drug release profile of pure glipizide and drug loaded nanoparticles was studied in 
phosphate buffer solution as the medium at pH 6.8. Pure glipizide released 51 % of drug 
after 5 minutes. However, a significant increase was observed in drug release (up to 70 
%) of total drug in phosphate buffer solution (pH 6.8) after 10 minutes (Figure 6.8) (p < 
0.05, ANOVA followed by Tukey’s test), as glipizide becomes more ionised in solution 
– the weakly acidic sulfonylurea groups of glipizide become protonated at higher pH,  due 
to the delocalisation of the nitrogen electron pair from the sulfonyl group (Jamzad and 
Fassihi, 2006). In contrast, the slightly delayed release of drug from nanoparticles may 
be attributable to the drug molecules requiring some time to diffuse out from 
nanoparticles. Similar observation for a burst of drug release after 10 minutes for films 
containing nanoparticles (p < 0.05, ANOVA followed by Tukey’s test). Due to the film 
forming polymer (KP) being very hydrophilic and after slow release of drug from 
nanoparticles, the burst effect was triggered by the pH condition of the medium (pH 6.8). 
Also, the rapid dissolution profile after 10 minutes was attributed to the small size of 
nanoparticles, making a large surface area available for wetting the films (Pandya et al., 
2011, Saharan et al., 2015). Thus, ODF could be the potential carrier of nanoparticles to 
enhance the bioavailability of poor soluble drug,  
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Figure 6.8- Drug release studies of pure glipizide and KP film consisting of glipizide loaded nanoparticles 
in PBS (pH 6.8). Results as express of mean ± SD, n=3.  
 
 
6.2.6 SEM  
 
SEM was carried out to investigate the surface morphologies of films. As shown, different 
morphologies were captured for the different film samples (Figure 6.9). Pure glipizide 
exhibited a smooth surfaced, rectangular crystal into films (Figure 6.9 A) (Kushare and 
Gattani, 2013). However, blank nanoparticle loaded films revealed a homogenous 
distribution of nanoparticles, with a slight adhesion to each other (Figure 6.9 B). 
Compared with the morphology of films containing blank nanoparticles, the surface 
morphology of drug loaded nanoparticles showed the absence of glipizide, which 
suggested that the drug was successfully incorporated and molecularly dispersed inside 
the polymer matrix (Figure 6.6 C). These results could be further confirmed by additional 
studies such as Raman spectroscopy. 
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B)  
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C)  
 
Figure 6.9- SEM images of A) pure glipizide loaded film B) blank nanoparticles loaded ODF and C) 
drug loaded nanoparticles incorporated into ODF. 
 
6.2.7 Drug entrapment efficiency 
The drug entrapment efficiency is the evaluation of the amount of drug that can be 
embedded into the prepared nanoparticles. The studies were carried out by loading 
glipizide at 20 mg and 40 mg in the same volume of organic phase (10 mL) at the polymer 
solvent of 0.2 % w/v and 0.5 % w/v PCL. Results showed that the entrapment efficiency 
was in the range of 62.12 ± 4.15 % to 80.55 ± 3.25 % (Table 6.1). The solubility of drug 
in the organic phase and aqueous phase could influence the entrapment efficiency. As 
seen, the higher entrapment efficiency was found in case of an increase of polymer 
concentration, as glipizide is soluble in the acetone as an organic solvent  Also, an 
increase in polymer concentration creates more polymer available for the formation of 
nanoparticles that allows more spaces for drug entrapment. A similar observation for the 
effect of polymer used was studied (Youan et al., 2001). Although there was an increase 
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in entrapment level at both doses, but recorded significantly difference for the individual 
dose of glipizide (p < 0.05, ANOVA followed by Tukey’s test). This is possibly due to 
high polymer concentration lead to an increase in viscosity of the organic phase, resulting 
in increase in larger size of particles that creates diffusional resistance of drug molecules 
into the aqueous phase, thereby enhancing the entrapment of drug. 
 
Table 6.2- Entrapment efficiency of drug loaded nanoparticles at different solvent concentration. Result 
are expressed in triplicate, mean ± SD. 
Dose of glipizide Volume of organic 
phase 
Polymer solvent 
concentration 
Entrapment 
efficiency (%) 
20 mg 10 mL 0.2 % w/v  PCL 62.12 ± 4.15 
20 mg 10 mL 0.5 % w/v  PCL 70.55 ± 2.65 
40 mg 10 mL 0.2 % w/v  PCL 72.12 ± 2.65 
40 mg 10 mL 0.5 % w/v  PCL 80.55 ±  3.25 
  
6.3 Conclusion 
With a low capacity of drug loading into the ODF formulation, the use of nanoparticles 
was prepared by incorporation of the drug nanoparticles into films with the aim to 
enhance the bioavailability of a poorly soluble drug, glipizide and potentially improve the 
drug loading efficiency. The blank nanoparticles and drug nanoparticles were prepared 
by the solvent replacement method in the range of 0.2 to 0.5 % w/v of the organic phase, 
which were then mix with film forming polymer, KP, for casting and drying. Films 
developed with either blank or drug nanoparticles were flexible and transparent. 
Regarding the amount of PCL used, the particle sizes of  blank nanoparticles was  
recorded as 208 ± 4.79 nm, 220 ± 3.53 nm, 225 ± 4.03 nm and 244 ± 5.02 nm and the 
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polydispersity index of 0.102 ± 0.007, 0.098 ± 0.012, 0.106 ± 0.014, 0.101 ± 0.015,  in 
the range of 0.2 to 0.5 % w/v, respectively. Furthermore, the particle sizes observed a 
significant increase after dispersion with the KP solution with the same range of PCL 
used, possibly as a result of the extent of agglomeration of particles, due to particles 
getting in close contact with the film forming polymer during the drying process. The 
results showed that not only the polymer solvent, but also incorporation with film solution 
potentially affects the particle size and polydispersity index. All films dissolved in less 
than 20 seconds, and there was no significant difference in the disintegration time of the 
films containing blank nanoparticles or drug loaded nanoparticles; however, there was a 
slight delay for films to completely dissolve due to more time required for water 
molecules to gain access for breaking the polymer matrix of nanoparticles and the film 
forming polymer. In term of mechanical properties, blank nanoparticles showed no effect 
on the properties of films, but recorded a minor increase in mechanical properties of films 
loaded with drug nanoparticles, which could potentially perturb the particles in the film 
forming polymer, hence the distribution of nanoparticles have no impact on the 
mechanical properties of films, which indicates films remained strong and flexible. Pure 
glipizide and drug nanoparticles loaded films released an initial burst up to 70 % of the 
total amount of drug after 10 minutes in PBS solution at pH 6.8, due to large surface area 
and small particle size available, which reinforces the ability of ODF to enhance the 
dissolution rate of poorly water soluble drug via nanoparticles production. No drug 
particles were observed on the surface morphology of films, which indicated that drug 
was incorporated successfully inside film. High drug loading was obtained with an 
increase in polymer concentration used, which demonstrated the potential use of 
nanoparticles for poorly water soluble drugs with the aim to enhance the drug loading 
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into films. Overall, ODFs containing nanoparticles is a novel approach to fast release of 
BCS class II drug. 
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7.1 General Conclusion and Future work 
Developing formulations for children with the appropriate adapted doses is a particular 
challenge in drug development, since children are not small adults and they go through 
different stages of growth and development. As administration of the APIs via the oral 
route is the most popular choice, most are generally available in solid (e.g. tablets, 
capsules) or liquid (e.g solutions, suspensions and emulsions) formylations. However, the 
traditional dosage forms are limited by the dose rigidity, risk of choking and some adverse 
effects associated with the excipients.   
 
ODFs have gained attention and are acknowledged as a new potential dosage form for 
paediatric use, which is more advantageous over traditional dosage forms, in terms of 
improved patient compliance and convenience. Yet, although there has been extensive 
interest in developing this technology, they are associated with certain limitations as a 
new, dosage form undergoing development; low dose capacity (less than 40 mg API), 
since the small, thin size is the limiting factor, therefore restricting their use to potent 
drugs that are clinically efficacious at lower doses.. Moreover, the currently available 
methods for preparation of ODFs are generally based on the solvent evaporation method, 
where the manufacturing process is a controlling parameter to produce uniformity in 
thickness, which also makes achievement of drug content uniformity challenging, 
especially for poorly water soluble drugs.  
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The formulation of ODFs is highly dependent on the selection of the key component: the 
film-forming polymer. Given that ODFs target fast release and rapid onset of action, the 
appropriate selection of type and concentration of film forming polymer is a critical 
parameter for forming a film forming polymer that can be easily removed without damage 
or rupture, as it is important for storing and handling, achieve efficient mechanical 
properties, disintegration time, as well as the drug loading of the ODFs. In order to 
optimise the formulation of ODFs, screening of a range of polymers was initially carried 
out using the baking tray method (Chapter 1). SA, pectin, and KP were selected as film 
forming polymers, as they exhibited good texture with excellent film forming capacity; 
other polymers were excluded from further studies, as they were difficult to peel or no 
film developed. Also, the use of plasticiser is essential for film formulation, as it helps to 
improve the flexibility and reduce brittleness of the film. Types of plasticiser and the 
amount of plasticiser concentration must be compatible with the polymer and 
appropriately used to enhance the strength of the ODF. Among the selected polymers, 
Kollicoat protect (KP) was the appropriate polymer candidate for extensive studies in the 
development of ODFs, due to its instant release profile, great flexibility, good film 
forming agent with taste masking and moisture barrier properties, as well as great 
compatibility with the selection of plasticiser (glycerol) and a variety of loaded drug. 
However, when incorporating drug into films, although the uniformity in weight was 
achieved, the uniformity of drug failed due to uneven distribution of drugs in the films 
using this baking tray technique. Since the ODFs have a critical issue to obtain a uniform 
dose for the individual unit of films, a new alternative method has been approached for 
further ideal film development in order to achieve content uniformity. Following on from 
the optimisation process above for the content uniformity of films, the Elcometer Film 
Applicator, which is equipped for applying uniform and reproducible film products, based 
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on the principal application of solvent casting technology, was ideally selected for further 
study of film formulation.  
 
Formulation for poorly water soluble drugs remains a challenging task for the design of 
oral dosage forms, as most of the drugs being developed in the pipeline today are poorly 
water soluble. The associated low aqueous solubility and slow release of drugs in the 
gastrointestinal tract results in low oral bioavailability, leading to consequences such as 
ineffective treatment and frequent dose escalations to achieve therapeutic effects. In 
addition, most drugs have a bitter taste and it becomes a serious problem affecting patient 
compliance and acceptability, particularly to paediatric patients. Besides that, the high 
drug loading becomes a challenge as a result of poor powder flowability and sticky 
tendency. Inclusion of BCS class II drug, glipizide, with different types of natural and 
synthetic cyclodextrins (CDs) was investigated for improving the aqueous solubility and 
bioavailability of this drug via the formation of inclusion complexation, as well as to taste 
mask this bitter drug. The solubility of glipizide was enhanced by incorporating within 
the complexes in both water and PBS solution. Also, the stability constant of 
complexation is strongly dependent on the strength of the interactions of the guest 
molecule and the CD cavity, which show that a typical AL type was observed for 
glipizide–CD complexation. The incorporation of taste masking agents may affect the 
mechanical properties of ODFs, as they could aggregate and break down the polymer 
matrix. Other physicochemical properties of films, including moisture content and 
disintegration time, were not influenced by the CD complexation. Although there was an 
improvement in the solubility of poorly water soluble drug and drug uniformity by the 
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CD complexation, there still remains a low drug loading efficiency due to poor loading 
capacity of cavity volume of CDs. 
 
Furthermore, the use of polymeric nanoparticles have been extensively used as particulate 
carrier systems, which is advantageous for poorly water soluble drugs, due to the increase 
in the surface area to volume ratio of drug particles, as well as improved stability of the 
API. The exploration of nanoparticles into ODFs, with the aim to enhance the 
bioavailability of poorly soluble drug, glipizide, and potentially improve the drug loading 
efficiency was investigated. Nanoparticles prepared by the nanoprecipitation method 
gave an average size from 180 to 300 nm. Results showed that the particle size of blank 
or drug nanoparticles, before and after dispersion with polymer solution, increased with 
an increase in polymer concentration, as it is clear that not only the polymer solvent, but 
also incorporation within ODFs causes an extent of agglomeration of particles, due to 
particles being in close contact with the film forming polymer during the drying process. 
The mechanical properties of films either loaded with blank or drug-loaded nanoparticles 
produced clear, flexible films; however, when the drug-loaded nanoparticles were 
incorporated into the ODF, there was a slight delay in disintegration time of film 
observed, but this remained within the recommended time (30 seconds). Moreover, the 
dissolution profile of drug was also improved by the use of nanoparticles, due to the 
availability of a large surface area and small particle size. High entrapment efficiency of 
drug (up to 80 %) indicated the potential use of nanoparticles for incorporation of poorly 
water soluble drugs, with the aim to enhance the drug loading into films. 
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As this is a new innovative technology, a set of associated limitations and challenges arise 
in the quality control of ODF formulations. ODFs are designed for quick release purposes 
when applied onto the tongue. Following the European Pharmacopeia, orodispersible 
tablets (ODTs) should disintegrate in less than 180 seconds (European Pharmacopoeia 
Commision, 2013) and less than 30 seconds by FDA guidance (FDA, 2008); whereas 
ODFs, recently subordinates to the “oromucosal preparations” monographs, only stated 
as “dissolve rapidly” without a defined time limit (European Pharmacopoeia Commision, 
2013), although the disintegration time limit of 30 seconds or less is a recommended value 
for ODFs (Barnhart et al., 2008). However, no standard pharmacopoeia disintegration 
test method for ODFs exists. As such, the studies described here took a developmental 
approach to a more relevant and suitable testing method for the disintegration time of 
ODFs, by dissolving films into a beaker with gentle stirring and through the use of a 
texture analyser, in order to better reflect the dynamic physiological environment of the 
human mouth. Media volume is an important controlling factor that could influence the 
disintegration behaviour of the dosage form, especially to ODFs, as they are quickly 
hydrolysed upon contact with the saliva. Results showed that the amount of test media 
and the media itself (e.g. distilled water or saliva solution) did not lead to crucial 
differences in disintegration time of ODFs, conducted by either a TA-CT3 texture 
analyser with probe or simply stirring in a beaker. However, the probe method developed 
using a small volume of media is more biorelevant to the oral cavity volume and provides 
a clear end-point determination and is, therefore, more suitable for control performance 
in terms of reproducibility compared to the beaker method. Furthermore, the prototype 
packaging was used as an alternative approach for ODF packaging, where films were 
packed either in a cold sealed blister or aluminium foil. As a result, aluminium foil was 
considered to be the better choice for packaging of ODFs, as expected, due to its great 
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protection from moisture. It also is important to maintain the integrity of products and 
stability profile of ODFs, since they are easily to exposed to the environment; stability 
studies were carried out for films packed by these prototypes packaging at long term (25 
± 2 0C and 60 ± 5 % RH) and accelerated stability conditions (40 0C ± 2 0C and 75 ± 5 % 
RH). Films exhibited strong, flexible properties over a period of 3 months, with no change 
in the mechanical properties, retaining its instant release (less than 25 seconds), with good 
uniformity of dosage, which is available at such low dose, and therefore, those 
formulation could more viable industrially and clinically through the product 
developmental stages.   
 
7.2 Future work 
- Investigation of permeability of drug through the buccal cells to predict the 
processing of drug transport across the buccal mucosa membrane and in terms of 
toxicity. 
 
-  Exploring different manufacturing methods for preparation of nanoparticles in 
order to enhance drug loading and drug content uniformity, especially for poorly 
water soluble drug.  
 
 
- Optimisation the suitable appropriate volume of media for dissolution studies and 
standardised packaging for further improvement in performance of ODFs. 
 
- Conduction of clinical survey to predict the potential use of ODFs in the children.
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Appendix 1 
 
 
Appendix 1- Calibration curve of glipizide in 70: 30 v/v ethanol: water 
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